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SUMMARY 
Antigens (Ags) expressed by cancer cells can be specifically recognised by T cells 
contributing to anti-tumour immunity. For this reason, tumour Ag-specific T helper type 
1 (Th1) cells can be detected in cancers and their infiltration is predictive of a prolonged 
disease-free survival. However, their activity is suppressed by T cells with inhibitory 
functions i.e. regulatory T cells (Tregs). High infiltration of tumours by these cells often 
correlates with poor survival. It is therefore crucial to understand their activity. Since Th1 
and Treg cells are activated after Ag recognition, it is plausible that tumour Ag-specific 
Tregs inhibit Th1-mediated tumour immunity. Furthermore, vaccination, rather than 
inducing effector T cells, may be detrimental by activating Tregs. 
 
Increased numbers of CD25hi Treg cells are found in cancer patients, including 
CRC. However, in contrast to many cancers, the phenotype of these cells has not been 
studied in CRC patients. In this thesis, phenotypes of circulating, colon and tumour 
infiltrating Tregs are described. A high percentage of intratumoural CD4+CD25hi Tregs 
was found to express immunosuppressive molecules and these cells were enriched in late-
stage CRC tumours. In addition, this thesis describes the measurement of Th1 and Treg 
cells recognising the oncofetal Ag, 5T4. Four immunogenic regions within the oncofoetal 
tumour Ag 5T4 and 14 peptides able to bind to most commonly found human HLA-DR 
alleles were identified. CD4+CD25hi cells mediated the control of tumour Ag 5T4-specific 
Th1 responses in CRC patients and their suppressive activity was not restricted to Th1 
cells of the same Ag specificity. Also, responses to some, but importantly not all, 
immunogenic helper peptides discovered were influenced by Tregs. Thus Tregs may 
contribute to CRC progression by influencing tumour Ag- specific responses of Th1 cells.  
 
This body of work brings more information regarding the tumour Ag-specificity of 
Tregs and offers a future rationale to design peptide-based vaccines which exclude Treg 
peptides.  
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CHAPTER 1. INTRODUCTION 
1.1. Cancer cells 
1.1.1. Tumour establishment 
Tumourigenesis is a gradual process consisting of several steps depending on the 
acquisition of mutations in cells. Cancers can arise from small numbers of mutations 
although tumour cells usually exhibit a high number of mutations (1). Indeed, among all 
mutated genes, mutations in the tumour-suppressor gene p53 are key events in 
tumourigenesis of many human cancers (2). As a result of p53 mutations, cells are unable 
to engage apoptosis or senescence and acquire new functions in cell migration (3). Studies 
have shown that rare cells within tumours are able to drive tumourigenesis suggesting 
that tumours originate from the transformation of normal stem cells (4). This cancer stem 
cell (CSC) model has been recently described in different studies with mouse models of 
brain, skin and intestinal tumours where CSCs that self-renew could produce terminally 
differentiated tumour cells, reviewed in (5). The intrinsic features of stem cells make them 
good candidates for acquisition of mutations leading to cancer. Indeed, they are found in 
several tissues and may persist for a lifetime.   
 
1.1.2. From cancer immune surveillance to immunoediting 
Lewis Thomas and Frank Macfarlane Burnet were the first to formally propose that the 
immune system was able to prevent cancer establishment in immunocompetent hosts by 
recognizing and killing tumour cells (6). This hypothesis was named cancer 
immunosurveillance. The immunology community long remained sceptical as strong 
experimental evidences were lacking. For instance, athymic-nude (not totally 
14 
 
immunodeficient) and normal mice showed no difference in cancer incidence (7). The 
use of knock-out (gene-targeted) mice revolutionized immunology and clearly showed 
the link between immunity and cancer suppression. Indeed, RAG2-/- mice (lacking 
adaptive immunity) and IFNGR1-/- mice (lacking IFN-γ receptor), were found to be more 
susceptible to tumour development (8). Similarly, IFNAR1-/- mice (lacking IFN- 
receptor complex) demonstrate increased carcinogen-induced tumourigenesis (9). In 
humans, the use of immunosuppressive drugs during organ transplantation is also 
associated with cancers, as shown after kidney transplantation (10). However, slightly 
conflicting results have emerged which may reflect differences in immunosuppressive 
regimens. Other evidence supporting the cancer immunosurveillance hypothesis is that 
high numbers of tumour infiltrating lymphocytes (TILs) predict long-term survival, after 
surgical intervention, in patients with advanced ovarian carcinoma (11) and CRC (12). 
The concept that the immune system is involved in protection against tumours 
during the early stage of tumourigenesis is seen as too simplistic: if this is the case, 
cancers should not develop in immunocompetent individuals. Instead, it is now proposed 
that cancer immunosurveillance is part of a complex process called immunoediting where 
immune cells also shape tumour immunogenicity.  In a study published in 2001, tumours 
isolated from immunodeficient mice were more immunogenic (no sign of growth in naïve 
wild type recipient) than tumours from immunocompetent mice (tumour growth in naïve 
wild type recipient) (3). The first tumours were unedited while the second tumours were 
edited. The authors postulated that immunoediting is characterized by 3 distinct phases: 
elimination, equilibrium and escape. The elimination phase corresponds to the cancer 
immunosurveillance where innate and adaptive cells clear tumours before clinical 
manifestations. Observing this phase in vivo is challenging as tumours remain silent. 
Tumour cells that are not destroyed enter the equilibrium phase and are subjected to cells 
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of the adaptive immune system that not only prevent their outgrowth but also shape/edit 
their immunogenicity. This state of cancer dormancy is the longest (potentially lasting a 
lifetime) and enables tumour cells to adopt the most immunoevasive mutations. Koebel 
et al confirmed the existence of a long-term cancer control by the adaptive immune 
system. By using a mouse model, they showed that sarcoma cells held in equilibrium are 
highly immunogenic (unedited phenotype and rejected in wild-type mice), unlike less 
immunogenic tumour cells (edited) eventually exiting this phase and entering the escape 
phase (13). In order to reveal early tumour Ags (before immunoediting) and the effect on 
immune cells, Matsushita et al transplanted 3-methylcholanthrene-induced sarcoma cells 
into immunodeficient mice, sequenced the sarcoma cell exomes and identified a sequence 
corresponding to a highly immunogenic mutant (spectrin-β2) peptide recognised by 
cytotoxic T lymphocytes (CTLs) (14). In immunocompetent mice, only tumour cells 
lacking expression of this peptide could grow thereby revealing a T cell-dependent 
mechanism of immunoediting. During the last phase, tumours escape immunity and 
become invisible. This loss of immune control can be explained by deficient Ag 
presentation on tumour cell surface, i.e. loss of presentation of spectrin-β2 peptide; or the 
induction of an immunosuppressive environment [production of vascular endothelial 
growth factor (VEGF) and indoleamine 2,3-dioxygenase (IDO) enzyme and/or 
recruitment of regulatory immune cells]. Although many cell types of the innate (NK cells 
and macrophages) and the adaptive (T and B cells) immune system are involved in cancer 
control, the relative contribution of these immune cells in the 3 phases of cancer 
immunoediting is not completely understood (with the exception of CTLs). 
In humans, the existence of cancer immunosurveillance (elimination phase) is 
demonstrated by the higher risk of cancer development in immunosuppressed patients. 
However, these patients have greater susceptibility to viruses which may reflect an 
16 
 
impairment in anti-viral immunity and not a reduced immunosurveillance of cancer. Yet, 
immunodeficient individuals have a higher probability of developing cancers with no 
known viral etiology, reviewed in (15). 
 
1.2. T cell development 
1.2.1. TCR gene recombination 
All the lineages of the immune system arise from a common lymphoid progenitor, 
differentiated from a haematopoietic stem cell in the bone marrow. T cell precursors 
(thymocyte) reach the thymus for maturation whereas B cells develop in the bone marrow. 
Both organs are indispensable for T and B cell development and are called primary 
lymphoid organs. The thymus has specific environments (cortex and medulla) allowing 
T cell receptor (TCR) gene rearrangement and thymocyte selection. These processes 
respectively generate an enormous repertoire of TCRs that can recognize a very large 
array of self and foreign peptides and select thymocytes with TCR of intermediate affinity 
to self-peptide–major histocompatibility complex (MHC) ligands.  
Functional TCRs are heterodimers consisting of an -chain and a -chain, each 
presenting a variable (V) amino-terminal region and a constant (C) region (Figure 1.1.A). 
The organization of the TCRα and TCRβ loci is shown in (Figure 1.1.B). The TCRα locus 
(similarly to the immunoglobulin light chains) has V and joining (J) gene segments (Vα 
and Jα). The TCRβ locus (similarly to the immunoglobulin heavy-chain) has diversity 
(D) gene segments in addition to Vβ and Jβ gene segments. The TCRα locus 
(chromosome 14) consists of 70–80 Vα gene segments, each having an exon encoding 
the leader sequence (L). The Jα gene segments are followed by an unique C gene, which 
contains the exons encoding the constant domain, the hinge, the  
17 
 
  
V V 
C C 
Carbohydrates 
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Transmembrane 
region Cytoplasmic 
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Antigen 
combining site 
TcR chain locus 
L V x 70-
80 
C 
TcR  chain locus 
D 1 J1 x 6 C 1 D 2 J2 x 7 C 2 
J x 61 
L Vx 52 
A 
B 
Figure 1.1. Structure of the TCR. A. The TCR heterodimer is composed of two 
trans-membrane glycoprotein chains, α and β. B. Organization of the human TCR 
α and β loci. 
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transmembrane region and the cytoplasmic region. The TCRβ locus (chromosome 7) is 
characterized by a different organization. A cluster of 52 functional Vβ gene segments is 
located distantly from two separate clusters each having a single D gene segment, six or 
seven J gene segments and a single C gene.  
The TCR gene segments rearrange in the thymus during T cell development to form 
a complete V-domain exons. The TCR gene segments are flanked by recombination 
signal sequences (RSSs). The mechanism of V(D)J recombination involves two proteins, 
called Recombination Activating Gene (RAG) -1 and RAG-2. The RAG-dependent DNA 
cleavage phase begins when RAG1 and RAG2 bind at the RSS (Figure 1.2, depicted as 
filled triangles) adjacent to each V, D or J element (Figure 1.2, depicted as filled 
rectangles). Then, the two RAG1/RAG 2 complexes bind to each other and bring the V 
region adjacent to the DJ region (phase 2). The RAG protein cuts the DNA at each signal 
and the nicks are closed to form a hairpin structure at the end of the V and D regions 
(phase 3). A number of proteins (e.g. Ku70 and Ku80) and kinases bind to the hairpins 
and open the hairpinned V and D ends. Then, exonucleases and transferases remove or 
add random nucleotides to the gap between the V and D region. This junctional diversity 
accounts for the even greater diversity of TCR specificity. Finally, DNA ligase IV joins 
the ends of the V and D region to form the coding joint and the two signal-ends to form 
the signal joint (phase 4).  
The TCR alpha chain is generated by VJ recombination, where a Vα gene segment 
rearranges to a Jα gene segment to create a functional V-region exon. In contrast, the beta 
chain is generated by VDJ recombination, where Vβ, Dβ, and Jβ gene segments 
reearrange to create a functional V-region exon. Finally, VJand VDJβ V-region exons 
are transcribed and spliced to join to Cand C, respectively.  
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joint  Figure 1.2. Mechanism of TCR gene recombination.  
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1.2.2. Naïve T cells 
In the medulla, double positive CD4+CD8+ thymocytes further differentiate into CD8 
single-positive (CD4−CD8+) or CD4 single-positive (CD4+CD8−) lineages and then 
circulate constantly throughout secondary lymphoid organs (SLOs) via blood circulation 
as mature naïve T cells. SLOs can be encapsulated (e.g. spleen) or diffuse (mucosa-
associated lymphoid tissue) and are the sites of Ag exposure where primary immune 
responses are initiated. Naïve T cells are found primarily in SLOs as these cells express 
a unique set of receptors allowing migration and homing in lymph nodes (LNs). For 
instance, naïve T cells express the receptor CCR7 that binds to CCL21 and CCL19 
attracting the cells to LNs and express L-selectin adhesion molecule (also known as 
CD62L) mediating entry into LNs. 
During an infection, Ag-presenting cells (APCs) capture Ags and further process 
them into peptides. Internalisation of pathogens is mediated by pattern recognition 
receptors (PRRs) on APCs surface. For naïve CD4+ T cell activation, these peptides are 
loaded onto MHC class II molecules and peptide-MHC are presented on the APC surface 
(naïve CD8+ T cells require peptide loaded on MHC class I). APCs displaying Ag taken 
up in the periphery are then transported to T cell areas of SLOs. In vivo, among the cells 
expressing MHC class II molecules, only dendritic cells (DCs) mediate naïve T cell 
activation. Indeed, macrophages are mainly localized in nonlymphoid tissues and B cells 
are inefficient at presenting Ags (16). During migration, pathogen-activated DCs undergo 
maturation leading to a better ability to interact with naïve T cells in SLOs.  
Whilst naïve T cells follow a restricted migratory pattern, some of them can be 
found in non-lymphoid tissues. During chronic inflammation, naïve T cells can home to 
the affected tissue following the development of tertiary lymphoid tissue that helps 
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sustain their activation (17). Also, naïve T cell infiltration and differentiation has been 
observed at tumour site (18).  
DCs provide three signals that are required for the activation of Ag-specific naïve 
T cells. Depending on the stimulus encountered, DCs can modify these signals in order 
to differentiate naïve T cells into activated Ag-specific helper T cells (19). In contrast, 
after priming by DCs, naïve CD8+ T cells differentiate into CTLs.   
1.2.3. Signal 1  
Signal 1, Ag-specific signal, is induced by recognition of peptide-MHC class II or class I 
complexes by the TCR and is crucial for removing T cells from quiescence (nondividing 
state). There are three classical class II molecules (isotypes) in Human: human leukocyte 
antigen (HLA)-DP, -DQ, and -DR. The most highly expressed on APCs is HLA-DR. In 
parallel, two non-classical molecules, HLA-DM and –DO, are involved in peptide loading 
in the cells but do not present Ags on APCs.  
Crystallography studies have characterised the MHC class II structure (20) (Figure 
1.3). They are heterodimers of two polypeptide chains  and ) made of single 
transmembrane sequences and short cytoplasmic tails. Terminal 1 and 1 regions 
combine to form a peptide-binding groove that presents peptides to CD4+ T cells. Stern 
et al crystallized the HLA-DR1 molecule with influenza peptide hemagglutinin and 
showed that the peptide bound within 4 distinctive pockets (P1, P4, P6 and P9) in the 
binding groove whereas the flanking regions extended out of the groove (21). The anchor 
residues at positions 1, 4, 6 and 9 on MHC class II-bound peptides are crucial for stable 
interactions. Because MHC class II molecule have an open-ended binding groove theycan 
present peptides of highly variable lengths (12-24 amino acids) (22). MHC class II-bound 
peptides have a core of 9  
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Figure 1.3. Structure of MHC class II molecule. The five pockets in the binding 
groove of one HLA-DR1 molecule are highlighted (P1 in red; P4 in yellow; P6 in 
green; P7 in blue and P9 in purple). Figure adapted from Yeturu et al.  
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amino acid and residues outside this nonameric binding region are called peptide flanking 
residues (PFRs). PFRs have a critical effect on TCR recognition and T cell function (23) 
and their modifications can result in enhanced CD4+ T cell activation (24). Residues that 
do not interact with the binding pockets on the MHC class II (mainly residues at positions 
2, 5 and 8) are available to interact with the TCR and alterations influence the signal that 
T cells receive through their TCRs (25).  
Upon ligand binding, TCRs cannot transmit signal 1 into the cell without CD3 
molecules and CD4/CD8 coreceptors, the latter of which interact directly with MHC class 
II and class I respectively. Both CD3 molecules and coreceptors serve to translate the 
binding with MHC class II into intracellular signals (phosphorylations by kinases) 
required for T cell activation. Furthermore, Huang et al characterized the functional 
sensitivity of CD4+ T cells and showed that a single peptide-MHC could stimulates naive 
T cells to secrete cytokines (26). 
Regarding CD4+ T cells, a close correspondance between the strength of the TCR 
signal and polarization has been demonstrated (27). In vivo, strong TCR signals induce T 
helper type 1 (Th1) differentiation whereas weak induce Th2 cells. The strength of TCR 
stimulation in vivo is influenced by variables such as Ag concentration, affinity of pepide 
for MHC and/or stability of T cell-APC interaction.  
 
1.2.4. Signal 2 
Although TCR stimulation is necessary, it is not sufficient to support T cell activation. 
Engagement of co-stimulatory molecules is required to complement and amplify 
TCR/CD3/CD4- or CD8-generated signals. The most prominent signal is provided by 
CD80 and CD86, which are highly expressed on activated DCs. These trigger the CD28 
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receptor expressed by T cells. However, CD28 is not the only receptor capable of 
delivering a costimulatory signal and other receptors can compensate to a limited extent 
its absence (28). Indeed, after activation by pathogen or inflammatory molecules, mature 
DCs upregulate many additional co-stimulatory receptors, classified as members of the 
B7 or TNF-Receptor families.   
Stimulation in the presence of only TCR stimulation in the absence of signal 2 can 
lead T cell to anergy (nonresponsive to Ag stimulation) or apoptosis. Originally thought 
to be signal II independent, the activation of memory T cells also requires CD28 
costimulation (29). The same costimulatory molecules on DCs can also mediate T cell 
inactivation through engagement with other receptors expressed on T cells. Indeed, after 
activation, T cells up regulate cytotoxic T-lymphocyte antigen 4 (CTLA-4), which binds 
with high affinity to CD80 and CD86 leading to inhibition of T cell function (30). CTLA-
4 has a central role in the inhibition of excessive T cells expansion, as shown with CTLA-
4-deficient mice developing lethal lymphoproliferative syndrome and patients treated 
with anti-CTLA-4 therapy developing autoimmune disorders (31, 32).  
 
1.2.5. Signal 3 
Signal 3 is the polarizing signal mediated by DC-released cytokines. Already 
differentiated T cells do not need this third signal. After signals 1 and 2, T cells upregulate 
receptors, which permit them to receive signal 3. This signal corresponds to the 
inflammatory cytokines that reflect the nature of the pathogen encountered by DCs and 
the nature of the infected tissue. For instance, after activation by intracellular pathogens, 
DCs release IL-12 which promotes Th1 cell development (33).   
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1.2.6 Memory T cells 
Once activated and polarized Ag-specific naïve T cells differentiate into effector T (Teff) 
cells: T helper (Th) cells (for CD4+ T cells) or CTLs (for CD8+ T cells) that proliferate 
and produce IL-2, which is required for autonomous clonal expansion. The majority of 
the Teff cells die by apoptosis after Ag clearance whilst others become long-lived 
memory cells (central TCM or effector memory TEM cells). TCM, expressing both CD62L 
and CCR7, are located primarily in SLOs and TEM in nonlymphoid tissues (34). Current 
dogma indicates that memory T cells proliferate in response to lower doses of Ag and are 
less dependent on costimulatory molecules than naive T cells permitting a faster response 
when reencountering a pathogen (35). However, recent in vivo studies have shown that 
CD28 costimulation is critical for secondary T cell responses [reviewed in (36)].   
1.2.7. T cell tolerance 
1.2.7.1. Peripheral tolerance 
After TCR recombination (see above) in the thymic cortex, immature T cells (called 
thymocytes) express an active TCR and both the CD4 and CD8 molecules (double 
positive). The strength or avidity of the interaction between the TCRs and pMHC 
molecules is a crucial factor that determines the fate of immature T cells. After 
interactions with cortical thymic epithelial cells (cTEC), if the TCR – pMHC- interaction 
is of intermediate affinity the cell undergoes positive selection (Figure 1.4). Those DP 
thymocytes with a functional TCR will then become single positive cells (expressing 
either CD4 or CD8) and migrate to the thymic medulla. The others, 90% of the 
thymocytes, express “useless” TCR with very weak affinity for self pMHC complexes 
and die by neglect. In the medulla, thymocytes interact with medullary thymic epithelial 
cells (mTECs) and DCs presenting self-peptides. During this stage, thymocyte that 
expresses a TCR that has an above threshold affinity to self-peptides will go through  
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apoptosis (negative selection). Thymocytes that have passed the thymic selection leave 
the thymus and reach the periphery as mature, naïve T cells. 
The generation of natural Treg cells in the thymus is believed to occur as the result of an 
altered negative selection process. Data from TCR-transgenic mouse studies formed the 
basis for the current notion that natural Treg development occurs when the TCR avidity 
for self-antigens lies between the TCR avidities that drive positive selection and negative 
selection (37). In other words, Treg differentiation is thought to result when their 
TCR/antigen affinity is just weaker than the affinity needed for negative selection, but 
high enough to pass the positive selection (38) (Figure 1.4). Therefore, Tregs derived 
from the thymus are selected on their ability to interact with self-antigens with high TCR 
affinity, which has great implications for their protective role against autoimmune 
diseases. 
A vital molecule involved in central tolerance is the transcription factor 
Autoimmune Regulator (AIRE). AIRE plays a critical role in negative selection as 
mutations are associated with failure to delete autoreactive T cells in the thymus (39) (40). 
In the thymic medulla, AIRE is expressed by medullary thymic epithelial cells, which 
also express MHC class II and co-stimulatory molecules (41). During negative selection, 
these cells present tissue-specific Ags (self Ag only expressed in peripheral organs) to 
thymocytes. 
Besides driving the deletion of autoreactive T cells, AIRE is also required for 
thymic development of Tregs. As a result, thymus derived Tregs (tTregs) mostly 
recognize self-Ags encountered during thymic selection. AIRE is also required for 
tumour-associated Ag specific Tregs (42). In details, Malchow et al showed that tTregs, 
specific for a prostate-associated Ag, are enriched in prostate cancer. These tumour 
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associated Ag – specific Tregs required AIRE-dependent self Ags during thymus 
development. These data suggest that tumours recruit tTregs reactive to Aire-dependent 
self Ags associated with the organ of cancer origin.  
 
1.2.7.2. Peripheral tolerance 
Central tolerance is efficient but also incomplete, as not all self-Ags are expressed in the 
thymus. Therefore, self-reactive T cells are still present in the periphery of normal 
individuals (43). Peripheral tolerance, or Ag-specific unresponsiveness, is vital to 
suppress these potentially autoreactive lymphocytes. Several mechanisms are involved in 
the control of auto-reactive T cells in the periphery avoiding the development of 
autoimmune diseases. DCs can induce anergy or deletion (apoptotic cell death) by partial 
activation when, for instance, low doses of tissue Ags are presented to T cells or when 
Ags are presented in the absence of co-stimulatory molecules. In addition to these 
mechanisms, Tregs are critical to maintenance of self-tolerance.  
 
1.3. T cells in cancer 
1.3.1. CD8+ T cells 
One of the key cells for tumour eradication are CD8+ CTLs. Naïve CD8+ T cells are 
activated upon recognition of tumour Ags in the context of MHC class I on DC surfaces 
in SLOs and become activated in the presence of costimulatory molecules such as CD80 
and CD86 with the help of the CD4+ T cells secreting IL-2 (44). Activated Ag-specific 
CD8+ T cells traffic from the lymphoid organs to the peripheral site of infection via the 
blood. CTLs can directly recognize and kill tumour cells provided they express MHC 
class I molecules (MHC class II molecules being expressed by some tumours only). 
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CTLs can induce cell death of intracellular pathogen-infected and transformed cells 
with granules or Fas/Fas-ligand cytotoxic pathways, both triggering cell apoptosis. The 
granules are made of perforin (pore-forming protein) and granzyme (serine proteinases) 
that act together to efficiently inducing apoptosis in target cells (45). The role of CTLs in 
cancer immune surveillance was highlighted in the 1990s when a higher incidence of 
carcinogen-induced tumours was observed in perforin-deficient mice (46). Fas ligand 
(FasL or CD95) is upregulated on activated CTLs following Ag stimulation and binds to 
its receptor expressed on rapidly proliferating cells, such as tumour cells. This interaction 
results in the apoptosis of the target cell (47). Inactivation of the Fas-mediated cell death 
by mutation of Fas or FasL was shown to increase the development of B cell lymphomas 
in mice (48). Recently, one study reported that the FasL-mediated death pathway 
constitutes a crucial factor of T cell–mediated immune surveillance of murine B cell 
lymphoma (49).  
 
1.3.2. T helper cells 
As described above, the CD4 cell surface protein is expressed by a subset of lymphocytes. 
After Ag-induced activation in the periphery, naïve CD4+ T cells polarize into Teff cells 
called CD4+ Th cells. These lymphocytes can be divided into several subsets with 
different functions and cytokine signatures (50). This cellular polarization is dependent 
on the up regulation of transcription factors that are induced by the microenvironment 
present at the time of the initial Ag encounter by DCs. Indeed, DCs can polarize and 
promote the development of a specific Th cell subset depending on the pathogen 
recognized by their PRRs (19).  
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1.3.2.1. Th1 T cells 
The Th1 developmental pathway is driven by IL-12 produced by activated APCs, 
including DCs (51), as shown by reduced Th1 responses in mice deficient for IL-12 or 
the IL-12 receptor β1 (52). This critical cytokine activates the transcription factor STAT4, 
whose absence results in a failure to generate Th1 cells (53). Two other cytokines 
influence Th1 development, IL-18 (54) and IFN-γ. Signals transmitted via the TCR after 
Ag recognition also upregulate (in concert with IFN-γ and IL-12) transcription factors 
such as T-bet, a “critical regulator” to initiate the Th1 differentiation program (Figure 1.5) 
(55).  
Expression of lineage-specific transcription factors induce cytokine production and 
expression of genes encoding chemokine receptors. IFN-γ is produced predominantly by 
Th1 cells and is considered the signature cytokine for this subset within the CD4+ T cell 
population. Other cell types can also however secrete relevant amounts of IFN-γ, 
including CD8+ T cells  and NKT cells (56). IL-2 and tumour necrosis factor-α (TNF-α) 
are also cytokines used to discriminate Th1 cells. 
Th1 cells were first described in 1980s as a determinant of the concept of T cell 
‘help’ where it was observed that CTL activation and expansion required Th1 cells (57). 
During primary responses, the nature of the 'help' includes local IL-2 production and/or 
indirect priming through accessory cells. This second alternative is based on the 
activation by Th1 cells of APCs, through CD40-CD40L interactions, which can 
subsequently directly activate CTLs (58). Although Th1 cells can be dispensable for 
primary CTL activation  (Th-independent responses), IL-2-secreting Th1 cells are 
absolutely required for secondary CTL expansion (59) (60). 
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Figure 1.5. Differentiation of CD4+ T cell subsets.  After activation by APCs and in the 
presence of the indicated cytokines, naïve CD4+ T cells can differentiate into 5 different T 
helper cells or in pTreg. Each differentiated cell expresses a characteristic transcription 
factor. 
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 Alongside their “indirect” helper activities for cellular immunity against 
intracellular pathogens and tumour cells, Th1 cells also have “direct” role in anti-tumour 
immunity. Indeed, before activating CTL, Th1 cells can activate cells of the innate 
immunity that have anti-tumour activities. IFN-γ released by Th1 cells is the main 
cytokine involved in this activation and is therefore vital to tumour surveillance, as shown 
by enhanced tumour growth in mice lacking the IFN-γ receptors (61). IFN-γ allows CD4 
Th1 cells to promote anti-tumour responses against tumour cells that do not express MHC 
class II molecules.  
Indeed, IFN-γ derived from tumour Ag-specific Th1 cells activates macrophages, 
inducing secretions of tumouricidal factors such as reactive oxygen and nitrogen species 
(62). Furthermore, IFN-γ can induce the expression of the chemokine receptor CXCR3 
and its ligands CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC (63) that recruit innate 
cells (NK cells and type I macrophages) to the tumour site from blood vessels by 
diapedesis. Observations that blood vessel growth is reduced in tumours of IFN-γ 
receptor+/− mice demonstrated that Th1 cells can target tumour stroma and inhibit 
angiogenesis in an IFN-γ–dependent way (64). Also, IFN-γ increases tumour immune 
surveillance by up regulating MHC class I expression on APCs and tumour cells (65) and 
thus facilitating CTL recognition and killing.  
IFN-γ has also been shown to inhibit cancer cell proliferation by activating STAT1 
that increases expression of cyclin dependent kinase inhibitor p21 (66) and to promote 
tumour cell apoptosis by inducing TRAIL molecule on natural killer (NK) cells (67). 
More recently, IFN-γ- and TNF-producing Th1 cells have been shown to drive cancer 
into senescence (68). Therefore, IFN-γ with its pleiotropic effects on multiple cells is key 
to immune-mediated control of tumour development. Also, IFN-γ has been shown to 
drive cancer immunoediting, selecting tumour cells with reduced immunogenicity (8). 
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Even though IFN-γ has been shown to be important in preventing and suppressing 
the development of cancers, a dual role of this cytokine in tumour immunity has been 
reported indicating that, paradoxically, IFN-γ may also contribute to cancer development 
(Figure 1.6). Several mechanisms involved in the tumour-promoting effects of IFN-γ 
have been proposed. Dong et al have shown that IFN-γ up regulates B7-H1 (PD-1 ligand) 
on the surface of tumour cell lines inducing apoptosis of Ag-specific human T cell clones 
in vitro (69). As tumour infiltrating CD4+ T cells express programmed death-1 (PD-1), 
B7-H1-induced apoptosis has been described as a mechanism of tumour evasion. In 
addition, IFN-γ, produced by immune cells may induce expression of IDO in tumour cells 
(70). IDO catalyses the degradation of tryptophan: the metabolites and reduced 
tryptophan concentration induce T cell apoptosis in the tumour microenvironment. The 
development and function of both monocytic and granulocytic myeloid-derived 
suppressor cells (MDSC) require IFN-γ (71). MDSCs inhibit innate (NK cells) and 
adaptive anti-tumour immune responses (e.g. induction of cysteine deprivation) and are 
therefore a component of the pro-tumourigenic functions of IFN-γ. 
 
1.3.2.2. Th2 T cells 
Th2 cell differentiation is initiated by IL-4 that activates STAT6 and GATA3 (Figure 
1.5). These key transcription factors are crucial for Th2 development and indispensable 
for Th2 cytokine secretion, including IL-4, IL-5, and IL-13 (72). Although both Th1 and 
2 cells have been shown to provide help for Ab secretion by B cells (73), Th2 cytokines 
are more specialized in immunoglobulin isotype switching (74).  
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Figure 1.6. Anti- and pro-tumour functions of T helper cells. Even though T helper 
cells are important in preventing and suppressing the development of cancers, some of 
these cells may also contribute to cancer development. 
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There is evidence that specific factors of the Th2-mediated immune response can 
elicit anti-tumour activity. Indeed, IL-4 can rapidly elicit an inflammatory infiltrate 
comprising eosinophils and macrophages capable of killing tumour cells (75). In animal 
studies, the presence of eosinophils in tumour infiltrates has been shown to be driven by 
Th2 cells and was STAT6-dependant (76). In addition, tumour eradication can be 
mediated by anti-angiogenic cytokines such as IL-4, arguing for a positive role of Th2 
cells in promoting tumour immunity (77). Although Th2 cells can contribute to tumour 
clearance, there is no evidence that they exert selection pressure arguing that Th1 cells 
have a more important role in tumour immunity.  
In contrast to the above, many studies have demonstrated that Th2 cells have 
tumour-promoting capabilities (Figure 1.2). DeNardo et al revealed that IL-4-expressing 
T cells promote pulmonary metastasis of mammary carcinomas by eliciting the pro-
tumoural activities of macrophages (78). The pro-metastatic Th2 response promoted the 
activation of M2 tumour-associated macrophages that in return released TGF-β and 
epidermal growth factor facilitating tumour progression. The finding that the Th2 CD4+ 
T cells influenced metastasis but not primary tumour development implies opposing 
effects of T cells on primary carcinogenesis versus metastasis. In mice, IL-4 neutralizing 
antibodies (Abs) have been shown to limit pulmonary metastasis suggesting that anti-
cancer therapies targeting Th2 cells and IL-4 might be relevant for treating late-stage 
disease. 
 
1.3.2.3. Th17 T cells 
The recent discovery of a third Th cell subset updated the Th1-Th2 dichotomy. Th17 cells 
are different from Th1 and 2 cells by their unique profile of effector cytokines and their 
development is independent of key cytokines central to Th1 and Th2 cells. The generation 
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of IL-17-producing T cells is dependent on IL-6 and TGF-β and expression of the 
transcription factor RORγt is critical for their differentiation (Figure 1.5) (79, 80). Along 
with IL-17, Th17 cells also produce IL-21, IL-22, and IL-26.  
Th17 cells and the cytokines produced by these cells mediate immunity against 
extracellular bacteria that colonize exposed mucosal surfaces. Indeed, Th17 cells have 
been shown to mediate clearance of alveolar epithelium colonized by Klebsiella 
pneumoniae (81) and intestinal lumen colonized by Streptococcus pneumoniae in order 
to maintain lung and intestinal homeostasis (82). Mouse models have also indicated a 
protective effect of Th17 cells against fungal pathogens such as Candida albicans 
infecting oral mucosal (83). One of the mode of actions used by Th17 cells is the 
recruitment of monocytes/macrophages and neutrophils to sites of infections (82). The 
chemokine receptor CCR6 is highly expressed on Th17 cells, in contrast to CD62L or 
CCR7, suggesting that these cells do not home to lymphoid tissues but are recruited to 
inflamed tissues including tumours (84). Indeed, tumour cells, such as colon cancer cells, 
and inflamed tissues can express high level of CCL20 (CCR6 ligand), directing the 
migration of Th17 cells in these tissues (85). 
The use of IL-17a−/− mice demonstrated the role of Th17 in cancer 
immunosurveillance as these mice were more susceptible to melanoma in the lung (86). 
This study also showed that IL-17 secretion at the tumour site induced CCL2 and CCL20 
production, which in turn attracted DC capable of promoting CTL activation. Moreover, 
the use of IL-7 as an adjuvant was found to increase Th17 cell activity and enhance 
vaccine-induced anti-tumour immunity (87). Similarly, IL-17A was reported to elicit the 
activation of tumour-specific CD8+ T cells (86).  
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Pathologically, Th17 cells have been implicated in promoting inflammation leading 
to several autoimmune disorders including psoriasis, inflammatory bowel disease or  
rheumatoid arthritis (88). IL-17, preferentially produced by Th17 cells, can act on various 
non-immune cells. For instance, IL-17 stimulates epithelial cells to secrete inflammatory 
cytokines (IL-6 and IL-8) leading to inflammation or matrix metalloproteinase (MMP) 
by macrophages leading to joint damage (89). 
As IL-17 has inflammatory properties it has been suggested that Th17 cells drive 
inflammation-dependent tumour growth (Figure 1.2). Wu et al have tested this hypothesis 
in mouse and have shown that a commensal bacteria causing colitis promotes colon 
tumour formation by activating Th17 cells (90). IL-17 can enhance tumour growth 
directly through activation of STAT3 in tumour cells leading to the up regulating of pro-
survival (Bcl-2) and pro-angiogenic (VEGF, MMP9) genes (91). In addition to the 
induction of blood vessel growth, IL-17 can promote lymphangiogenesis, favoring the 
spread of tumour metastasis to LNs (92). Recently, tumour-infiltrating Th17 cells from 
melanoma, colon and lung carcinoma tumour-bearing mice were found to express CD39 
and CD73 ectonucleotidases which contribute to immunosuppression through facilitating 
adenosine production (93). Moreover, adoptive transfer of Th17 cells was shown to drive 
tumour growth in a CD39-dependent fashion. Furthermore, the expression of Th17-
associated genes is associated with poorer outcome in CRC demonstrating the pro-tumour 
role of Th17 cells (94).  
 
1.3.2.4. Th9 T cells 
The latest addition to the list of CD4+ T cell lineages is the Th9 subset. After activation 
by APCs in the presence of TGF-β and IL-4, naïve CD4+ T cells differentiate in vitro into 
Th9 cells that secrete high levels of IL-9 and IL-10 (Figure 1.1) (95). Th9 development 
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require signals from both TGF-β and IL-4 receptors. Indeed, the transcription factors 
PU.1, downstream of the TGF-β signal, and IRF4, expressed in response to IL4-activated 
STAT6, are essential for the development of IL-9-secreting T cells (96) (97). 
Furthermore, Th9 cells represent a distinctive subset of T cells, as they express none of 
the major transcription factors of other Th cells (T-bet, GATA-3, RORγt, and Foxp3) and 
therefore none of their cytokines, except IL-10 (98). 
Depending on the cytokines present in the environment during naïve T cell 
activation, IL-9 has been found to be secreted by other CD4+ T cells than Th9 cells, 
including Th17 cells (when activated with TGF-β + IL-6) or Tregs (with TGF-β + IL-2) 
(99). TGF-β and IL-4 have also been found to be able to reprogram Th2 cells toward a 
Th9 phenotype (98). Therefore, the IL-9 system provides an example of Teff cell 
plasticity (at least in vitro) and precautions must be taken when evaluating the role of IL-
9-secreting Th9 cells.  
Licona-Limón et al unambiguously addressed the role of IL-9 when secreted by 
Th9 cells by investigating the influence of IL-9-derived Th9 cells on the type 2 immune 
responses in the context of parasitic helminth infections (100). The use of IL-9 fluorescent 
reporter mice identified Th9 cells and type 2 innate lymphoid cells as main source of IL-
9 in vivo. By using IL-9−/− mice, they showed that IL-9 was required for IL-5 and IL-13 
expression leading to parasite expulsion. Moreover, adoptive transfer of Th9 cells in 
Rag2-deficient mice, in contrast to Th2 cells, was associated with worm expulsion. These 
observations were the first to demonstrate IL-9-secreting Th9 cells as regulators of type 
2 immune response in vivo. A recent paper characterized the presence of Th9 cells in a 
model of chronic airway hyperreactivity, driven by type 2 immunity (101). Mice exposed 
to allergens displayed an accumulation of IL-9-, but not IL-4 and IL-13-, secreting T cells 
39 
 
in their lungs. These cells were classified as Th9 cells. Treatment with anti–IL-9 Abs 
reduced the inflammation.  
A protective effect of Th9 cells has been described in two mouse models of 
melanoma (102) (103). Purwar et al showed that tumour-Ag-specific Th9 cells could 
suppress subcutaneous melanoma growth and neutralisation of IL-9 abrogated the effect. 
Also, the percentage of Th9 cells was higher in the skin and blood than metastatic lesions 
of melanoma patients, supporting that a paucity of Th9 cells promotes tumour growth 
(102). In addition, Lu et al reported that Th9 cells inhibited pulmonary melanoma 
progression by promoting CD8+ T cells activation through recruitment of DCs into 
tumour tissues (103).  
Recently, Th9 cell-derived IL-9 has been implicated in the development of 
ulcerative colitis (UC) (104). Authors found that patients with UC had increase numbers 
of mucosal T cells expressing IL-9 and PU.1 compared to control subjects. Also, these 
patients had more intestinal epithelial cells expressing IL-9 receptor than control subjects. 
This study used a mouse model of oxazolone-induced colitis which revealed that IL-9 
produced by Th9 cells promoted disease by impairing intestinal barrier function. As 
ulcerative colitis is associated with an increased risk for the development of CRC, Th9 
cells may also play a role in this disease (105).  
 
1.3.2.5. Follicular helper T cells 
One way that Th cells offer host protection against specific pathogens is the generation 
of Abs that neutralize and clear pathogens. In order to differentiate into Ab-secreting 
plasma cells, B cells need to interact with Th cells. Th2 cells were thought to provide help 
to B cells, but their roles seem to be restricted to isotype switching as mice lacking 
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regulators of Th2 differentiation form germinal centres and maintain Ab responses (106). 
Instead, another CD4 subset was found to express the chemokine receptor CXCR5 and 
provide help for B cells differentiation in B cell follicles (107). These cells were termed 
follicular B helper T cells or Tfh cells.  
Like their CD4 T cells counterparts, Tfh cells require specific cytokines (IL-21) and 
transcription factors (Bcl6) (Figure 1.1) (108). Studies have also shown that Tfh cells 
express a unique association of activation markers (CD40L, PD-1), inducible T cell 
costimulator (ICOS), CD84 receptor and secrete B helper cytokines such as IL-21 (109). 
These molecules play a central role in Tfh cell function and the delivery of helper signals 
for B cell activation and survival. Indeed, CD40L– CD40 interactions induce maturation 
of DCs, which in return support Tfh cell activation, CXCR-5 expression and migration in 
B cell follicles (110). PD-1 plays a role in promoting humoral response as PD-1-deficient 
Tfh cells secrete lower amounts of B-cell-helping cytokines IL-4 and IL-21 leading  to  
reduced numbers of Ab-producing plasma cells (111). ICOS, a CD28 family member, is 
required for Tfh differentiation as ICOS-deficient mice show poor T cell-dependent B-
cell responses (112) and reduced numbers of CXCR5+CD4 T cells (113). The same loss 
of Tfh cells was observed in ICOS-deficient patients in association with disturbed 
germinal centre (GC) formation (113). 
Tfh cells have been associated with the development of autoimmune diseases. For 
instance, high levels of CD4+CXCR5+PD1+ T cells have been detected in the peripheral 
blood of patients with rheumatoid arthritis suggesting a role for Tfh cells in mediating 
autoimmunity (114). In contrast, loss of Tfh cells has been linked to immunodeficiency 
as CD40L- or ICOS-deficient individuals have altered humoral responses and lack intact 
GCs in secondary lymphoid tissues (114).  
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The role of Tfh cells in tumour immunity is not yet clear. A recent analyses of 
tumour-infiltrating lymphocytes in breast cancers however revealed a high proportion of 
Tfh cells. Also, the presence of Tfh cells had a positive prognostic value (115). These 
data imply that Tfh-dependent humoral immunity is required for an optimal anti-tumour 
response. Moreover, the same study showed that Tfh cells are an important constituent of 
tertiary lymphoid structures in breast tumours. It is therefore plausible that Tfh cells 
influence the formation of a distinct structure to improve tumour immunity. Moreover, 
these tertiary lymphoid structures have been observed in many cancers and their presence 
correlates with a better prognosis, reviewed in (116). 
Within the follicular lymphoma microenvironment however, Tfh cells have a 
crucial role in the survival of malignant B cells (117). Gene expression analysis of sorted 
follicular lymphoma-derived Tfh revealed an over-expression of CD40L and IL4 
compared to tonsil-derived Tfh. Importantly, these two molecules, implicated in normal 
B-cell growth, rescued malignant B cells from anti-CD20 mAb rituximab-induced 
apoptosis. 
 
1.3.3. Regulatory T cells 
Sakaguchi et al in 1990s observed that inoculation of CD25 (IL-2 receptor α-chain)-
depleted CD4 population to immune-compromised (athymic nude) mice induced 
autoimmune diseases (118). Also, the pathology could be prevented by co-injection of 
CD25+ cells. This was the first evidence of CD25-expressing T cells maintaining self-
tolerance in the periphery by suppressing autoreactive T cells that escape thymic negative 
selection. Based on CD25 marker, a new population of Tregs derived from the thymus 
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and naturally nonproliferative (i.e. anergic) to TCR stimulation in vitro was described in 
the peripheral blood of normal human adults (119).  
Although IL-2 receptor is essential for Tregs as IL-2 is critical for their development 
and peripheral expansion, CD25 is also upregulated by activated T cells. Subsequent 
studies in humans and mice discovered another marker more specific for Treg: the 
Forkhead box protein 3 (Foxp3) transcription factor. In humans, mutations in Foxp3 gene 
is associated with IPEX syndrome, characterized by multiorgan autoimmunity as a result 
of defective Treg immunosuppressive functions (120). Similar symptoms of autoimmune 
diseases are observed in scurfy mice with a frameshift mutation in Foxp3 gene (121). 
Foxp3 is critical for Treg development and function. Indeed, mice lacking Foxp3 
are associated with fatal multi-organ autoimmune pathology driven by uncontrolled 
autoreactive T cells (122). But Tregs can also mediate immune responses in different 
contexts such as intestinal homeostasis (123), virus infection (124) or cancer (125). In 
addition to the thymus-derived Treg (tTregs), other Treg subtypes, with the same ability 
to regulate the immune system, can be found (depending on environmental conditions), 
such as peripherally-induced Tregs (pTregs). Because Tregs can also be generated in vitro 
from non-Treg cells (named induced or iTregs), suggestions were made to use the term 
pTregs to describe the Tregs that differentiate in vivo in periphery (126). 
 
1.3.3.1. Thymus-derived Tregs 
The large majority of Foxp3+ Tregs that are present in the periphery arise from the thymus 
(127). The first indication that Tregs arise from the thymus was obtained in 1969 when it 
was observed that neonatal thymectomy resulted in the development of inflammation of 
the ovary (128). Whilst this was at first thought to be due to an endocrine function of the 
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thymus, later experiments indicated that the pathology was in fact due to the absence of 
Treg-mediated immunosuppression (129) 
Strong TCR interactions with self-Ag expressed by MHC class II molecules on 
thymic epithelial cells in the presence of co-stimulation select immature thymocytes as 
Foxp3−CD25+ Treg precursors. This high-affinity interaction for self-peptide is crucial 
for the selection of CD4+CD25+ precursors; thymocytes expressing lower affinity TCRs 
are not selected to become Tregs (38). The recognition of self-peptides by TCRs 
expressed by thymic Treg triggers several downstream signalling pathways leading to the 
induction of Foxp3 expression. After selection, tTregs leave the thymus as mature cells 
with a defined phenotype in contrast to the other thymus-derived naive T cells where 
lineage commitment occurs upon Ag exposure.  
tTregs can be specific for both self and exogenous Ags expressed by bacteria, virus 
or tumours demonstrating the diversity of their TCR repertoire. Indeed, although tTregs 
represent 5–10% of the circulating CD4+CD25- T cells in humans, their TCR repertoire 
is as diverse as the CD4+CD25− T cell repertoire (130). Furthermore, the tTreg TCR 
repertoire only partially overlaps with CD4+CD25− T cell TCR repertoire as a broad TCR 
specificity for a large set of self-Ag is required for tTregs (131). 
 
1.3.3.2. Peripherally-induced Tregs 
Even though Foxp3+ tTregs represents a specific T cell lineage, CD4+ T cells can up 
regulate this transcription factor after Ag stimulation in the periphery. Foxp3 induction 
and differentiation into immunosuppressive T cells that occur in vitro after TCR 
interaction and co-stimulatory signalling is dependant of TGF-β (Figure 1.1). In vivo, the 
gut environment is a preferential site to generate pTregs because of its ability to secrete 
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large amount of TGF-β. Sun et al showed that this peripheral conversion of Tregs required 
DCs from the lamina propria, whose action was dependent on TGF-β and retinoic acid 
(132).  
Although commonly accepted, the in vivo conversion of Foxp3- T cells into Foxp3+ 
Tregs is difficult to observe by phenotypic analysis as definitive lineage biomarkers 
distinguishing tTregs and pTregs are lacking. Two markers, the transcription factor 
Helios (133) and neuropilin-1 (Nrp-1) (134), were found to be expressed at high level on 
tTregs. However, Helios is considered to be a more reliable marker to define tTregs as 
Nrp-1 can also be expressed by pTregs during certain circumstances (inflammation, APCs 
encountered) (135). 
There is a small overlap between the TCR repertoires of pTreg and tTreg and hence 
these populations are believed to recognize different Ags (136). tTregs are most likely to 
be specific for self-Ags recognized during thymic selection, while pTregs, as derived 
from CD4+ T cells, recognize foreign Ags. Consistent with this, Josefowicz et al showed 
that mice deficient in pTregs spontaneously developed Th2 inflammation at mucosal sites 
(gastrointestinal tract and lung) (137). Therefore both populations may have distinct 
functions with tTregs controlling systemic autoimmunity and pTregs suppressing allergic 
inflammation at mucosal interfaces. 
Several studies have investigated the origin of tumour Tregs focusing on Helios 
expression. In colorectal tumours, the proportion of tumour-infiltrating Tregs expressing 
Helios was slightly lower than in peripheral blood suggesting that conversion is not the 
main mechanism that contributes to enrich the intratumoural Treg population (138). 
Instead, the specific recruitment, from the mucosa and blood, or the local expansion of 
Tregs may largely contributes to increase the Treg population in tumours. 
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1.3.3.3. Polarized Treg subtypes 
Recent studies have demonstrated that Foxp3+ Treg population is not homogenous but 
includes subpopulations with specific phenotypes and distinctive functions, reviewed in 
(139). As described previously, several transcriptional regulators orchestrate 
differentiation into specific Th CD4+ cells (T-bet for Th1 cells, IFR4 for Th2 cells, RORγt 
for Th17 cells and Bcl6 for Tfh cells). The same transcription factors can effectively drive 
Treg differentiation towards one particular subset to control the corresponding helper 
CD4+ T cells types on the basis of tissue localization. 
This “Th class”-specific control suggesting that Tregs can specialize and adapt to 
particular environments has been described in 5 different studies. Koch et al showed that 
acquisition of T-bet by Tregs induced the expression of the chemokine receptor CXCR3, 
which enabled the migration of Tregs at sites of Th1 cell-mediated inflammation (lungs 
of M. tuberculosis-infected mice) and the suppression of Th1 cell-mediated responses 
(140). Mirroring the development of Th1 cells, signaling through the IFN- receptor was 
required for T-bet induction in Tregs as lower frequency of CXCR3+T-bet+ Treg was 
observed in IFNGR1-/- or STAT1-/- mice. In another study, Zheng et al demonstrated that 
Foxp3 induce IRF4 expression in Tregs in order to facilitate their control of Th2 responses 
(141). Indeed, mice containing IRF4-deficient Tregs showed a selective dysregulation of 
unprovoked pathogenic Th2 responses (high serum concentration of IL-4-dependent 
IgG1 and IgE and plasma cell tissue infiltration). Similarly, Chaudhry et al demonstrated 
that selective ablation of STAT3 (transcription factor mediating Th17 induction) in Tregs 
resulted in uncontrolled Th17-dependent pathology characterized by the development of 
a fatal intestinal inflammation (142). Finally, Tregs expressing Bcl6 have been shown to 
be essential in the regulation of germinal centre responses, through the expression of 
CXCR5 (indispensable to enter B-cell follicles) (143). Mice containing CXCR5−/− Tregs 
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and Bcl6−/− Tregs were inefficient in controlling germinal centre reactions as higher 
affinity maturation of Abs and plasma cell differentiation were observed in these mice. 
Consistent with these results, Linterman et al showed that the CXCR5+Bcl6+ Tregs 
control germinal centre B cells indirectly through the regulation of Tfh cell numbers 
(144).  
Transcription factors contributing to the gain of specialized suppressive functions 
in Tregs are known, unlike the molecules mediating these effects. A recent study 
addressed this point and characterized a distinct Treg subset expressing the coinhibitory 
molecule TIGIT, which mediated the selective suppression of Th1 and Th17 cells, leaving 
intact the Th2 cells (145). This inhibition by TIGIT+ Tregs was dependent on fibrinogen-
like protein 2 secretion, known to inhibit DCs (146).  
This concept that a subset of Tregs inhibits a corresponding Th CD4 T cell subset 
has great implications in human cancer. Indeed, one Treg subtype suppressing a beneficial 
Th anti-tumour response might be specifically targeted to increase host anti-tumour 
immunity. In other words, rebalancing Tregs subsets instead of eliminating the Treg 
population. Identification of surface molecule, such as TIGIT, expressed by Tregs with 
specialized functions against Th cells may serve as targets in cancer therapy.  
Few studies have investigated the role of these polarized Tregs in cancers. CXCR3+ 
T-bet+ Tregs are highly enriched in ovarian cancer and selectively suppress Th1 beneficial 
responses (147). Another study showed that RORγt-expressing Tregs expand in human 
colon cancer and are associated with disease progression because RORγt+ Tregs have 
impaired anti-inflammatory activities (148). Consistent with this, β-catenin was found to 
trigger RORγt expression in Tregs in colitis and colon cancer, and could compromise 
Treg properties by affecting their anti-inflammatory properties (149).  
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1.3.3.4. Inhibitory cytokines 
IL-10 
Determining the mechanisms used by Tregs is an area of intense research and should 
increase our knowledge of the regulation of peripheral tolerance and may improve anti-
tumour therapy efficacy by revealing ways in which Tregs can be selectively targeted. 
Firstly, Tregs can suppress by secretion of inhibitory cytokines, mainly interleukin-10 
(IL-10) and TGF-Originally thought to be exclusively secreted by Th2 cells to inhibit 
Th1 responses, IL-10 is also produced by DCs, macrophages and Foxp-3- T cells, 
including Th1 cells during parasite infections or Teff cells during influenza infections, 
reviewed in (150) (151). IL-10 has significant anti-inflammatory properties allowing the 
inhibition of macrophages and DCs. They first lose their ability to secrete pro-
inflammatory cytokines and secondly, fail to mature and express co-stimulatory 
molecules (150). Therefore, the suppressive effects of IL-10 on T cells are predominantly 
indirect. However, some studies have reported a direct inhibitory effect of IL-10 on T 
cells, impairing IL-2 production and growth (152) (153).  
IL-10 secreted by Tregs can control allergic responses (asthma or eczema) by 
inhibiting allergen-specific Th2 responses indicating that Tregs can suppress responses 
to environmental Ags, reviewed in (154). This inhibition is likely to be altered in those 
who develop allergic diseases. Early observations showed that IL-10 deficient mice 
suffered from chronic enterocolitis that began after colonization of the gut with the adult 
microflora (155). Studies relying on adoptive T cell transfers into immunodeficient mice 
indicated that IL-10 is crucial in the ability of Tregs to control responses against intestinal 
Ags (156). Furthermore, in addition to the colon, the selective knockout of IL-10 
expression in Foxp3+ cells was associated with inflammation in lungs and skin 
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demonstrating that IL-10 secretion is necessary to regulate immune responses at the 
body’s environmental interfaces (157). In the same mouse model, IL-10-deficiency was 
not followed by the development of spontaneous systemic autoimmunity suggesting that 
IL-10-mediated Treg function is a mechanism utilised in specific tissues. 
In addition to bacterial, parasitic and inflammatory diseases, IL-10 is involved in 
tumour pathology. Indeed, the presence of IL-10 in advanced metastases and the positive 
correlation between serum IL-10 levels and cancer progression suggest an important role 
of this cytokine within the tumour  (158).  However, no link with Tregs was found in 
these studies as tumour cells were identified as the main source of IL-10 (159).  In 
contrast, there is evidence that IL-10 secreting Tregs have beneficial effects by controlling 
tumour-driven inflammation. Indeed, within the tumour of mice with MC38 
adenocarcinoma, activated Tregs were the main source of IL-10 that could suppress pro-
inflammatory tumour infiltrating Th17 cells (160). Also, IL-10 secreted by Tregs 
suppresses Th17 cell-driven colitis (161). These data indicate that therapeutic approaches 
aimed at suppressing tumour infiltrating Treg activity may be harmful when the Tregs are 
inhibiting Th17-driven inflammation. 
TFG-
TFG-is a critical regulator of the immune system: TGF-β1−/− mice develop multi-organ 
inflammatory diseases leading to organ failure and death (162). Like IL-10, different cell 
types express TGF-β1, thereby making it difficult to analyse its involvement in Treg 
function. Conflicting in vitro studies have shown that Treg suppressor function can occur 
in the absence of TGF-1 production (163) while other studies indicated that in vitro-
stimulated Tregs exert immunosuppression by cell-surface-bound TGF-1 (164). 
However, there is clear in vivo evidence that TGF- produced by Tregs is important in 
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the control of autoreactive CD8+ T cells in type 1- diabetes (165). Further evidence of the 
direct inhibitory effects of TGF-β is the observation that in mouse models of 
inflammatory bowel disease (IBD), CD4+ T cells that cannot respond to TGF-β (absence 
of a functional TGF-β receptor) escape Treg–mediated control and induce colitis (166).  
Strauss et al investigated Tregs in patients with head and neck squamous-cell 
carcinoma and reported that Tregs were enriched within the tumour (167). These Tregs 
were IL-10+TGF-β1+ (revealed by staining of the tumours by immunofluorescence) and 
mediated stronger suppression than peripheral Tregs. Neutralizing IL-10 and TGF-β 
abrogated these effects. In a mouse model of colon carcinoma, Tregs were able to 
abrogate tumour-specific-CD8+ T cell-mediated tumour rejection. This inhibition was 
TGF-β-dependent as tumour-specific CD8 cells expressing dominant-negative TGF-β 
receptors were resistant to suppression (168). Therefore, Tregs acting through TGF-β 
signaling can inhibit anti-tumour immunity.  
 
1.3.3.5. Cytolysis 
Cytolysis mediated by the perforin/granzyme B pathway was originally thought to be 
only used by NK cells and CD8+ T cells to kill target cells. Grossman et al showed that 
Tregs can exhibit cytotoxicity against autologous target cells through the 
perforin/granzyme-dependent pathway (169). In this study, Tregs could kill a variety of 
cells, including CD4+ and CD8+ T cells and immature or mature DCs. Further in vivo 
study showed that perforin/granzyme B were involved in Treg cell-mediated suppression 
of tumour clearance (170). In this model, RMAS lymphoma, B16 melanoma and acute 
myeloid leukemia tumours provoked granzyme B expression in Tregs to induce NK and 
CD8+ T cell death (Figure 1.7). Another study revealed by in vitro cytotoxic assay and 
live microscopy that DCs bearing tumour Ags can be killed by Tregs in tumour-draining  
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Figure 1.7. Suppressive mechanisms of tumour-infiltrating Tregs. Different 
mechanisms are used by intratumoural Tregs to inhibit targeted cells. Surface molecule 
CTLA-4 by binding to CD80/86 can impair DC ability to stimulate T cells and by 
inducing kynurenine production promotes T cell apoptosis. CD39 ectoenzyme by 
generating adenosine from ATP induces T cell inhibition. Two other enzymes, perforin 
and granzyme B, mediate cytolysis.  
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LNs inhibiting effective CD8+ T cell priming (171). This Treg-mediated DC death was 
perforin dependent and involved direct contact between the two populations via MHC 
class II molecules on APCs. 
 
1.3.3.6. Metabolic disruption 
IL-2 
IL-2 is not essential for Treg development in the thymus but is crucial for maintenance of 
these cells in the periphery as observed by the absence of peripheral Tregs in IL-2 
deficient mice (172). Therefore, although Tregs do not produce IL-2, they require this 
cytokine for their survival. IL-2 is also an essential cytokine for T cell activation and 
proliferation. In an in vivo study, Pandiyan et al showed that Tregs can induce IL-2 
deprivation leading to the apoptosis of CD4+ Teff cells  (173).  
Ectoenzymes 
Tregs can suppress through metabolic disruption. The ectoenzymes CD39 and CD73 are 
expressed by Tregs and facilitate production of pericellular adenosine from extracellular 
nucleotides, such as ATP and ADP (Figure 1.3). Importantly, the binding of adenosine to 
adenosine receptors on CD4+ Teff cells inhibits their functions and Tregs from CD39-
null mice are compromised in their ability to suppress T cells (174). Stagg et al showed 
that CD73 expression on Tregs is involved in their pro-tumourigenic effect (175). Treg-
mediated suppression may also include the direct transfer of inhibitory cAMP into CD4+ 
T cells via membrane gap junctions during intercellular communication (176).  
 
1.3.3.7. Effects via APCs 
CTLA-4 
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Direct inhibition of T cells is not the only mode of action used by Tregs as they can also 
directly influence the performance of APCs. Tadokoro et al revealed by intravital 
microscopy that Tregs can attenuate the establishment of stable contact between Ag-
specific T cells and Ag-expressing DCs in LNs in vivo by direct interaction with DCs thus 
preventing T cell activation (177). These imaging data suggest that Treg inhibition takes 
place during the early phase of the immune response (priming) in LNs. Although the 
mechanism involved in this process is not clear, data suggest the involvement of CTLA-
4. Indeed, CTLA-4 expressed in Foxp3+ Tregs has been shown to mediate the down-
regulation of CD80 and CD86 on mature DCs limiting the activation of naive T cells via 
CD28 (Figure 1.3) (178). CTLA-4–deficient mice develop a lethal lymphoproliferative 
disease, indicating the vital role of CTLA-4 as a negative regulator in lymphocyte 
homeostasis (31) 
Early experiments in murine models using anti-CTLA-4 specific Abs have been 
shown to enhance anti-tumour immunity, thus revealing the potential of CTLA-4 as a 
target in cancer therapy (179). This was confirmed with one trial using human anti-
CTLA-4 monoclonal Abs in patients with metastatic melanoma where prolongation in 
overall survival was found (180). Evidence suggests that Tregs may be involved in these 
beneficial effects. Indeed, Tregs lacking CTLA-4 have impaired in vivo and in vitro 
suppressive functions, leading to enhanced tumour immunity (178). While Tregs 
constitutively express CTLA-4, Teff cells only upregulate this co-stimulatory molecule 
after activation in order to attenuate the immune response (181). Peggs et al showed that 
blockade of CTLA-4 on both Teff and Treg cells contributes to the anti-tumour effect of 
administering anti–CTLA-4 Abs (182).  
An explanation for CTLA-4-mediated inhibition was provided by Fallarino et al. 
They showed that Tregs can promote the IDO-mediated catabolism of tryptophan in DCs 
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in a CTLA-4-dependent manner (183). The product of tryptophan catabolism (kynurenin) 
is pro-apoptotic and leads to Teff cell apoptosis (Figure 1.3). Os et al described another 
mechanism in which CTLA-4 can capture CD80 and CD86 from APCs by trans-
endocytosis (184). Subsequently, these ligands were degraded in CTLA-4+ cells 
impairing costimulation by CD28. 
LAG-3 
Lymphocyte-activation gene 3 (LAG-3) is another key molecule involved in direct 
regulation of DCs. This transmembrane protein, with a 30% homology to CD4 (185), was 
observed in mouse to be expressed on activated Tregs with suppressor activity (186). 
LAG-3 is involved in cell-contact interaction between DCs and Tregs by binding 
to MHC class II molecules expressed on immature DCs (187). This interaction induces 
the ITAM-mediated inhibitory signaling pathway which requires FcγRγ and ERK for the 
recruitment of SHP-1 (187). As a result, DC maturation and stimulatory activities are 
inhibited. As LAG-3 was described as a Treg-associated marker in mice, several studies 
aimed at identifying LAG-3+ Treg in human tumours have been conducted. Camisaschi 
et al found that LAG-3-expressing Tregs represent a small population within 
CD4+CD25high (CD25hi) T cells but increased in the peripheral blood mononuclear cells 
(PBMCs) and tumours of melanoma and CRC patients (188). These cells, from PBMCs 
of healthy donors, had enhanced suppressor activity as compared with the LAG-3−/low 
Tregs. A recent study revealed that LAG-3 is not restricted to Foxp3+ Tregs but can be 
expressed in Foxp3- T cells with more potent immunosuppressive activity (138).  
Neuropilin-1 
It has been shown that Nrp-1 expression on Tregs prolongs their interaction with 
immature DCs during Ag recognition in vitro (189). Therefore Nrp-1 molecules promote 
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TCR signaling on Tregs allowing their preferential stimulation over Teff cells of the same 
specificity (189). Moreover, the addition of lipopolysaccharide (LPS) restored the long 
interaction between naïve T cells and DCs suggesting that Nrp-1 provides adhesive 
features on Tregs in the absence of danger signal (such as LPS) in mice. The restored 
interaction between naïve T cells and DCs with LPS was most likely caused by changes 
in DC morphology. However, induction of Nrp-1 expression on naïve T cells was not 
verified.  
Recent work showed that Nrp-1 is involved in the ability of Tregs to inhibit tumour 
immunity (190). Indeed, mice with Nrp1-deficient Tregs exhibit delayed B16 melanoma 
tumour growth, a higher percentage of tumour-infiltrating CD8+ T cells, and increased 
survival compared to those with wild type Tregs. Moreover, blockade of Nrp1 using 
monoclonal Abs in wild type mice promoted anti-tumour immune responses and 
significantly decreased tumour growth. 
GITR 
In order to identify genes encoding unique Treg molecules, a study conducted by McHugh 
et al compared by microarray, gene expression in CD4+CD25- and CD4+CD25+ T cells 
(191). Several genes were found to be overexpressed by CD4+CD25+, suggesting their 
involvement in Treg activity. Among the mRNAs induced at high level in the CD25+ 
subpopulation was that of glucocorticoid-induced tumour necrosis factor-related receptor 
(GITR). GITR, a member of TNF receptor superfamily, is constitutively expressed on 
Foxp3+ Tregs and is also upregulated on CD4+ Teff cells following activation (191). The 
addition of anti-GITR Abs in co-cultures of Treg and Teff cells abrogates the suppressive 
effects of Tregs suggesting that GITR had a vital role in Treg function (191).  
PD-1 
55 
 
Costimulatory interactions between PD-1 receptor and its ligands PD-L1 and PD-L2 are 
crucial for the regulation of immune tolerance. The first role of PD-1 as negative regulator 
of immune responses came from the observation that PD-1-/– mice exhibit lupus-like 
autoimmune diseases (192). PD-1: PD-L interactions mediate peripheral tolerance in 
several ways. After T cell activation PD-1 is upregulated and engagement with its ligands 
on APCs transduces a signal leading to suppression of T cell proliferation (193). PD-1 is 
also expressed at high level by Tregs, suggesting a role for this molecule in Treg function. 
There is no clear data showing PD-1-mediated inhibition by Tregs but as PD-1 ligands 
are expressed by DCs, Tregs may restrain the magnitude of the immune response by 
suppressing DC activity through PD-1 signaling.  
 
1.4. Tumour antigens 
1.4.1. Classification 
1.4.1.1. High tumour specificity 
 
Three classes of Ags with high tumour specificity can stimulate immune response against 
tumour cells: certain viral Ags only expressed in tumour cells, mutated Ags and Ags 
encoded by cancer-germline genes.  
Viral Ag 
Some cancers are attributable to viral infections; 15 % of the worldwide cancer incidence 
(194). Several viruses are associated with human malignancies, including Epstein-Barr 
virus (EBV) and human papillomaviruses (HPVs). As intracellular pathogens, viruses 
encode proteins that interfere with intracellular signalling pathways leading to modified 
cellular activity and tumourigenesis. However, some of the key viral proteins expressed 
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in tumour cells can be recognized by T cells inhibiting tumour growth. For instance, EBV-
specific CTLs have been characterized in the blood and tumours of patients with 
nasopharyngeal carcinoma (195). 
Mutated Ag 
Neo-Ags expressed by tumour cells are derived from oncogenic mutations. These tumour-
specific Ags (TSAs) can be generated after single amino acid changes, due to mutations 
which alter reading frames (neoORFs) or modifications of stop codons. A few studies 
have characterized T cell responses against neo-tumour Ags. For instance, tumour-
infiltrating CD4+ T cells were able to recognize a peptide derived from frameshift 
mutations in TGFβRII in colon cancer patients (196). Even though mutated Ags are 
difficult to use in large-scale vaccination, as mutations are often spontaneous and unique 
to individual tumours, RNA sequencing of tumour and normal tissues is currently being 
used to identify new and potentially more useful targets. In this regard, Schumacher et al 
demonstrated that a vaccine comprising mutated anti-isocitrate dehydrogenase type 1 
could be used as a therapeutic treatment for isocitrate dehydrogenase type 1-mutated 
tumours (197). 
Cancer-testis Ag 
Cancer-germline (or cancer-testis) genes can encode for many T cell Ags expressed by 
tumours, the melanoma-associated Ags (MAGE) family being the first described in 
humans (198). These genes are uniquely expressed in tumours, male germline cells and 
trophoblastic cells after demethylation.  However, the two last cell types do not express 
HLA class I or class II molecules (they are present in immune privileged sites) and 
therefore only cancer germline Ags on tumour cells can be targeted by the immune 
system. These TSAs are expressed by many different tumours, for instance the 
trophoblast glycoprotein 5T4 is expressed on breast, renal and colon cancers (199). 
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1.4.1.2. Low tumour specificity 
Two classes of Ags with low tumour-specificity (also called tumour-associated Ags) have 
been found.   
Differentiation Ag 
Differentiation Ags are encoded by genes expressed in tumour cells and in the normal 
tissues from where the tumours emerged. Such Ags were originally described in 
melanoma patients where CTLs specific for MART1 and GP100 were shown to kill both 
melanoma cells and melanocytes (200). The use of these Ags in immunotherapy can 
stimulate anti-tumour immunity leading to longer progression-free survival (201). 
Overexpressed Ag 
In some cases, tissue Ags can be expressed at lower levels on normal cell types than on 
tumour cells. This overexpression can confer some degree of tumour specificity as T cells 
require strong TCR signalling to be activated. Indeed, some of these Ags can be 
recognised by T cells without causing autoimmunity. In a recent study, Chapuis et al 
injected CTLs specific for the overexpressed Wilms tumour Ag 1 (WT1), after 
hematopoietic cell transplantation, and demonstrated anti-leukemic activity without 
obvious autoreactivity in patients (202).  
 
1.4.2. Tumour antigen-specific Tregs 
The recognition of Ags by Tregs in cancer patients can lead to the suppression of CD4+ 
Teff cell activity (Table 1.1). Wang et al established Treg clones from TILs of melanoma 
patients and found that LAG-1- and ARTC1- (cancer germline Ags) specific Tregs could 
be identified (203) (204). In both studies, Tregs activated by these Ags could inhibit the 
ability of CD4+ Teff cells to secrete IL-2 after recognition of tumour cells. Another study  
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Antigen Antigen feature Treg feature Cancer Ref. 
LAGE-1
108-120
 Cancer germline Ag Secrete IFN- and IL-
10, express GITR, 
cell/cell contact–
dependent suppression, 
isolated from TILs 
Melanoma (203) 
ARTC1 
(15-mer 
peptide) 
Mutated Ag Secrete IFN- and IL-
10, cell/cell contact–
dependent suppression, 
isolated from TILs 
Melanoma (204) 
gp100
369–383
 
TRP-1
449–463
 
Survivin
54–67
 
NY-ESO-1 
Differentiation Ag 
Differentiation Ag 
Overexpressed Ag 
Cancer germline Ag 
Secrete IL-10, cell/cell 
contact–dependent 
suppression, 
proliferation upon Ag 
stimulation, isolated 
from blood 
Metastatic 
melanoma 
(205) 
WT1
333-347
 Overexpressed Ag Th2 cytokine profile, 
secrete granzyme B 
Leukemia (206) 
Telomerase 
CEA 
Mucin-1 
HER2/neu 
EGFR 
Overexpressed Ag 
Differentiation Ag 
Cancer germline Ag 
Overexpressed Ag 
Overexpressed Ag 
Inhibit proliferation of 
Teff cells 
Colon 
cancer 
(207) 
E6, E7 Viral Ag Inhibit proliferation of 
Teff cells 
Cervical 
cancer 
(208) 
EBNA1 Viral Ag Clones express GITR 
and mediate suppression 
in soluble factor–
dependent or cell/cell 
contact dependent 
manners 
/ (209) 
mam
34-48
 Overexpressed Ag Control INF- secretion 
of Ag-specific Teff cells 
after Ag activation 
Breast 
cancer 
(210) 
Table 1.1. Regulatory T cells specificity for tumour antigens. 
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by Vence et al characterized circulating Tregs specific for four different tumour Ags in 
cancer patients without the need to clone TILs (205). It is noteworthy that certain regions 
of one tumour Ag (NY-ESO-1) that contained Treg epitopes also contained many CD4+ 
helper T cell epitopes (211). Tumour Ag-specific Tregs have also been reported in 
leukemia patients (206). These Tregs could produce granzyme B after Ag stimulation and 
selectively induce apoptosis in APCs, but not in leukemia cells, expressing the same 
tumour Ag. In order to characterize Treg specificity in colon cancer, Bonertz et al found 
circulating Tregs specific for a variety of tumour Ags in CRC patients and that in vitro 
depletion of these cells could unmask tumour Ag-specific T cell responses (207).  
Tregs in cancer patients also recognize foreign tumour Ags encoded by tumour 
viruses. Van der Burg et al have demonstrated that HPV-specific Tregs (isolated from LN 
biopsies of cervical cancer patients) suppress both proliferation and cytokine production 
(IFN-γ and IL-2) by CD4+ T cells of various Ag specificities (HIV-1 or influenza derived 
peptides) (208). This capacity required activation by HPV-derived Ags (or anti-CD3 
Abs). Moreover, tumour Ag-specific Tregs can also be identified in healthy donors as 
shown with EBNA1, an EBV latent Ag expressed in all EBV-associated tumours. Tregs 
specific for EBNA1 have been characterized after in vitro peptide stimulation of PBMCs 
from healthy donors with asymptomatic infections (209). These Tregs could recognize 
the same epitopes as CD4+ T cell clones. Tregs activated with these EBNA1-derived Ags 
could suppresses IL-2 production from EBNA1-specific T cells as well as the 
proliferative response of naïve CD4+ T cells to anti-CD3 Ab stimulation.  
Recent progress in peptide-MHC class II tetramer technology has allowed reliable 
analyses of the presence and frequency of tumour Ag-specific Tregs in cancer patients. 
Schmidt et al generated MHC class II molecules presenting a peptide derived from 
mammaglobin, a protein overexpressed in all breast tumours. In breast cancer patients, 
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circulating mam
34-48
-specific Tregs and CD4+CD25- T cells represented 0.2% of their 
respective populations, which was higher than that observed in healthy donors (0.07%). 
1.5. Colorectal Cancer  
1.5.1. Pathways controlling colorectal tumorigenesis 
CRC is the second leading cause of cancer morbidity and mortality worldwide 
(212). The 5-year survival expectation for colon cancer patients ranges from 93% for 
early stages to 8% in fully advanced stages (213). Two kinds of pathways have been 
shown to drive the process of colorectal neoplasia. 85% of CRCs generally develop 
following the ‘traditional’ pathway, also called the chromosomal instability pathway 
(CIN) or ‘suppressor’pathway (214). The ‘traditional’ pathway is associated with 
mutation in oncogenes (such as KRAS) and tumor-suppressor genes (such as APC and 
p53) that directly regulate cell birth and cell death (214). These mutations take place 
within the tumour in a defined sequence (Figure 1.8). CRC is initiated by inactivation of 
the adenomatous polyposis coli (APC) tumour-suppressor pathway. Mutation of APC is 
found in approximately 60% of colon cancers and 82% of rectal cancers (215). The 
intestinal crypt (where the APC-mutant cell is) becomes dysplastic when abnormal cells 
accumulate. This slowly forms a polyp. More mutations (e.g. KRAS oncogene) are 
probably required to develop bigger polyps. Between 10 and 20% of large polyps will 
lead to cancer. The acquisitions of mutations in  genes of other pathways (e.g. p53) is 
required for their development.  
CRC development (from the APC mutation to the metastases) takes between 20 and 
40 years. During this time, genetic instabilities increase. They are an integral component 
of human neoplasia (216). A low percentage of CRC patients (15%) has a genetic 
instability characterized by mismatch repair (MMR) deficiency. This instability was first  
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Genetic instability: MMR deficiency  
Figure 1.8. Pathways to colorectal cancer.  
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found in stretches of repetitive DNA, it was thus named microsatellite instability 
(MSI). 85% of CRC patients do not show a MMR deficiency but have an abnormal 
chromosomal content (aneuploid).  
The CpG Island Methylator Phenotype (CIMP) pathway is the second most 
common pathway to CRCs. 15% of CRCs generally develop following this pathway. The 
CIMP pathway provides the epigenetic instability required for cancers to methylate the 
promoter regions of key tumour suppressor genes. Such hypermethylation leads to the 
inactivation of the expression of these genes (e.g. MLH1). BRAF is another important 
factor in the CIMP pathway as showed with the association of CIMP-positive cancers 
and BRAF mutation in CRC patients (217). The mechanism responsible of this epigenetic 
instability is uncertain. Environmental factors may contribute to colorectal DNA 
methylation in CRC patients (218).  
1.5.2. Tumour infiltrating immune cells 
A number of innate immune cells have anti-tumour effects in CRC. Indeed, in CRC 
patients, extensive intratumoural infiltration of NK cells is associated with a better 
prognosis (219). Similarly, dense macrophage infiltration in tumours has been shown to 
correlate with improved survival (220). The role of unconventional T cells in cancer has 
also been studied. High number of tumour-infiltrating human invariant natural killer T 
(NKT) cells is a favourable prognostic factor in CRC (221). NKT cells share surface 
markers with NK cells, and have a restricted TCR repertoire. Analyses of the tumour 
infiltrate of CRC revealed that γδ T cells, characterized by MHC-unrestricted 
cytotoxicity, can also recognize and kill tumour cells (222).  
TILs play a central role in the anti-tumour immune response and can be used as 
prognostic markers. Galon et al showed that the type, density and location of immune 
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cells within tumours are more predictive of overall survival than the standard 
histopathological methods used to stage CRC (12). In particular, patients with low 
densities of CD3+ T cells and CD45RO+ memory T cells in the centre of the tumour and 
the invasive margin have a very poor prognosis. Consistent with this, human CRCs with 
a high density of infiltrating TEM cells are less likely to disseminate to lymphovascular 
structures and to regional LNs, processes that characterize early steps in the metastatic 
processes (223). Altogether, these data suggest that an immune criterion could be used as 
a biomarker to predict survival in CRC patients following surgery. Pages et al used these 
criteria in stages I and II CRC patients (early-stage tumours) and showed that a high 
density of memory and cytotoxic T cells at the tumour site could predict tumour 
recurrence and survival of these patients (224). This finding was then confirmed with a 
patient cohort encompassing all stages of CRC (225).  
Other T cells of the adaptive immune response have been analysed in human CRC. 
Patients displaying high expression of Th17-related genes in tumoural tissues have a poor 
prognosis and those with an increased expression of Th1 genes have prolonged disease-
free survival (94). In this study, Th2 genes were not predictive of prognosis. However, as 
these helper T cells can have anti- or pro-tumour effect, it will be relevant to stratify the 
results according to tumour stages and the type of cancer (sporadic or colitis-associated 
CRC).  
The role of Tregs in CRC is disputed (226). In one study, a high density of tumour-
infiltrating Foxp3+ Tregs was shown to be associated with improved survival (227). 
However, a study by Sinicrope et al suggests a negative contribution of Foxp3+ TILs in 
CRC as indicated by the association of low CD3+/Foxp3+ ratios and poor clinical 
outcome. These results highlight the need to characterize, for every CRC patient, the type 
of tumour-associated inflammation as this can affect the influence of Treg. For instance, 
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Th17-mediated responses are usually pro-tumoural thus inhibition by RORγt+ Tregs may 
be beneficial. 
 
1.5.3. Immunotherapy in colorectal cancer 
Although 80% of CRC patients have macroscopic clearance of the tumour by surgery, 
50% will relapse because of micrometastasis undetected during surgery (228). Therefore, 
alternative treatments are needed. Better comprehension of interactions between tumour 
and immune cells has made immunotherapy a possible future option for CRC. This active 
therapeutic approach aims to stimulate patients' own T cells in order to trigger a tumour-
specific immune response.  
As DCs can provide the three signals required to induce immunity, several clinical 
trials based on vaccination with tumour Ag-loaded DC have been conducted in CRC 
patients. One of these used DCs pulsed with altered peptide sequences from 
carcinoembryonic antigen (CEA) in an attempt to improve T cell activation (229). Two 
of 12 patients had dramatic tumour regression with CTL recognizing tumour cells 
expressing CEA. Vaccination with irradiated autologous tumour cells, expressing known 
and unidentified tumour Ags, has also been used to treat CRC patients. In one trial, 
autologous tumour cell-BCG vaccination induced clinical benefit in stage II CRC patients 
(230).  
Peptide-based vaccines represent another approach. Even though many target 
tumour Ags have been identified (peptide database available on 
www.cancerimmunity.org/peptide), mouse colon cancer models and clinical trials with 
CRC patients have not led to major clinical benefits. A growing body of evidence indicate 
that peptide-based vaccines not only expand desirable Teff cells, but also detrimental 
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Tregs. Indeed, peptide-based vaccines targeting MAGE-A3 (231), E6/E7 (232) and NY-
ESO-1 (233) have been shown to induce Tregs in melanoma, cervical cancer and 
advanced melanoma cancer patients respectively. Therefore it appears that the choice of 
peptide sequence used in vaccination may be key to eliciting the appropriate T cell 
population. 
1.5.4. 5T4 glycoprotein 
5T4 (also known as trophoblast glycoprotein, TPBG, and Wnt-activated inhibitory factor 
1, WAIF1) is a transmembrane glycoprotein expressed in normal human placental tissues, 
absent in other normal tissues and overexpressed by many carcinomas, e.g. bladder, lung, 
breast, oesophagus, pancreas and colon (199).  
A poorer clinical outcome is observed in CRC patients with 5T4-positive tumours 
(234). A role for 5T4 proteins in invasion processes was therefore proposed. Carsberg et 
al were the first to observe that 5T4 modifies the adhesion and motility of cultured 
epithelial cells (235). Later, Kagermeier-Schenk et al described the intracellular 
mechanism regulated by 5T4 (236). They showed that 5T4 augments activation of the β-
catenin-independent Wnt signaling pathway in zebrafish embryos. Because Wnt signaling 
regulates tumour growth and metastasis (237), it is most likely that 5T4 promotes cancer 
cell invasion by acting on this pathway.  
As an oncofetal Ag, 5T4 is a promising candidate for immunotherapy treatment 
because its expression is restricted to cancer cells. Modified vaccinia Ankara (MVA) 
encoding the entire 5T4 human protein (trade name TroVax) was shown to induce an anti-
tumour immune response in a mouse model of colon cancer (238) and to transiently boost 
5T4-specific immune responses in a phase I/II clinical trial (239). Although this trial 
66 
 
revealed a correlation between the development of an anti-5T4 Ab response and patient 
survival, no long-lived 5T4-specific humoral immunity was observed.  
Some HLA-restricted 5T4 epitopes have been identified (Table 1.2) and using these 
epitopes may be more effective for cancer treatment than the entire protein, as these 
defined peptides may avoid activating undesirable T cells with nontherapeutic activities. 
Four HLA class I-restricted peptides derived from 5T4 have been identified. Redchenko 
et al identified a minimal HLA class I-restricted CD8+ T cell epitope, PLADLSPFA, using 
PBMC from healthy individuals (240). Authors identified HLA-Cw7 as the HLA 
restriction element for this peptide. HLA-Cw7-positive CRC patients vaccinated with 
TroVax showed strong IFN-γ ELISpot responses to this Ag. Similarly, another study 
employing the ex vivo IFN-γ ELISpot assay, identified 3 different 5T4 peptides from CRC 
patients vaccinated with TroVax (241). In this study, LTYVSFRNL peptide was HLA-
A*01-restricted whereas RLARLALVL and FLTGNQLAV peptides were HLA-A*02-
restricted.  
Th cells are crucial for facilitating optimal CTL thus helper epitopes should be 
included in the design of peptide-based vaccines (242). In an attempt to identify 5T4-
helper epitopes in healthy donors, Elkord et al showed that initial depletion of 
CD4+CD25+ Tregs from PBMCs of healthy donors before in vitro stimulation with 
peptides could generate higher frequencies of 5T4-specific CD4+ T cells than observed 
in unmanipulated cultures (243). In this study, the authors also identified the 15-mer 
peptide YVSFRNLTHLESLHL as a CD4+ T cell epitope in HLA-DR4 positive healthy 
individuals. When looking at the reactivity of TILs from a regressing renal cell carcinoma, 
they found that 2 overlapping peptides could stimulate IFN-secretion from CD4+ T cells 
and one of these peptides was HLA-DR-restricted. Similarly, anti-tumour immune  
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Table 1.2. Reported 5T4 peptides 
 
 
 
 
  
Peptide Position HLA Reference 
RLARLALVL 17-25 HLA-A*02 (241) 
FLTGNQLAV 97-105 HLA-A*02 (241) 
PLADLSPFA 153-161 HLA-Cw7 (240) 
LTYVSFRNL 249-257 HLA-A*01 (241) 
YVSFRNLTHLESLHL 254-265 HLA-DR4 (243) 
MADMVTWLK 
ETEVVQGKDR 
LTCAYPEKMRNRV 
302-333 HLA-DR (243) 
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responses to tumour Ags CEA and 5T4 were suppressed in vitro by Tregs in one third of 
a cohort of 62 CRC patients in Cardiff (244). Interestingly, the team in Cardiff I worked 
with also showed that selective reduction in the proportion of circulating Tregs by low-
dose cyclophosphamide corresponded to an increase in anti-5T4 T cell responses in CRC 
patients (245). Therefore, these results suggest that in addition to helper T cells, 5T4 
peptides can be recognized by suppressive Tregs, which may impair vaccine efficacy. 
 
 1.6. Summary 
The CD4+ T cell population is made of distinct subsets, each characterised by 
specific transcription factors and cytokine signatures. Their impact on the immune 
response, and on tumour immunity in particular, is also very different. Th1 cells promote 
induction of cellular immunity and have direct anti-tumour functions. They are involved 
in cancer immunosurveillance by clearing tumours before clinical manifestation and 
vaccines aim at stimulate these cells to induce their anti-tumour activity. In contrast, Tregs 
can inhibit host immune responses against tumours and support tumour escape. Although 
an accumulation of CD4+CD25hi Tregs has been observed in CRC patients, their precise 
phenotype has not been reported. Furthermore, the oncofoetal Ag 5T4 is overexpressed 
by a wide variety of human cancers including CRC. Although the entire 5T4 protein is 
immunogenic in CRC patients, only a few 5T4 peptide Ags recognised by CTLs and Th1 
cells have been reported. As Tregs can control responses to 5T4 protein, they are likely 
to recognise specific 5T4 Ags. Therefore, defining Th1 and Treg cells specificity for 5T4 
may profoundly help to design more effective vaccines.  
The experiments described in this thesis were performed with the following hypotheses:   
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1. CD25hi Tregs, enriched in tumour tissues of CRC patients with a distinctive 
immunosuppressive phenotype, may contribute to CRC progression.  
2. 5T4-specific responses are under the control of Tregs in CRC patients. 
3. Specific regions and peptides are more immunogenic than others within 5T4 
protein. 
4. Th1 and Treg cells may recognise the same or different 5T4 peptides in CRC 
patients 
 
1.7. Objectives 
Experiments described in this thesis were performed to fulfil the following objectives:  
1. To define the phenotype of CD4+CD25hi cells isolated from the blood, normal and 
tumour colon of CRC patients. 
2. To analyse the effect of Treg-depletion on 5T4-specific responses. 
3. To map immunogenic regions within 5T4 protein. 
4. To evaluate the frequency of 5T4 peptide-specific Th1 and Treg cells in the blood 
of healthy donors and CRC patients. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1. Patients 
Patients were consented before surgery in order to obtain colorectal tumour and healthy 
colon specimens as well as 30 mls of blood (see Appendix section for a copy of Patient 
Information Sheet and Consent form). HLA type was determined, if possible, from blood 
samples (Welsh Transplantation and Immunogenetics Laboratory, Pontyclun, Cardiff). In 
total, a cohort of 64 CRC patients was enrolled in this study. Lymphocyte analysis was 
performed in 30 of these patients (patient characteristics summarized in Table 2.1) and 
cultured T cell responses were analysed in 34 of these patients (patient characteristics 
summarized in Table 2.2). A number of blood and tumour samples were analysed from 
same patients. The Bro Taf Local Research Ethics Committee granted ethical approval 
for this study.   
 
2.2. Patient specimens 
Within 1 hour after resection, CRC specimens were taken to the pathology department 
for analysis. Autologous colon samples were cut from a normal section of the tissue, 
approximately 10 cm from neoplastic tissue. Small tumour samples were also resected 
from the specimen. After dissection, healthy and tumour samples were taken to the lab 
for further analysis.  
Consultant pathologists at the University Hospital of Wales carried out staging of 
the resected colorectal cancers. Two staging systems were used to define the extent of 
tumour invasion: Dukes’ classification and the international TNM system.  
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Table 2.1. CRC patient characteristics whose lymphocytes were analysed by FACS. 
 
  
  Male Female 
n  24 6 
Age range  33-87 67-81 
TNM Stage, 5
th
 Edition (%) T1 2 (8) 0 (0) 
 T2 4 (17) 2 (33) 
 T3 10 (42) 2 (33) 
 T4 8 (33) 2 (33) 
Lymph Node Spread N0 15 (62) 5 (83) 
 N1 4 (17) 0 (0) 
 N2 5 (21) 1 (17) 
Dukes’ Stage (%) A 4 (17) 2 (33) 
 B 11 (46) 3 (50) 
 C1 9 (37) 1 (17) 
 C2 0 (0) 0 (0) 
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Table 2.2. CRC patient characteristics whose T cell specificity for 5T4 has been 
analysed.  
  Male Female 
n  21 13 
Age range  33-84 47-84 
TNM Stage, 5
th
 Edition (%) T1 2 (10) 1 (8) 
 T2 3 (14) 3 (23) 
 T3 11 (52) 4 (31) 
 T4 5 (24) 5 (38) 
Lymph Node Spread N0 11 (52) 8 (62) 
 N1 6 (29) 3 (23) 
 N2 4 (19) 2 (15) 
Dukes’ Stage (%) A 3 (14) 4 (31) 
 B 8 (38) 4 (31) 
 C1 10 (48) 5 (38) 
 C2 0 (0) 0 (0) 
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Dukes’ classification: 
Dukes’ A: Tumour is confined to the bowel wall. 
Dukes’ B: Tumour go through the bowel wall without lymph nodes involved. 
Dukes’ C1: Tumour extent into the muscularis propria with less than 4 lymph nodes 
involved. 
Dukes’ C2: Tumour completely penetrate the muscularis propria with more than 4 lymph 
nodes involved.  
TNM system: 
T refers to the depth the tumour has penetrated the colon wall: 
T1: Tumour is ≤ 2 cm across. 
T2: Tumour is > 2 cm and ≤ 5 cm across. 
T3: Tumour is > 5 cm across. 
T4: Tumour of any size growing into adjacent tissues. 
N refers to the lymph node involvement: 
N0: Tumour has not spread to regional lymph nodes. 
N1: Tumour has spread to 1 to 3 axillary lymph nodes. 
N2: Tumour has spread to more than 4 lymph nodes. 
M refers to the metastases: 
M0: no metastatic spread. 
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M1: Distant metastases. 
 
2.3. Healthy donors 
Blood was taken from healthy individuals with no history or clinical evidence of 
malignancy. All individuals were consented before giving blood. Blood was collected 
into heparinized tubes.  
 
2.4. Purification of human lymphocytes  
PBMCs were isolated by Ficoll-Hypaque gradient centrifugation. Whole blood was 
layered over lymphoprep (Axis-Shiled, Oslo, Norway) and centrifuged at 2000 rpm for 
20 min at 25o C. PBMCs were recovered from the interface using a Pasteur pipette and 
washed twice in R+ (RPMI-1640 containing Pen-Strep, L-glutamine and sodium 
pyruvate). Then, they were diluted 1:1 with Trypan blue and counted using a 
haemocytometer.  
 
2.5. Single cell suspensions from tissues 
Healthy colon and tumour tissue samples were mashed with blades in a Petri dish and 
forced through 70 µm cell strainers using syringe plungers. Strainers were changed when 
clogged.  When a single cell suspension was achieved, cells were washed twice in 10 mls 
of extraction media (IMDM containing 2 % AB serum, 20 µg/ml gentamicin, 2 µg/ml 
fungizone and Pen-Strep) and plated for further analyses. In order to preserve the integrity 
of the cells, no enzymatic digestion with collagenase and DNase was used.  
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2.6. Depletion of CD25+ regulatory T cells 
PBMCs were resuspended in MACS buffer (1×PBS, 0.5% bovine serum albumin, 5 mM 
EDTA), with 80 µl MACS buffer per 107 cells, and anti-human CD25 coated beads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) were added, with 20 µl of CD25 coated 
beads per 107 cells. Then, cells were incubated for 15 minutes at 4oC, washed and 
resuspended in 500 µl of MACS buffer. MS columns were used for positive selection and 
effluent CD25hi-depleted and labelled CD25hi cells were collected. The efficacy of 
depletion confirmed by flow cytometry. Cells were washed twice with R+ before use. 
Assays were set up using either undepleted or CD25hi-depleted cells.   
 
2.7. Generation and culture of human T cell lines 
Isolated PBMCs or CD25hi-depleted fractions were washed in R+ then resuspended at 
2x106/ml in advanced RPMI supplemented with 5% AB serum (R5). Cells were plated at 
100 µl / well in 96 well plates, i.e. 2 x 105/ well. Three PBMC lines were established for 
each 5T4 peptide pool or 5T4 single peptide and plates were kept in incubator (37oC, 5% 
CO2) for 12-14 days. Recall Ags Tetanus Toxoid TT (Statens Serum Institut) or tuberculin 
purified protein derivative PPD (Statens Serum Institut) and PHA were also used. In order 
to enrich Ag-specific T cells, 10 µl of CellKine media (Helvetica Healthcare) was added 
on day 3 and 100 µl of R5 containing 40 IU/ml IL-2 (therefore at 20 IU/ml final 
concentration) was added on day 6. On day 9, 100 µl of culture supernatant was removed 
and 100 µl of R5 containing 40 IU/ml IL-2 was added. 
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2.8. 5T4 antigens 
20-mer peptides overlapping by 10 amino acids and spanning the entire 5T4 protein were 
synthesized with purity > 95% (GLBiochem, Shanghai, China).  The sequence of 5T4 
protein is shown Figure 2.1. A total of 41 peptides were used to generate peptide pools 
(Table 2.3). Peptides were dissolved in DMSO at 50 mg/ml and diluted in PBS at 1 mg/ml. 
13 peptide pools were created in a matrix system where 1 peptide was present in 2 pools 
(Table 2.4). Each peptide pool contained 5-7 peptides. Peptides were added at a final 
concentration of 5 µg/ml/peptide for T cell assays, so the total concentration of peptide 
was between 25 and 35 µg/ml. 
 
2.9. IFN-ELISpot assays  
ELISpot plates (Millipore, Moslheim, France) were coated with 50 µl of anti-human IFN-
γ capture Ab (Mabtech, Natka, Sweden) and left at 4oC overnight. Wells were extensively 
washed four times with 150 µl of PBS to remove excess Ab and 100 µl of R5 was added 
for 1h at 37oC in order to block the wells. The R5 was removed before adding cells. The 
short term lines cultured in triplicate were pooled, washed and resuspended at 5x105 / ml 
in R5. 150 µl (75 000 cells) were plated per well in the absence or presence of the 
corresponding 5T4 peptide pool or single peptide. The plates were subsequently 
incubated for 18 hours (37oC, 5% CO2).  
Following overnight incubation, cells were removed, plates were washed 5 times 
with 150 µl of PBS and 50 µl of secondary biotinylated anti-human IFN-γ Ab was added 
for 1 hour (37oC, 5% CO2). Wells were washed 4 times with PBS followed by the addition 
of 50 µl streptavidin-alkaline phosphatase (Mabtech, Sweden) diluted at 1:1000. After 1 
hour incubation at room temperature, wells were washed 4 times with PBS and  
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MPGGCSRGPA   AGDGRLRLAR    LALVLLGWVS     SSSPTSSASS    FSSSAPFLAS  
 
AVSAQPPLPD  QCPALCECSE  AARTVKCVNR   NLTEVPTDLP      AYVRNLFLTG  
 
NQLAVLPAGA   FARRPPLAEL   AALNLSGSRL   DEVRAGAFEH    LPSLRQLDLS  
 
HNPLADLSPF   AFSGSNASVS     APSPLVELIL     NHIVPPEDER      QNRSFEGMVV  
 
AALLAGRALQ  GLRRLELASN   HFLYLPRDVL    AQLPSLRHLD     LSNNSLVSLT  
 
YVSFRNLTHL  ESLHLEDNAL   KVLHNGTLAE   LQGLPHIRVF    LDNNPWVCDC  
 
HMADMVTWLK ETEVVQGKDR LTCAYPEKMR NRVLLELNSA     DLDCDPILPP 
 
SLQTSYVFLG IVLALIGAIF   LLVLYLNRKG    IKKWMHNIRD     ACRDHMEGYH  
 
YRYEINADPR     LTNLSSNSDV 
Figure 2.1. Amino acid sequence of 5T4 protein.  
  
60 70 80 90 100 
110 120 130 140 150 
160 170 180 190 200 
210 220 230 240 250 
260 270 280 290 300 
310 320 330 340 350 
360 370 380 390 400 
410 420 
10 20 30 40 50 
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Table 2.3. 20-mer 5T4 sequences.  
No. Sequence No. Sequence 
1 MPGGCSRGPAAGDGRLRLAR 21 AALLAGRALQGLRRLELASN 
2 AGDGRLRLARLALVLLGWVS 22 GLRRLELASNHFLYLPRDVL 
3 LALVLLGWVSSSSPTSSASS 23 HFLYLPRDVLAQLPSLRHLD 
4 SSSPTSSASSFSSSAPFLAS 24 AQLPSLRHLDLSNNSLVSLT 
5 FSSSAPFLASAVSAQPPLPD 25 LSNNSLVSLTYVSFRNLTHL 
6 AVSAQPPLPDQCPALCECSE 26 YVSFRNLTHLESLHLEDNAL 
7 QCPALCECSEAARTVKCVNR 27 ESLHLEDNALKVLHNGTLAE 
8 AARTVKCVNRNLTEVPTDLP 28 KVLHNGTLAELQGLPHIRVF 
9 NLTEVPTDLPAYVRNLFLTG 29 LQGLPHIRVFLDNNPWVCDC 
10 AYVRNLFLTGNQLAVLPAGA 30 LDNNPWVCDCHMADMVTWLK 
11 NQLAVLPAGAFARRPPLAEL 31 HMADMVTWLKETEVVQGKDR 
12 FARRPPLAELAALNLSGSRL 32 ETEVVQGKDRLTCAYPEKMR 
13 AALNLSGSRLDEVRAGAFEH 33 LTCAYPEKMRNRVLLELNSA 
14 DEVRAGAFEHLPSLRQLDLS 34 NRVLLELNSADLDCDPILPP 
15 LPSLRQLDLSHNPLADLSPF 35 DLDCDPILPPSLQTSYVFLG 
16 HNPLADLSPFAFSGSNASVS 36 SLQTSYVFLGIVLALIGAIF 
17 AFSGSNASVSAPSPLVELIL 37 IVLALIGAIFLLVLYLNRKG 
18 APSPLVELILNHIVPPEDER 38 LLVLYLNRKGIKKWMHNIRD 
19 NHIVPPEDERQNRSFEGMVV 39 IKKWMHNIRDACRDHMEGYH 
20 QNRSFEGMVVAALLAGRALQ 40 ACRDHMEGYHYRYEINADPR 
  41 YRYEINADPRLTNLSSNSDV 
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Table 2.4. 5T4 matrix. Numbers in bold indicate the pools (1 to 13) containing 7 (pools 
1 to 6) or 6 (pools 7 to 13) peptides. 
  
1 2 3 4 5 6  
1 2 3 4 5 6 7 
7 8 9 10 11 12 8 
13 14 15 16 17 18 9 
19 20 21 22 23 24 10 
25 26 27 28 29 30 11 
31 32 33 34 35 36 12 
37 38 39 40 41   13 
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spots were developed by the addition of a colorimetric substrate kit (Bio-rad, Hercules, 
California) consisting of 5% AP development buffer, 1% of substrate A and B in dH2O. 
100 µl of this substrate kit was added into each well and left for 15 minutes at room 
temperature. To stop the reaction, wells were washed with tap water. After drying the 
wells, IFN- spots were counted using an automated reader (Autoimmun Diagnostika 
GMBH, A.I.D., Strasberg, Germany). Counting was checked manually by using the 
ELISpot 5.0 software. The number of spots was normalized to x /105 cultured PBMCs. 
Positive cultured responses were identified as having at least 25 spot forming cells (SFC) 
per 105 cultured PBMC, after subtraction of the background, and as having double 
background.  
 
2.10. EBV-transformed B cell assays 
In order to determine which of the DR serotypes were responsible for Ag presentation, 
HLA-DR matched EBV-transformed B cells were used as Ag-presenting cells to 
stimulate 5T4-expanded T cells. HOM2 and HO104, respectively homozygous for HLA-
DR*0101 and HLA-DR*1501, were bought from Public Health England. EBV-
transformed B cells were incubated overnight with 5T4 peptides (37oC, 5% CO2) in R5, 
washed 4 times and added at a 1:1 ratio to 5T4-expanded T cells in an ELISpot assay. 
After 6 hours of stimulation in R5, IFN- spots were revealed as described above.  
 
2.11. Antibody blocking assays 
To determine whether T cells recognition of 5T4 peptide was HLA-DR restricted, IFN-γ 
secretion was measured in ELISpot assays in the absence or presence of blocking Abs. 
10 µg/ml of anti-class I (clone w6/32, Biolegend), anti-DQ (clone 1a3, Leinco) and/or 
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anti-DR (clone L243, Biolegend) Abs were added to 5T4-expanded T cells in ELISpot 
assays. 5T4 peptides were added after incubation at room temperature for 1h.  
 
2.12. Antibody staining 
2x106 cells were initially stained for viability with aqua amine-reactive viability dye 
(Invitrogen). The cells were washed twice with PBS and stained with the viability marker 
previously diluted at 1:10 in PBS. After 15 minutes at room temperature in the dark, cells 
were washed twice with fluorescence activated cell sorting (FACS) buffer and 
resuspended in 50 µl FACS buffer for cell surface staining. Several combinations of anti-
human Abs were used to stain the cells (Table 2.5). Staining was performed at 4oC for 15 
minutes.  
After two washes with FACS buffer, cell membranes were permeabilized using 
Fixation/Permeabilization kit (eBioscience) according to the manufactures’ instructions. 
Before intracellular staining, cells were left in the fridge for 15 minutes in 
Permeabilization buffer containing 2% rat serum in order to block Fc receptors. Abs 
specific for various intracellular markers were added and cells were incubated in the dark 
at 4oC (Table 2.6). Then cells were rinsed in 1X Perm buffer and fixed in PBS containing 
1% paraformaldehyde (Sigma-Aldrich). Stained cells were kept in the dark at 4oC for a 
maximum of 1 hour before acquisition on a BD FACSCanto II. Representative flow 
cytometry plots in the CD4+CD25-, CD25int and CD25hi populations are shown (Figure 
2.2). Gates were drawn based on fluorescence-minus-one (FMO) controls (Appendix 
Figure 1). 
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Table 2.5. Human antibodies used for cell surface staining. 
 
 
  
Antigen Conjugate Clone Company Final conc. 
(μg / mL) 
CD4 Pacific Blue RPA-T4 BD 2 
CD25 APCh7 M-A251 BD 6 
CD39 PECy7 eBioA1 eBioscience 3 
CD45RA PerCPCy5.5 HI100 eBioscience 3 
CD45RO FITC UCHL1 BD 3 
CD127 PECy7 eBioRDR5 eBioscience 3 
HLA-DR PECy7 L243 BioLegend 2 
ICOS FITC C398.4A BioLegend 4 
ICOS PerCPCy5.5 C398.4A BioLegend 4 
LAG-3 PE Polyclonal R&D Systems 4 
LAP PerCPCy5.5 TW4-2F8 BioLegend 4 
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Table 2.6. Human antibodies used for intracellular staining.  
 
 
 
 
 
  
Antigen Conjugate Clone Company Final conc. 
(μg / mL) 
CTLA-4 PE BNI3 BD 2 
Helios FITC 22F6 BioLegend 2 
Foxp3 APC 236A/E7 eBioscience 6 
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2.13. Statistics and graphical analysis 
GraphPad Prism Version 5 was used for all statistical analyses. Mean values ± 95 % 
confidence interval were used for all appropriate results. Unpaired t-tests were used to 
analyse quantitative differences between different groups of CRC patients or when 
comparing healthy donors and CRC patients. FlowJo version 10 was used to analyse flow 
cytometry data. 
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Figure 2.2. Representative flow cytometry plots. The expression of the indicated 
markers in the different CD25 populations is shown.  
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Figure 2.2. Representative flow cytometry plots. The expression of the indicated 
markers in the different CD25 populations is shown.  
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CHAPTER 3. ANALYSIS OF HUMAN 
REGULATORY T CELLS PHENOTYPE 
3.1. Introduction 
Colorectal cancer is the third most common cancer in the world, with more than 1 million 
individuals diagnosed every year (246). Recently, immunotherapy treatments have been 
developed as active therapeutic approaches. Although tumour-specific responses are 
detected, these effects do not lead, in the vast majority, into improved clinical status. 
Several mechanisms may account for this limited therapeutic efficacy. In CRC patients, 
one particular cell type, named Tregs, expressing the transcription factor Foxp3, can 
suppress anti-tumour immune responses (247). In addition, studies have shown that 
cancer vaccines can induce tumour-specific regulatory T cells (248). Thus, it is likely that 
Tregs play a central role in the efficacy of tumour vaccines.   
In contrast to mice where CD4+CD25+ cells are highly suppressive, the CD25 
marker in human does not represent a homogenous population (249). The discovery of 
Foxp3 as a crucial gene for CD4+ Treg development and function confirmed initial 
findings showing that human CD4+CD25hi T cells are highly enriched for Tregs (250). 
However, the use of Foxp3 expression to define Tregs should be used in conjunction with 
CD25hi cells, as Foxp3 can be transiently expressed on activated CD4+CD25int T cells, 
without conferring suppressive activity (251). Indeed, unlike CD4+CD25hi T cells, FACS-
sorted CD4+CD25int cells do not inhibit the proliferation of co-cultured CD4+ CD25− cells 
(249). 
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Increased numbers of CD25hi Treg cells have been found in the peripheral blood of 
patients with different types of cancer, such as CRC patients (247), prostate cancer 
patients (252) and patients with multiple myeloma (253). Also, the phenotype of tumour-
infiltrating Tregs has been investigated in cancers. In renal cell carcinoma patients, 
intratumoural CD25hi Tregs were found to have marked changes in their phenotype in 
comparison to the circulating Tregs (254). In CRC, no studies have examined the 
phenotype of CD4+CD25hi T cells. In order to better understand how colorectal cancers 
evade tumour immunity, a detailed comparative phenotypic analyses of Treg populations 
was performed in healthy donors and CRC patients. 
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3.2. Results 
3.2.1. Gating strategy to identify CD25hi cells 
In humans, the CD4+CD25+ population is not clearly distinguishable from CD25- cells 
and instead a gradation of expression is observed. Therefore, defined parameters must be 
applied when gating on the CD4+CD25hi Treg population. Previous works in our group 
and from others have attempted to define these parameters (247) (255). In this study, total 
lymphocytes, identified according to their SSC/FCS and live cells were gated based on 
negative Aqua Live/Dead expression (Figure 3.1). Following gating on CD4+ cells, 
CD25hi or intermediate cells were identified as those where CD25 expression was higher 
than observed on CD4- cells (indicated by the dashed line). 
 
3.2.2. CD25hi T cells exhibit a “classic” Treg phenotype 
As mentioned above, Tregs cells do not represent a distinct CD25 population and other 
markers have to be included in their analyses. Expression of naïve (CD45RA) and 
memory (CD45RO) markers was analysed in the CD25 populations (Figure 3.2). 
CD45RO was expressed on a significantly higher proportion of CD25hi cells (85.14% ± 
5.47) compared to CD25int (58.36% ± 12.4) and CD25- cells (44.42% ± 17.85). Its 
reciprocal marker, CD45RA, showed the opposite expression profile. Indeed, CD45RA 
was predominantly expressed by CD25- cells (62.36% ± 15.1), compared to less than 40% 
of CD25int cells. Only a few CD25hi cells expressed CD45RA (12.08% ± 9.65). These 
data are consistent with an enrichment of naïve cells within the CD25- population rather 
than Ag-experienced cells as observed within the CD25+ population. The data also 
confirm that the vast majority of circulating Tregs are of an activated/memory phenotype, 
as observed in previous studies (249).   
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Figure 3.1. Gating strategy to identify T regulatory cells. Lymphocytes were identified 
based on forward and side scatter characteristics. Then, live cells were gated based on 
negative Aqua Live/Dead staining. CD4+CD25hi cells were identified as those expressing 
CD25 at a level higher than observed on CD4- cells (represented by dashed lines). Finally, 
CD4+ cells were gated from the live cells and the same gates previously determined were 
applied to distinguish the three CD25 populations.   
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Figure 3.2. CD4+CD25hi cells have a memory phenotype. PBMC isolated from 
peripheral blood of CRC patients were stained with live/dead, anti-CD4, anti-CD25, anti-
CD45RO and RA Abs. Percentage of CD4+CD45RO+ and CD4+CDRA+ T cells within 
each of the three CD25 populations is indicated. Representative FACS plots are shown. 
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Liu et al have shown that “true” Tregs do not require IL-7 for survival and 
predominantly exhibit a CD127-/low phenotype (256). CD127 expression was compared 
in the CD25 populations described herein (Figure 3.3). Over 85% of CD25hi cells within 
the CD4 population were CD127-/low, approximately 40% in the CD25int population 
whereas the majority of CD25- cells were CD127+. Altogether, these data indicate that the 
CD25hi population identified has a “classic” Treg phenotype, thus validating the gating 
strategy used.  
 
3.2.3. Treg identification in blood and colon tissues. 
In order to characterise the Treg phenotype in cancer, freshly resected uninfected colon 
and tumour tissues from CRC patients were mashed, filtered and stained for several 
markers. This ex vivo analyses allowed an accurate determination of the phenotype as 
tissue-infiltrating Tregs may upregulate or downregulate proteins during in vitro 
incubation. In parallel, when possible, PBMCs were isolated from matched peripheral 
blood samples and stained for the same markers. One representative FACS plot is given 
in Figure 3.4. The percentage of live cells was lower in the colon (68%) and in the tumour 
(28%) tissues than in the blood (96%). It is likely that some cells died during the isolation 
process but presence of dying cells (especially from the tumour) is also a likely 
contributing factor. Following the gating strategy described above, CD25hi Tregs were 
identified within the CD4 population in blood, colon and tumour samples. 
 
3.2.4. Foxp3 expression in peripheral and tissue-infiltrating cells 
The transcription factor Foxp3 was originally thought to be a specific Treg marker. 
However, CD25int T cells can upregulate this factor following activation. In order to  
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Figure 3.3. Expression of CD127 in CD25 populations. Cells were gated on live CD4+ 
circulating cells from CRC patients and then gated on the indicated CD25+ population. 
FACS plots depicting CD127 staining are shown as representative examples. Significant 
differences are indicated, ***p < 0.001 (Student’s unpaired t test). 
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Figure 3.4. Ex vivo phenotype of Tregs in CRC patients. Representative FACS plots 
showing CD25 staining on live cells in the peripheral blood, healthy colon and tumour 
tissues of one CRC patients. Numbers are the percentage of cells in the indicated gates.  
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verify that the CD4+CD25hi T cells correspond to a homogenous Foxp3+ population, the 
expression of this marker was assessed in the three CD25 subpopulations present in the 
live CD4+ population (Figure 3.5.A). In the 25 CRC patients studied, over 85% of 
circulating CD4+CD25hi T cells expressed Foxp3 whilst 40% of CD25int expressed this 
marker (Figure 3.5.B). Negligible Foxp3 expression was observed in CD25- cells. This 
pattern was the same in CD25hi cells infiltrating unaffected and tumour colon tissues. This 
predominance of Foxp3 expression in CD4+CD25hi cells is in accordance with other 
reports (244) and is in line with previous observations showing that these cells are 
CD45RO+ and CD127-/low.  
It has been shown that Foxp3 expression correlates with immunosuppressive 
function (257). Thus the level of Foxp3 expression was determined by calculating the 
mean fluorescence intensity (MFI) of Foxp3 in the different CD25 populations (Figure 
3.6). The level of Foxp3 expression was significantly higher in CD25hi cells compared to 
the CD25int population (CD25hi 4985 ± 667 vs. CD25int 1338 ± 510, p < 0.0001). Also, 
the few cells expressing Foxp3 in the CD25- population exhibited relatively reduced 
expression levels (CD25- 552 ± 180 vs. CD25int 1338 ± 510, p = 0.0040). 
 
3.2.5. Tregs are enriched in blood and tumour of CRC patients  
Tregs in PBMCs isolated from peripheral blood of healthy controls and CRC patients 
were analysed by flow cytometry. Frequencies of CD4+CD25hi T cells among CD4+ T 
cells were increased in the CRC patients (patients 4.64 ± 1.06 vs. controls 1.56% ± 0.79, 
p = 0.0138; Figure 3.7.A). Next, the proportion of Tregs infiltrating the colon of CRC 
patients was analysed. There was a higher percentage of CD4+ T cells expressing high 
levels of CD25 in tumours compared to benign colon tissues (tumour 17.39% ± 3.42 vs. 
colon 7.02% ± 3.99%, p = 0.0006). Also, this percentage was higher than the frequency 
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Figure 3.5. Foxp3 expression in the three CD25 populations in CRC patients.  A. 
Representative FACS plots showing Foxp3 expression in CD4+CD25-, CD25int and 
CD25hi cells. B. Percentage of cells expressing Foxp3 in the indicated CD25 population 
in blood (n = 25), unaffected colon (n =9) and tumour tissues (n = 19) of CRC patients. 
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Figure 3.6. Analyse of Foxp3 expression level in CD25 populations. Mean fluorescence 
intensity (MFI) of Foxp3 in the indicated cells. PBMCs were isolated from CRC patients 
and stained with live/dead, anti-CD4, anti-CD25 and anti-Foxp3 Abs. 
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of Tregs in the blood of CRC patients (blood vs. tumour, p < 0.0001). These data are in 
line with numerous reports showing that Tregs accumulate in human carcinomas (252).  
Increased levels of suppressive Tregs, defined as CD4+CD25hi T cells, have been 
reported in the peripheral blood of patients with CRC or with head and neck squamous 
cell carcinomas (247, 258). The frequency of CD25hi T cells in the CD4 population was 
next compared in CRC patients with different tumour stages (Figure 3.7.B). Patients with 
Dukes C cancers had a significantly elevated peripheral level of these cells in comparison 
to those with Dukes A cancers (Dukes C 6.04% ± 1.67 vs. Dukes A 2.62% ± 1.07, p = 
0.0046). Similarly, patients with T3 tumour stage had an increased frequency of 
circulating CD4+CD25hi T cells (T3 5.25% ± 1.96 vs. T2 2.60% ± 1.07, p = 0.0406). 
Noteworthy, patients with Dukes B /C and T3/4 tumour stage had higher percentage of 
circulating Tregs than observed in healthy donors.  
In order to better characterise the role of Tregs in tumours, frequencies of 
intratumoural CD4+CD25hi cells were compared between patients of different Dukes 
stages (Figure 3.8). Late stage Dukes C tumours were found to have a significant 
enrichment of Tregs compared to Dukes A (Dukes C 23.88% ± 5.17 vs. Dukes A 13.90% 
± 11.06, p = 0.031) and B tumours (Dukes C 23.88% ± 5.17 vs. Dukes B 15.55% ± 4.78, 
p = 0.0253). These data show that proportions of tumour infiltrating Tregs increase with 
tumour progression in CRC patients. 
 
3.2.6. Thymus-derived Tregs predominate in colorectal tumours 
It has been suggested that two groups of Tregs with different origins can be 
distinguished based on expression of the transcription factors Helios; the Helios+ thymus-
derived Tregs (tTregs) and the Helios- peripherally induced Tregs (pTregs) (133). Over   
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Figure 3.8. Frequency of tumour infiltrating Tregs according to Dukes stages.  
Percentage of CD4+CD25hi T cells in the tumours of patients with Dukes A, B and C 
cancers. T cells were isolated from tumours of CRC patients and stained ex vivo for FACS 
analyses. Significant differences are indicated, *p < 0.05 (Student’s unpaired t test). 
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70% of circulating CD25hi cells in healthy donors expressed Helios (Figure 3.9.A) as 
described in the original report detailing Helios expression in CD4+Foxp3+ cells (133). 
Approximately the same percentage of cells was found to be Helios+ in the blood of CRC 
patients. Therefore, most of the circulating Tregs are of a thymic origin. Helios expression 
was then investigated in tissue infiltrating Tregs. There was a significant decrease of 
CD4+CD25hi cells expressing Helios in unaffected colon tissues compared to the blood 
of CRC patients (colon 46.94% ± 9.79 vs. blood 73.22% ± 3.68, p < 0.0001). Also, even 
though the majority of intratumoural Tregs expressed Helios, this fraction was 
significantly decreased compared to the blood (tumour 63.47% ± 7.52 vs. blood 73.22% 
± 3.68, p = 0.0130). Overall, these data suggest the conversion of naïve T cells into Tregs 
does not play a significant role in the enrichment of Tregs observed in tumours. Instead, 
the recruitment and expansion of thymus derived Tregs (tTregs) appears to be the main 
reason for Treg accumulation in tumours. In line with these results, our group has shown 
previously in a mouse model of carcinogen-induced tumours that Tregs and conventional 
T cells do not share the same TCR repertoires (259). The increased number of Helios- 
Tregs in unaffected colon is consistent with the increased frequency of Neuropilin-1- 
Tregs observed in this tissue by other groups and indicates that the gut is a site where 
peripherally induced Tregs (pTregs) accumulate (260).   
As Helios reflects the Treg pool that emerged from the thymus, thymic involution 
may affect the frequency of Treg cells expressing Helios. Consistent with this hypothesis, 
there was an inverse correlation between Helios expression on CD25hi cells in blood and 
the age of the CRC patients (p = 0.0328, R2 = 0.41; Figure 3.9.B). 
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Figure 3.9. Helios expression in CD4+CD25hi cells. A. Intracellular Helios staining was 
performed on CD25- and CD25hi cells within the CD4 population of PBMCs and tissue-
infiltrating cells. B. Linear regression comparing the percentage of peripheral CD25hi T 
cells expressing Helios with the age of the CRC patients. 
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3.2.7. High frequencies of CD25hi cells express MHC-DR 
molecules 
CD4+ T cells upregulate expression of MHC class II molecules after activation. 
Considered to be late T cell activation markers, these molecules are also functional and 
can be used to present peptides to other T cells (261). Moreover, studies have shown that 
MHC class II expression on CD4+CD25hi T cells defines a population of highly 
proliferative activated Tregs acting through early contact-dependent inhibition (262). We 
therefore investigated MHC class II expression on Tregs in CRC patients.  
The majority of peripheral CD25hi cells within the CD4 population expressed HLA-
DR molecules as opposed to CD25- cells, which did not (CD25hi 53.92% ± 22.49 vs. 
CD25- 5.96% ± 3.73, p = 0.0004; Figure 3.10.A). The same was observed with unaffected 
and colorectal tumour-infiltrating Tregs. Thus, the proportion of activated Tregs is similar 
in peripheral blood and tumours. 
It is noteworthy that compared to peripheral blood more CD25- cells expressed 
HLA-DR in colon tissues (healthy and malignant) indicating a differential expression of 
activation markers in these tissues. Furthermore, about 30% of CD25int cells expressed 
HLA-DR in the three different samples suggesting that this fraction contains a 
heterogeneous population of cells expressing early (CD25) and/or late activation markers  
(Figure 3.10.B).  
 
3.2.8. Intratumoural Tregs overexpress ICOS and CTLA-4 
Inducible co-stimulator (ICOS) protein is structurally and functionally similar to 
CD28 (263). Its interactions with ICOS ligand, on the APC surface, allows an efficient T 
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Figure 3.10. A high proportion of Tregs are HLA-DR+. Lymphocytes from peripheral 
blood, colon and tumour tissues were stained for FACS analyses. A. Percentage of CD25- 
(dots) and CD25hi cells (triangles) expressing HLA-DR. B. Percentage of CD25int cells 
expressing HLA-DR in the indicated fractions. Significant differences are indicated, ***p 
< 0.001 (Student’s unpaired t test). 
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cell response. Unlike CD28, which is constitutively expressed, ICOS is only upregulated 
after Ag recognition and thus represents an activation marker. Reports have shown that 
ICOS expression is not restricted to effector T cells but is also found on Tregs. Compared 
to ICOS- Tregs, ICOS+ Tregs have enhanced suppressor functions and secrete higher 
levels of the immunosuppressive cytokine IL-10 (264). In order to determine if the 
suppressive potency of Tregs varies within the tumour, we investigated ICOS expression 
by CD4+CD125hi cells.  
The percentages of CD25hi ICOS+ cells were comparable in peripheral blood and 
healthy colon tissue (approximately 50% of cells; Figure 3.11.A). A significantly higher 
proportion of intratumoural CD25hi cells express ICOS compared to circulating CD25hi 
cells (tumour 73.60% ± 7.33 vs. blood 44.34% ± 18.68, p = 0.0064). These results are 
line with previous report showing that higher number of Tregs, defined as CD4+Foxp3+, 
isolated from CRC tumours, are enriched for ICOS+ cells (138). As expected, ICOS was 
found on activated CD25int cells isolated from blood and tissues (Figure 3.11.B) whilst 
only very low frequencies (less than 8%) of CD25- cells expressing ICOS were observed 
in blood and colon of CRC patients.  
Another cell surface co-receptor, CTLA-4, is involved in the regulation of the 
immune response. When binding to its ligands B7-1/-2, CTLA-4 functions as a negative 
regulator of cellular activation (265). Like ICOS, CTLA-4 is marker of activation with its 
expression restricted to activated T cells. Tregs also express CTLA-4 and is implicated in 
mediating their suppressive effects.  
Intracellular CTLA-4, stored in the cells, can be recruited and be expressed at the 
cell surface and thus this stock represents the potential that a cell can express. In the blood 
of CRC patients, intracellular CTLA-4 was detectable in a high proportion (over 70%) of 
CD25hi cells to less than 5% in the naive CD25- population (Figure 3.12.A), consistent 
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Figure 3.11. CD4+CD25hi T cells expressing ICOS are enriched in CRC tumours. A. 
Percentages of T cells in the blood, colon and tumour of CRC patients expressing ICOS. 
B. Percentage of activated CD25int cells expressing ICOS. Significant differences are 
indicated, ** p < 0.01 (Student’s unpaired t test).Significant differences are indicated, 
***p < 0.001 (Student’s unpaired t test). 
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with a central role for CTLA-4 in dictating Treg activity. The same pattern of expression 
was found in colon and tumour tissues, where a slight but consistent increase in 
proportions of CD25hi cells expressing CTLA4 was observed compared to blood (tumour 
88.58% ± 5.17 vs. blood 71.15% ± 7.15, p = 0.0008). When compared with healthy colon, 
higher frequencies of tumour-infiltrating Tregs with detectable intracellular CTLA-4 
were observed. These data together with those shown in Figure 3.10 show that CD25hi 
cells in CRC tumours express high levels of costimulatory molecules associated with 
suppressive functions. 
Intracellular stores of CTLA-4 were also observed in CD25int effector T cells, 
particularly within the intratumoural CD25int cell population (Figure 3.12.B), albeit in a 
smaller proportion of cells than within the CD25hi population. This may reflect the higher 
activation status of tumour-infiltrating T cells.  
 
3.2.9. CD39 is upregulated by intratumoural CD4+CD25hi Tregs 
CD39 represents another key molecule playing an important role in the regulatory activity 
of Tregs. This ectonucleotidase facilitates the production of immunosuppressive 
adenosine from ATP.  
The frequency of peripheral CD4+CD25hi cells expressing CD39 was higher than 
within the CD4+CD25- population (CD25hi cells 43.2% ± 8.20 vs. CD25- cells 5.9% ± 
2.56, p < 0.0001; Figure 3.13.A). In the blood of CRC patients, the CD4+CD25int subset 
contained T cells with low CD39 expression (mean 13.4% ± 4.87; Figure 3.13.B). These 
data are consistent with reports showing that CD39 expression is restricted to 
CD4+CD25hi Tregs in the blood of healthy people (266).  
The proportion of CD39+ cells was significantly higher in CD4+CD25hi cells in the 
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Figure 3.12. Tregs express high levels of CTLA-4. A. Frequencies of T cells expressing 
intracellular CTLA-4 in blood, colon and CRC tumours. B. Frequencies of activated 
CD25int cells expressing CTLA-4. Significant differences are indicated, * p < 0.05, ** p 
< 0.01, ***p < 0.001 (Student’s unpaired t test). 
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Figure 3.13. Frequency of CD39+ cells is increased in intratumoural CD25hi Tregs. 
A. Percentages of CD25- (dots) and CD25hi (triangles) cells expressing CD39 in blood, 
colon and tumour of CRC patients. B. Percentage of CD25int expressing CD39 in CRC 
patients. Significant differences are indicated, ** p < 0.01, ***p < 0.001 (Student’s 
unpaired t test). 
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tumour compared to blood (tumour 72.04% ± 13.42 vs. blood 43.2% ± 8.20, p = 0.0004; 
Figure 3.13.A). This up regulation of CD39 in intratumoural Tregs was also observed in 
head and neck cancer patients (267). The extremely high frequency of intratumoural 
CD25hiCD39+ Tregs suggests that ATP hydrolysis might an important mechanism used 
to suppress effector T cells at the tumour sites. These data also demonstrate that CRC 
tumours are highly immunosuppressive since it has been shown that CD39-expressing 
Tregs have enhanced suppressive abilities compared to CD39- Tregs (174). 
It is noteworthy that the percentage of CD25- cells expressing CD39 was higher in 
the tumours compared to the peripheral blood of CRC patients (tumour 48.97% ± 12.65 
vs. blood 5.92% ± 2.57, p < 0.0001; Figure 3.13.A); a similar observation was made in 
healthy colon. These CD4+CD25-Foxp3-CD39+ cells, may also help counterbalance 
immune activation in healthy tissues, thereby helping maintain normal immune 
homeostasis but may contribute to inhibition of anti-tumour immunity in CRC. 
 
3.2.10. CRC patients have increased percentages of CD25hi 
LAG3+ and LAP+ cells 
The transmembrane LAG3 protein represents a marker reported to define Tregs with 
enhanced suppressor activity (268). Tumour infiltrating-LAG-3+ Tregs have been shown 
to supress immune responses in Hodgkin lymphoma patients (269).  
 
A discrete population of circulating LAG-3+ cells was detectable in CRC patients, 
particularly within the CD25hi subset (CD25hi cells 11.01% ± 4.53 vs. CD25- cells 3.99% 
± 2.26, p = 0.0059; Figure 3.14.A). Furthermore, the proportion of tumour-infiltrating 
CD4+CD25hi T cells that also express LAG3 was increased in CRC patients compared to 
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Figure 3.14. Increased frequency of CD4+CD25hi LAG-3+ cells in the tumours of CRC 
patients. A. Percentages of cells in the indicated CD25 subsets expressing LAG-3 in 
peripheral blood, colon and tumour of CRC patients. B. Percentage of CD25int cells 
expressing LAG-3 in the indicated samples from CRC patients. Significant differences are 
indicated, ** p < 0.01, ***p < 0.001 (Student’s unpaired t test). 
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peripheral blood (tumour 24.16% ± 7.31 vs. blood 11.01% ± 4.53, p = 0.0019). This is 
consistent with the findings of Camisaschi et al showing that melanomas are enriched in 
CD25hiLAG-3+ T cells (188). This enrichment of LAG3+ T cells within CRC was also 
seen on the CD4+CD25- T cells (tumour 12.17% ± 3.90 vs. blood 3.99% ± 2.26, p = 
0.0003; Figure 3.14.A). Proportions of circulating CD25- and CD25int cells expressing 
LAG-3 were similar implying that LAG-3 is not a marker of activation (Figure 3.14.B).  
 
TGF-β plays an important role in Treg activity, notably in the suppression of anti-
tumour immunity (168). Before being released, TGF-β interacts with Latency Associated 
Peptide (LAP) on the extracellular matrix. Lately, Chen et al have found that, in CRC 
patients, LAP-expressing Foxp3+ Tregs are activated cells with more potent suppressive 
activity dependent on TGF-β (270). The comparison between circulating and tumour-
infiltrating lymphocytes revealed an increase in the frequency of CD25hi cells expressing 
LAP in the tumours (blood 10.86% ± 1.95 vs. tumour 27.13% ± 7.54, p < 0.0001; Figure 
3.15.A). The percentage of CD4+CD25hiLAP+ cells was also significantly higher in non-
tumoural colon tissues compared with blood (colon 25.20% ± 18.85 vs. blood 10.86% ± 
1.95, p = 0.0002). The percentage of CD4+CD25- cells expressing LAP was also increased 
within the CRC in comparison to blood (tumour 9.12% ± 4.53 vs. blood 4% ± 0.9%, p = 
0.0025). Similar observations were found with CD4+CD25int cells.  
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Figure 3.15. Higher frequency of CD4+CD25hi LAP+ cells in colorectal tumours. A. 
Percentages of CD25- and CD25hi cells expressing LAP in the indicated CRC samples. B. 
Percentage of CD4+CD25int cells expressing LAP in CRC patients. Significant differences 
are indicated, ** p < 0.01, ***p < 0.001 (Student’s unpaired t test). 
114 
 
3.3. Discussion 
CD4+CD25hi T cells are considered to represent the human Treg population based on their 
strong in vivo and in vitro suppressive activity. These cells can inhibit the proliferation of 
CD4+CD25− T cells and the maturation of myeloid DC (249, 271). Whilst alterations of 
CD4+CD25hi T cell functions have been associated with autoimmune diseases (272), 
increased proportions of these cells are commonly observed in blood of cancer patients 
(252, 273-275). In CRC, CD4+CD25hi cells have been directly implicated in the inhibition 
of anti-tumour immunity. By depleting these cells from PBMC of CRC patients, Clarke 
et al showed that new tumour Ag-specific CD4+ T cell responses were generated (247). 
Although CD4+CD25hi cells are enriched in blood and tumours of CRC patients (247, 
276), their phenotype has not been comprehensively studied. This study reveals that 
intratumoural CD4+CD25hi cells overexpressed immunomodulatory molecules in CRC 
patients implying significant ability to impact negatively on anti-tumour immunity. 
Peripheral CD4+CD25hi cells invariably expressed high levels of Foxp3 and were 
CD127low, which are to date the best markers to define Tregs, when suppressive assays 
cannot be performed (256). These cells had the same phenotype (CD45RA-CD45RO+) as 
the suppressive human CD4+CD25hi cells originally reported by Baecher-Allan et al 
(249). The frequency of CD4+CD25hi cells was increased in the blood and at tumour site 
of CRC patients, confirming previous reports. This study showed that patients with late 
stage CRC had elevated percentage of circulating and tumour-infiltrating CD4+CD25hi 
cells compared to early stage. Also, this study demonstrates that recruitment or expansion 
of thymus-derived Tregs are the main mechanisms contributing to CD4+CD25hi 
enrichment in tumours. Factors supporting this accumulation, such as IDO and VEGF-a 
(277), represent good alternative therapies. In this respect, VEGF-a blockage has been 
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shown to decrease the number of intra-tumoural CD4+CD25hi in preclinical mouse models 
(278).  
In this study, 6 Treg-associated markers were used to define the CD4+CD25hi cell 
phenotype. HLA-DR was the only protein that was expressed by similar proportions on 
peripheral and tumour-infiltrating CD4+CD25hi cells (approximately 50%). This marker 
defines activated mature CD4+CD25hi cells involved in contact-dependent suppression. 
(262). Therefore, CD4+CD25hiHLA-DR+ cells may not be the main suppressive cells 
within the tumour of CRC patients. In contrast, ICOS, CTLA-4, CD39, LAG-3 and LAP 
were significantly expressed by more tumour-infiltrating CD4+CD25hi cells compared to 
circulating CD4+CD25hi cells in CRC patients. Some of these markers have been reported 
to be expressed with higher frequency on tumour-infiltrating CD4+CD25hi cells; ICOS 
(264), CTLA-4 (279) and LAG-3 (188), in melanoma patients. There is evidence that 
intratumoural CD4+CD25hi cells exhibiting a predominant immunosuppressive phenotype 
have enhanced suppressive activity (267). In this study, a striking high number, more than 
70%, of CD4+CD25hi cells expressed ICOS, CTLA-4 and CD39. These molecules may 
be key modulators of CD4+CD25hi cell activity and promote a strong immunosuppressive 
environment in tumours of CRC patients.  
Although blockade of ICOS, CTLA-4 and CD39 may enhance anti-tumour 
immunity, such treatment is likely to induce immune-related adverse events. Indeed, these 
proteins were also expressed, albeit at lower level, on CD4+CD25int cells either isolated 
from blood, colon or tumour tissues. These cells correspond to non-suppressive effector 
T cells (249), and 40% were found to express Foxp3; an event that may take place to 
attenuate T cell activation (280). Moreover, this Foxp3 expression in non-Treg cells may 
explain the high percentage of CD4+Foxp3+ cells, compared to CD4+CD25hi cells, 
observed in CRC patients (Appendix Figure 2). 
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 Therefore, since Tregs share many markers with CD4+CD25int cells, precautions 
must be taken in order to target the first population without impacting the second. This 
absence of specific Treg markers explains the immune-related adverse events during 
mAb-based therapies. For instance, autoimmune disorders are often associated with anti-
CTLA-4 mAbs (e.g. ipilimumab) treatment in metastatic melanoma patients (32). In 
addition to impacting Treg activity, anti-CTLA-4 mAbs are likely to prevent cell-intrinsic 
down-regulation of T cell activation resulting in harmful uncontrolled immune responses. 
Since high expression of CD25 is an unique feature of suppressive CD4+CD25hi cells, 
drugs specifically targeting this molecule on Tregs are less likely to lead to immune 
disorders. Using low dose of DAB389IL-2, a recombinant IL-2-diphtheria toxin conjugate, 
Dannull et al could selectively eliminate human CD4+CD25hi cells without impacting the 
function of CD4+CD25int cells (281). This approach has been reported to decrease the 
percentage of circulating Tregs in cancer patients (282)  and to induce tumour regression 
in some melanoma patients in a recent phase II clinical trial (283).   
In conclusion, this study showed that the majority of CD4+CD25hi cells express 
immunomodulatory molecules at tumour sites of CRC patients. In parallel, these 
molecules were also detected on CD4+CD25int effector cells. These results give insights 
into the mechanisms potentially mediating Treg suppressive activity in CRC patients. 
They also highlight the absence of unique Treg markers which has implications for the 
development of safe cancer immunotherapy.  
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CHAPTER 4. EFFECT OF TREGS ON 5T4-
SPECIFIC RESPONSES 
 
4.1. Introduction 
The aim of the work described in this Chapter is to characterise T cell responses to the 
5T4 Ag in CRC patients and healthy controls. As described in Chapter 1, there is evidence 
that 5T4 is an immunogenic protein but 5T4 immunogenicity has never been 
characterized in detail. Therefore, responses to peptide pools spanning the sequence of 
the 5T4 protein were analyzed (Table 2.4 in Material and Methods) in order to compare 
magnitude of T cell responses, and percentage of responders between healthy donors and 
CRC patients. Peptide pools, rather than the whole 5T4 protein, were used so that precise 
immunogenic regions and peptides recognised by CD4+ T cells could be identified. These 
peptides were overlapping by 10 amino acids to include all potential T cell epitopes. As 
cancer patients have high numbers of Tregs relative to healthy individuals, anti-tumour 
Ag responses are more likely to be controlled by these cells. Thus, the impact of Tregs 
on 5T4 responses was also studied.  
5T4-specific T cell responses were measured by IFN-γ production in ELISpot 
assays following overnight stimulation with 5T4 peptide pools. Even though ELISpot is 
a very sensitive functional assay, the frequency of 5T4-specific T cells in peripheral blood 
is too low to be consistently measured ex vivo. Therefore, a 12-day stimulation period 
was required to expand the 5T4-specific T cells in order to detect cognate T cells. In the 
assays used here, peptides were directly added to the PBMCs for loading onto MHC 
molecules and presentation to T cells.   
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4.2. Results  
4.2.1. ELISpot assay variability  
The first report of the use of ELISpot assay, to enumerate Ab-secreting cells, was 
published thirty years ago (284). Since then, the assay has evolved to measure Ag-specific 
T cell responses. It is an extremely sensitive assay (detection of frequencies as low as 
5/106 cells) but data on its variability is limited. I initially set out to examine this feature 
in the context of 5T4-specific T cell responses. All analyses done in the course of this 
PhD were performed with standard laboratory procedures in order to allow reliable 
comparisons. All assays were performed with freshly isolated PBMCs.  
Intra-assay precision 
In order to evaluate the level of intra-assay variability, PBMC from one healthy donor 
were stimulated with 5T4 single peptides in IFN- ELISpot assays. One representative 
example, after stimulation with peptide 2, is shown in Figure 4.1.A. Very low variation 
was found between the replicates in both control and stimulated wells. The same 
observations were obtained with two other peptides that elicited a response (Figure 
4.1.B). For instance, the mean response to peptide 20 was 166 spots / 105 cultured cells 
with 95% confidence interval of 126 to 206. This absence of substantial variability in the 
assay was observed throughout the study.  
Variation in T cell responses over time   
The variation in T cell responses was assessed at three different time points using PBMCs 
from the same healthy control. Reponses against five different candidate peptides were 
measured in duplicate at intervals of not less than two weeks. Positive responses to 3 
peptides (peptides 2, 20 and 26) were detected at two or more time points; a responses to  
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Figure 4.1. Intra-assay variability. PBMC from one healthy donor were stimulated with 
5T4 peptides for 12 days. Cells from three cell lines stimulated by the same peptides were 
then pooled, washed and added in ELISpot well. Cells were plated in triplicate wells. A. 
Example of IFN- ELISpot wells in the absence (-) or presence (+) of peptide 2. Numbers 
indicate the frequency of IFN- spots / 75000 cells. B. Data indicate the number of IFN-
 spots normalised to per 105 cultured cells. Circles: peptide 2; squares: peptide 12; 
triangles: peptide 20. Closed symbols represent background controls (no peptide 
restimulation) and open symbols represent 5T4-specific responses (peptide 
restimulation). Lines indicate means with 95% confidence interval. All experiments were 
performed in triplicate. 
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peptide 12 was only seen at the final time point; no response was found to peptide 38 at 
any time point. The responses to peptide 26 were consistently lower in frequency. Each 
positive assay at any particular time point demonstrated tight error bars suggesting, as 
shown in Figure 4.1, that the actual assays conducted at each time point were reliable, 
and that there is a natural variation in T cell responses over time. These results are 
summarised in Figure 4.2. 
It is therefore important to appreciate that an assay performed on an individual at 
only one time point may not reflect the full possible repertoire of cognate T cell responses 
to 5T4 peptides; this variation in 5T4 responses has been subsequently observed in an on-
going clinical trial in our laboratory where patients are tested 6-8 times over 15 weeks 
(Andrew Godkin and Martin Scurr: personal communication). This temporal variation 
has also been seen to other Ags such as influenza haemagglutinin (Andrea Schauenburg: 
personal communication). 
 
 
4.2.2. Broad 5T4-specific responses in healthy donors 
The T cell specificity for 5T4 peptides was explored in healthy individuals. A summary 
of donors’ details is shown Table 4.1. PBMCs from 9 healthy donors (HD) were 
stimulated with 5T4 peptides (utilising pools 7 - 13) representing adjacent regions of the 
protein (Table 2.4 in Material and Methods). Specific T cells were quantitated by IFN- 
ELISpot assay and were scored as spots per 105 cultured cells.  
Two representative examples are illustrated in Figure 4.3. HD205 was found to be 
positive for peptide pools 9, 11 and 13; and HD215 positive for pools 8, 10, 11 and 12. 
The robustness of these responses is illustrated with examples of IFN- ELISpot wells 
shown in Figure 4.3.B. A range in frequencies of peptide pool-specific  T cells was 
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Figure 4.2. IFN- responses measured by ELISpot assay change over time. PBMC 
from one healthy donor were stimulated with five 5T4 peptides in duplicate. T cell 
responses were monitored at three different time points, represented by bars. At least 
two weeks separated each time point. Data represent mean frequencies of responses 
with 95% confidence interval, after subtracting control background. A line was 
considered positive if there was >25 spots / 105 cultured cells (represented by dashed 
horizontal lines). 
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Healthy 
donor 
Gender HLA-DRB1 HLA-DQB1 
HD204 m *01, *15 *05, *06 
HD205 f *07, *13 *06 
HD206 f *03, *07 *02 
HD210 m *04, *15 *06, *03 
HD215 m *04, *07 *02, *03 
HD216 m *04 *03 
HD218 m *15, *10 *05, *06 
HD220 m *09, *14 *05, *03 
HD222 m *01, *07 *02, *05 
 
Table 4.1. Characteristics of the 9 healthy donors included in the IFN- ELISpot 
analysis  
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Figure 4.3. ELISpot assay permits the detection of T cells specific for 5T4 in healthy 
donors.  A. PBMCs from HD205 and HD215 were stimulated for 12 days with the 
indicated peptide pools. Black bars indicate stimulation with peptides and white bars 
indicate the negative background (stimulation in culture medium only). 
Phytohemagglutinin (PHA) was used as a positive control. Negative control (NC) 
indicates responses with unstimulated cells. Asterisks on the top of bars point to positive 
responses. B. Wells illustrating positive IFN-responses to 4 5T4 peptide pools in 
HD215. Each spot corresponds to a single T cell producing IFN-γ after stimulation. 
A 
PP 8 PP 10 PP 11 PP 12 
+ 
- 
B 
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observed in these 2 patients. For instance, HD205 had a frequency of pool-specific T cell 
that ranged from 1/1369 (peptide pool 13 with 73 IFN- spots / 105 cells) to 1/250 (peptide 
pool 11 with 399 IFN- spots / 105 cells). Similarly, in a second healthy donor the 
frequency of pool-specific T cell ranged from 1/3125 (peptide pool 12 with 32 IFN- 
spots / 105 cells) to 1/1075 (peptide pool 8 with 93 IFN- spots / 105 cells). Furthermore, 
several pools (3 for HD205 and 4 for HD215) stimulated IFN- secretion indicating that 
the 5T4-specific response is broad and not focused on one particular peptide.  
The same IFN- ELISpot assay was next applied to determine the frequencies of 
peptide-specific T cells in a further 9 healthy donors. Results are summarized in Table 
4.2. Responses to pools spanning the entire 5T4 protein were observed. Indeed, across all 
donors, we observed responses to each of the 7 pools. With the exception of HD220, all 
healthy donors responded to at least 3 peptide pools confirming that the response to 5T4 
is broad in these subjects. Individuals most frequently exhibited positive responses to pool 
13 (67%), followed by pools 8, 10 and 11 (56%) and then pools 9 and 12 (33%). 
 
The frequencies of 5T4 peptide-pool specific T cells in healthy donors are 
summarized in Figure 4.4. The magnitude of IFN-γ responses was also different between 
pools. Overall, the strongest response was observed against pool 11 with a mean response 
of 1/448 (i.e. 223 spots /105 cells) among responders. The weakest response was directed 
against pool 12 with mean response of 1/2222 (45 spots / 105 cells). From these 
experiments, pool 11 appears to be the most immunogenic on the basis that it is 
recognized by most donors, and often with high frequencies of specific T cells. With 
similar reasoning, pool 12 is the least immunogenic pool. 
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Table 4.2. 5T4-specific IFN- responses in 9 healthy donors. PBMCs were stimulated 
with 5T4 peptides assembled in peptide pools 7 to 13. ELISpot results from stimulated 
(symbolized with +) and unstimulated wells (symbolized with -) are shown. After 
subtracting the background (=), positive responses were underlined. All responses are per 
105 cultured cells. 
  
 Peptide Pools  
 
 7   8     9     10     11     12     13    
 + - = + - = + - = + - = + - = + - = + - =  
HD210 0 0 0 363 0 363 279 143 136 212 4 208 328 3 325 77 0 77 320 3 317   
HD222 36 7 29 235 9 225 25 7 19 61 25 36 204 132 72 31 3 28 47 23 24   
HD206 45 0 45 0 0 0 47 0 47 32 5 27 9 3 7 215 172 43 1 1 0   
HD204 27 0 27 0 0 0 400 0 400 3 0 3 400 127 273 4 0 4 121 7 115   
HD215 21 0 21 93 0 93 0 0 0 44 1 43 83 5 77 33 1 32 5 5 0   
HD205 9 8 1 3 0 3 113 39 75 24 21 3 400 1 399 5 4 1 73 0 73   
HD216 209 7 203 93 3 91 47 27 20 36 9 27 19 16 3 27 17 9 117 19 99   
HD220 29 16 13 21 19 3 24 12 12 37 15 23 51 32 19 32 15 17 105 3 136   
HD218 107 8 99 48 21 27 31 16 15 37 29 8 75 32 43 7 7 0 116 16 100   
Responders 5/9 5/9 3/9 5/9 5/9 3/9 6/9  
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Figure 4.4. Frequencies of specific T cells for each 5T4 pool in healthy donors.  Only 
positive responses are shown. Positive responses had at least twice the number of spots 
in unstimulated wells and at least 25 SFC/105 cells (threshold indicated by dotted line).  
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4.2.3. 5T4-specific T cells in CRC patients 
Using PBMCs isolated from CRC patients’ blood taken before surgery, IFN-γ ELISpot 
assays were performed to measure T cell responses to 5T4. A summary table of patients’ 
details is shown in Table 4.3. Results of ELISpot assays for two representative examples 
(patient MB2 and MB3) are shown in Figure 4.5. MB2 responded to pools 7, 10, 12 and 
13 with a frequency that varied between 1/2777 (peptide pool 12) to 1/751 (peptide pool 
7), whilst MB3 responded to pools 7, 11 and 13 with a range of 1/1818 (peptide pool 13) 
to 1/303 (peptide pool 11). Straight away, the frequencies can be seen to be within a 
similar range to the healthy controls, and individuals demonstrate responses to particular 
pools.  
I proceeded to test the pools in 16 patients pre-operatively before they underwent 
surgery for CRC. Table 4.4 summarizes the T cell responses to 5T4 in these 16 CRC 
patients. Each pool induced IFN-secretion in at least 3 out of 16 patients, with the top 
pools being pool 13 (9 out of 16 patients responded); pool 7 (8 out of 16); and pool 11 (7 
out of 16). In term of the mean magnitude of responses, overall, pool 11 induced the 
highest mean number of IFN- secretion with a frequency of 1/287 (348 spots / 105 cells) 
(Figure 4.6). The weakest mean response was observed with pool 12: frequency of 1/1613 
(62 spots / 105 cells).  
 
4.2.4. Comparison of 5T4-specific responses between healthy 
donors and CRC patients 
The overall summation of 5T4-specific T cells in the pools scored as positive (defined by 
≥25 specific spots / 105 cells), for pools 7 to 13 were calculated for each individual e.g. 
MB2 (Table 4.4) responded to pools 7, 10, 12 and 13 with 133, 107, 36 and 80 spots,   
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Table 4.3. Characteristics of the 16 CRC patients included in the INF- ELISpot 
analysis. n/a: not available 
CRC 
patient 
Gender Age HLA-DRB1 TNM 
Stage 
Dukes’ 
Stage 
MB01 M 67 n/a T3, N1 C1 
MB2 m 74 n/a T3. N2 C1 
MB3 m 63 *15, *04 T3, N2 C1 
MB4 m 62 n/a T1, N0 A 
MB6 m 67 *01, *07 T4, N1 C1 
MB7 m 56 *03, *04 T3, N2 C1 
MB8 m 81 *13, *15 T4. N0 B 
MB9 m 74 *04, *07 T3, N0 B 
MB11 m 84 *13, *15 T0, N2 C1 
MB12 m 70 *13 T3, N0 B 
MB14 f 67 *01, *14 T3, N0 B 
MB15 m 33 *15, *04 T2, N0 A 
MB16 m 60 *03 T4, N0 B 
MB19 f 68 *01, *04 T1, N0 A 
MB21 m 79 *04, *08 T3, N0 B 
MB23 f 69 *07 T2, N0 A 
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Figure 4.5. Representative IFN- ELISpot in two CRC patients.  PBMCs from MB2 
and MB3 were stimulated for 12 days with peptide pools and restimulated in ELISpot 
plates with the same pools (black bars) or in medium only (white bars). Asterisks indicate 
positive responses.  
 
 
 
  
130 
 
 
Table 4.4. 5T4-specific IFN- responses in 16 CRC patients. ELISpot results from 
stimulated (symbolized with +) and unstimulated wells (symbolized with -) are shown. 
After subtracting the background (=), positive responses were underlined. All responses 
are per 105 cells.  
  
 
Peptide Pools 
 
  
   7     8     9     10     11     12     13    
 + - = + - = + - = + - = + - = + - = + - =  
MB2 135 1 133 1 0 1 11 9 1 111 4 107 28 4 24 40 4 36 80 0 80   
MB3 73 4 69 8 5 3 8 7 1 9 12 0 393 64 329 7 0 7 60 5 55   
MB4 81 5 76 12 3 9 7 7 0 8 7 1 425 47 379 11 1 9 80 4 76   
MB6 16 0 16 36 12 24 237 7 231 280 4 276 439 3 436 97 0 97 1 0 1   
MB7 28 1 27 261 11 251 199 16 183 176 13 163 36 12 24 93 3 91 27 5 21   
MB8 3 0 3 40 0 40 7 5 1 8 3 5 1 1 0 8 3 5 400 1 399   
MB9 400 1 399 47 0 47 8 0 8 1 0 1 3 3 0 43 0 43 28 0 28   
MB12 217 13 204 23 12 11 9 4 5 8 0 8 155 1 153 15 21 0 400 9 391   
MB14 3 0 3 1 0 1 0 0 0 3 1 1 20 0 20 3 3 0 164 8 156   
MB15 83 0 83 320 0 320 197 5 192 249 1 248 416 71 345 12 0 12 111 0 111   
MB16 0 0 0 1 1 0 3 3 0 4 0 4 16 4 12 0 0 0 3 0 3   
MB19 68 0 68 71 5 65 5 0 5 3 3 0 11 0 11 12 9 3 100 97 3   
MB23 21 11 11 0 0 0 0 0 0 76 1 75 400 0 400 1 0 1 31 4 27   
MB01 36 47 0 60 60 0 116 125 0 44 53 0 104 127 0 69 23 47 97 111 0   
MB11 0 0 0 75 0 75 3 0 3 1 0 1 1 0 1 1 1 0 8 1 7   
MB21 19 19 0 0 0 0 7 7 0 4 4 0 400 0 400 16 8 8 7 0 7   
Responders   8/16     6/16     3/16     5/16     7/16     5/16     9/16     
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Figure 4.6. Frequency of 5T4-specific IFN--producing cells in CRC patients.  Dots 
indicate the individual frequencies of specific T cells for each pool in responders. 
Threshold of 25 SFC/105 PBMC is indicated by dotted line. N= 16. Significant 
differences were identified using ANOVA; *p<0.05 and ** p<0.01. 
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respectively; the total specific T cell response was therefore 356. The results for all 
subjects are shown Figure 4.7.A. No significant difference was observed between healthy 
donors and CRC patients, as the mean of the total number of 5T4-specific T cells was the 
same for each group (500 spots / 105 cells).  
When comparing mean responses against each of the pool, a strikingly similar 
pattern of reactivity was seen in both groups (Figure 4.7.B). Pool 11 was associated with 
the highest mean number of responding T cells (223 and 348 specific spots /105 cells for 
HD and CRC patients, respectively) and pool 12 was the least immunogenic pool (45 and 
62 specific spots / 105 cells for HD and CRC patients). There was no statistical difference 
between the mean IFN- responses for each pool between healthy donors and CRC 
patients.  
The number of responders to a given peptide pool represents another parameter of 
immunogenicity, and is shown as a percentage of responders to each pool in controls and 
patients (Figure 4.7.C). Compared to CRC patients, higher percentages of positive donors 
within the healthy group were observed for all the pools albeit the overall pattern was 
similar.  
In addition, there were more non-responders in the CRC patient group (6%) than in 
healthy donors (0%). Also, cancer patients recognized fewer pools than healthy 
individuals. Indeed, 33% of healthy persons responded to 1 to 3 peptide pools compared 
to 63% in the CRC group. The percentage of individuals that could recognize more than 
4 peptide pools was higher in the healthy group (67%) than in the CRC group (31%). 
These results are summarised in Table 4.5. 
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Figure 4.7. Magnitude and percentage of responders within healthy donors and 
CRC patients.  A. Overall total response of 5T4-specific T cells in HD and CRC patients. 
For each individual, the sum of positive responses to peptide pools 7 to 13 is shown. B. 
Mean number of 5T4-specific T cells in healthy donors and CRC patients. Only donors 
recognizing at least 1 pool were included in A and B. C. Percentages of responders to 
peptide pools 7 to 13 in healthy donors (n=9) and CRC patients (n=16). Significant 
differences are indicated, * p < 0.5, ** p < 0.01 (1 way Anova). 
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Table 4.5. Diversity of responses between healthy donors and CRC patients.  The 
percentage of non-responders (0 PP recognized) and percentages of individual 
recognizing 1 to 3 PP and more than 4 PP among the 7 pools (PP7 to 13) are indicated for 
healthy donors (n=9) and CRC patients (n=16). 
  
Number of  % of healthy donor % of CRC patient 
PP recognized     
0 0 6 
1 to 3 33 63 
>4 67 31 
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4.2.5. Depletion of CD25hi T cells 
In order to identify epitopes that might be influenced by Tregs, CD25hi cells were depleted 
from PBMCs before evaluating 5T4-specific T cell responses in 12-day cultures. Previous 
work in the lab empirically established that using CD25 MicroBeads II and a positive 
selection MS column allows deletion of mainly CD25hi cells. The CD25 marker allows 
detection of 3 different populations (Figure 4.8.A). Using CD25 beads, depletion of the 
CD25hi Tregs was consistently achieved (Figure 4.8.A). The percentage of CD4+CD25hi 
Tregs within the CD4+ population (5.20% ± 1.18) decreased significantly after depletion 
(0.49% ± 0.16) as shown in Figure 4.8.B. This was confirmed by a decrease of Foxp3+ 
cells (Figure 4.8.C). This significant decrease of CD4+Foxp3+ cells was confirmed in 
several individuals (before: 11.16% ± 1.28 vs. after: 3.79% ± 0.80) (Figure 4.8.D). 
However, as the CD25 marker does not clearly differentiate between Foxp3+ Tregs 
and activated Foxp3- T cells, it is clear that some CD25int cells, comprising the Foxp3- 
population, are also lost (Figure 4.8.E). However, the degree of loss is far less in the 
CD25int population compared to CD25hi which is almost completely removed. 
 
4.2.6. Effect of CD25hi T cell depletion 
The effect of the depletion of CD25hi cells on T cell responses has been observed 
previously using the same method (247). I designated the possible effects (on the 
magnitude of the T cell responses in peptide-pool driven short term T cell lines after 
depleting CD25hi cells) to five groups: i) increase by >50%; ii) decrease by >50%; iii) 
new response not seen in whole undepleted PBMCs; iv) loss of response only seen in 
whole undepleted PBMCs; v) neutral i.e. no marked effect- these are illustrated in Figure 
4.9. 
136 
 
  
 
  
A 
 
B 
 
Figure 4.8. Depletion of CD4+CD25hi Treg cells with anti-CD25 Ab-coated magnetic 
MicroBeads. A. Representative example FACS plots showing levels of CD25 expression 
on CD4+ T cells before and after depletion. B. Percentages of CD25hi T cells in the CD4+ 
T cell population before and after depletion in 17 subjects. C. Representative example of 
FACS plots of Foxp3 expression in CD4+ T cells before and after depletion. D. 
Percentages of Foxp3+ T cells in the CD4+ T cell population before and after depletion in 
17 subjects. E. Percentages of CD25int T cells in the CD4+ T cell population before and 
after depletion. 
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Figure 4.9. 5T4–specific responses 
following Treg depletion.  Representative 
examples (from two CRC patients) to 
illustrate the possible effects of depleting 
CD25hi cells. i)  “increase” was designated 
if depletion of Tregs enhanced the number 
of spots by at least 50%. ii) “decrease” a 
reduction by at least 50%. iii) “new” 
response only seen in Treg depleted lines. 
iv) “loss” when response removed by Treg 
depletion. v) “neutral”:  depletion no 
marked effect. 
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4.2.7. Influence of Tregs on 5T4-specific responses in HD and 
CRC patients 
Global effect of Treg depletion 
The impact of Treg-depletion was subsequently compared in the HD and CRC groups. 
The overall summation of responses to the pools 7 to 13 (that cover all 5T4) before and 
after Treg depletion were similar in both groups (Figure 4.10). No effect of Tregs was 
observed on the summed of responses against pools in these donors. However, overall 
summation pre- vs post- depletion may not be the most relevant parameters to evaluate 
the impact of the Tregs as differential effects amongst peptide pools may mask Treg-
mediated suppression. 
Individual-specific effect of Treg depletion 
I next analysed individual frequencies of 5T4 peptide pool-specific T cells before and 
after Treg depletion. The data are summarised in Table 4.6. Effects of Treg depletion are 
indicated in blue (increase response) or red (new response). In all healthy donors (HD in 
Table 4.6) the response to at least one peptide pool was affected by CD25hi removal. 
Responses from HD204 were the most influenced by CD25hi depletion as new responses 
against three peptide pools were unmasked and one peptide pool-specific response 
increased. In 9/13 CRC patients (MB in Table 4.6) responses to at least one peptide pool 
per patient was influenced by CD25hi depletion. 5T4 responses from MB9 and MB19 
were the most affected by CD25hi cells as responses against five pools were either 
increased or unmasked in these patients.  
Figure 4.11 shows the frequencies of responses to pools 7 to 13 (symbolized by 
dots) in MB9 and MB19. The lines link the frequencies obtained with and without Tregs 
for the same peptide pool. When stimulated by pools 7-13, MB9 and MB19 demonstrated  
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Figure 4.10. Effect of Tregs on 5T4-specific T cell frequencies.  Whole PBMC and 
CD25hi -depleted PBMC from 6 controls and 13 CRC patients were stimulated with 7 
different peptide pools (PP7 to 13). Each symbol represents the sum of responses to all 
the positive pools in one donor before and after Treg depletion.  
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Table 4.6. Magnitude of IFN- secretion in healthy donors and CRC patients before 
and after depleting Tregs.  Undepleted and CD25hi -depleted PBMC obtained from 
healthy donors (HD) and CRC patients (MB) were stimulated by 7 different pools. The 
numbers represent the spot-forming cells /105 cultured PBMC after subtraction of 
background spots, in the presence (+ sign) or absence (- sign) of CD25hi cells. Underlined 
numbers indicate positive responses. Blue numbers indicate an increase of at least 50% 
in depleted cells and red new responses, compared to undepleted cells.  
 7 8 9 10 11 12 13 
Number 
of pool 
 + - + - + - + - + - + - + - + - 
HD210 0 97 363 397 136 100 208 312 325 389 77 399 317 227 5 7 
HD222 29 0 225 259 19 11 36 75 72 9 28 15 24 28 4 3 
HD204 27 64 0 31 400 3 3 291 273 349 4 25 115 156 4 6 
HD205 1 37 3 12 75 8 3 28 399 393 1 0 73 232 3 3 
HD216 203 96 91 161 20 51 27 87 3 5 9 19 99 47 4 5 
HD218 99 37 27 55 15 13 8 15 43 36 0 8 100 0 4 3 
MB2 133 25 1 168 1 5 107 25 24 116 36 25 80 25 
 
4 
 
6 
MB3 69 27 3 28 1 72 0 0 329 39 7 0 55 0 
 
3 
 
4 
MB4 76 33 9 36 0 63 1 0 379 27 9 0 76 1 
 
3 
 
4 
MB6 16 4 24 1 231 0 276 0 436 0 97 0 1 5 
 
4 
 
0 
MB7 27 28 251 41 183 1 163 0 24 3 91 4 21 0 
 
5 
 
2 
MB8 3 25 40 12 1 25 5 4 0 1 5 7 399 312 
 
2 
 
3 
MB9 399 293 47 263 8 175 1 7 0 380 43 297 28 371 
 
4 
 
6 
MB12 204 25 11 1 5 0 8 0 153 9 0 0 391 111 
 
3 
 
2 
MB14 3 0 1 0 0 1 1 1 20 8 0 5 156 232 
 
1 
 
1 
 
MB15 83 237 320 236 192 25 248 112 345 35 12 440 111 239 
 
6 
 
7 
MB16 0 3 0 0 0 0 4 36 12 25 0 0 3 0 
 
0 
 
2 
MB19 68 157 65 56 5 3 0 105 11 93 3 93 3 229 
 
2 
 
6 
MB23 11 0 0 85 0 5 75 5 400 400 1 1 27 25 
 
3 
 
3 
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Figure 4.11. Responses from CRC patients pre and post CD25hi depletion.  
Increased (A), unchanged (B) and decreased (C) mean responses after Treg depletion. 
Each dot represents the number of IFN- spots / 105 cells in response to one of the 7 
pools. The lines indicate the changes after CD25hi depletion. The p values were 
calculated using an unpaired student's t-test. n.s = non-significant. 
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means of 75 and 22 specific spots / 105 cultured cells respectively. Both responses were 
significantly increased after Treg depletion to a mean of 255 and 105 specific spots / 105 
cells. Therefore, when analysing certain individual healthy donors and CRC patients, an 
influence of Tregs can be observed. Similarly, mean responses remained unchanged in 
some patients (Figure 4.11.B) or were decreased after Treg depletion (Figure 4.11.C).  
As showed in the previous part, responses against 5T4 is broad in healthy donors 
and CRC patients, but most of them recognised more peptide pools in the absence of 
CD25hi cells (last two columns of Table 4.6). Even though variations were observed, as 
described above, most healthy donors and CRC patients only had 2 pools affected by 
CD25hi cells suggesting that Tregs only control responses to certain regions in the 5T4 
protein. By increasing the total number of pools that can be recognised, CD25hi depletion 
reveals that other regions of the 5T4 protein are actually immunogenic in certain subjects, 
but these responses are often masked by Tregs.    
Peptide pools influenced by Tregs in healthy donors and CRC patients 
Since CD25hi cell-depletion unmasked or increased responses to 5T4 pools, I aimed to 
identify whether some pools were more influenced than others by CD25hi cells. In healthy 
donors, peptide pool 11 was the only one that was not associated with Treg effects. In 
contrast, pools 7 and 10 were the most influenced by CD25hi cells with 3/6 donors 
showing new or increased responses after depletion (Table 4.6). In CRC patients, pool 10 
was the less influenced by CD25hi cells with only 2/13 patients having new responses to 
this pool in the CD25hi-depleted PBMC fraction (Table 4.6). On the other hand, pool 8 
was more likely to be recognised after depletion as 5/13 patients had new or increased 
responses to this pool. These data suggest that different parts of 5T4 proteins are 
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influenced and potentially recognised by Tregs in healthy donors and CRC patients. 
However, there is no consistent pattern either within or between the two cohorts studied. 
4.2.8. Correlating Treg effect and HLA types of donors 
After the HLA-types of patients and healthy donors were obtained, responses pre- and 
post-CD25hi cell depletion were stratified based on the HLA class II genotype; Table 4.7 
shows results from all donors who expressed HLA-DRB1*0101, -DRB1*1501, -
DRB1*0301, -DRB1*0401, -DRB1*0701 and -DRB1*1301. Responses from healthy 
individuals and patients were grouped as low numbers of donors were tested.  
Responses against peptide pools 9 and 11 from HLA-DR1+ and –DR15+ donors 
were unaffected by CD25hi cells in contrast to the other DR groups. Almost all responses 
to pool 7 from HLA-DR15+ donors were either increased or only detected after CD25hi-
depletion. Similarly, high number of DR4+ donors had responses against pool 9 only in 
the absence of CD25hi cells. These results suggest that certain HLA class II alleles are 
associated with Treg-mediated inhibition of specific 5T4 sequences.  
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Table 4.7. Effect of Treg depletion in HLA-DR1, -DR15 (-DR2), -DR3, -DR4, -DR7 
and -DR13 individuals. The numbers represent the spot-forming cells /105 cultured 
PBMC after subtraction of background spots, in the presence (+ sign) or absence (- sign) 
of CD25hi cells. Underlined numbers indicate positive responses. Blue numbers indicate 
an increase of at least 50% in depleted cells and red new responses, compared to 
undepleted cells. 
 
 
 
     
 
 7 8 9 10 11 12 13 
 DR1+ + - + - + - + - + - + - + - 
HD222 *01, *07 29 0 225 259 19 11 36 75 72 9 28 15 24 28 
HD204 *01, *15 27 64 0 31 400 3 3 291 273 349 4 25 115 156 
MB6 *01, *07 16 4 24 1 231 0 276 0 436 0 97 0 1 5 
MB14 *01, *14 3 0 1 0 0 1 1 1 20 8 0 5 156 232 
MB19 *01, *04 68 157 65 56 5 3 0 105 11 93 3 93 3 229 
 DR15+               
HD210 *04, *15 0 97 363 397 136 100 208 312 325 389 77 399 317 227 
HD204 *01, *15 27 64 0 31 400 3 3 291 273 349 4 25 115 156 
MB3 *15, *04 69 27 3 28 1 72 0 0 329 39 7 0 55 0 
MB8 *13, *15 3 25 40 12 1 25 5 4 0 1 5 7 399 312 
MB15 *15, *04 83 237 320 236 192 25 248 112 345 35 12 440 111 239 
 DR3+               
MB7 *03, *04 27 28 251 41 183 1 163 0 24 3 91 4 21 0 
MB16 *03 0 3 0 0 0 0 4 36 12 25 0 0 3 0 
 DR4+               
HD210 *04, *15 0 97 363 397 136 100 208 312 325 389 77 399 317 227 
HD216 *04, *-- 203 96 91 161 20 51 27 87 3 5 9 19 99 47 
MB3 *15, *04 69 27 3 28 1 72 0 0 329 39 7 0 55 0 
MB7 *03, *04 27 28 251 41 183 1 163 0 24 3 91 4 21 0 
MB9 *04, *07 399 293 47 263 8 175 1 7 0 380 43 297 28 371 
MB15 *15, *04 83 237 320 236 192 25 248 112 345 35 12 440 111 239 
MB19 *01, *04 68 157 65 56 5 3 0 105 11 93 3 93 3 229 
 DR7+               
HD205 *07, *13 1 37 3 12 75 8 3 28 399 393 1 0 73 232 
HD222 *01, *07 29 0 225 259 19 11 36 75 72 9 28 15 24 28 
MB6 *01, *07 16 4 24 1 231 0 276 0 436 0 97 0 1 5 
MB9 *04, *07 399 293 47 263 8 175 1 7 0 380 43 297 28 371 
MB23 *07 11 0 0 85 0 5 75 5 400 400 1 1 27 25 
 DR13+               
HD205 *07, *13 1 37 3 12 75 8 3 28 399 393 1 0 73 232 
MB8 *13, *15 3 25 40 12 1 25 5 4 0 1 5 7 399 312 
MB12 *13 204 25 11 1 5 0 8 0 153 9 0 0 391 111 
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4.3. Discussion 
T cells from healthy subjects recognise 5T4 tumour Ag 
The first finding showed that healthy donors were more likely to respond to 5T4 peptides 
than CRC patients. Indeed, higher percentages of positive donors were observed within 
the healthy group for each of the 7 peptide pools. Moreover, in most cases, intensities of 
5T4-specific responses were comparable in healthy donors and cancer patients after 
peptide pool stimulation. These observations show the remarkable efficiency of 5T4 Ag 
to induce T cell responses. Such a high immunogenicity in healthy subjects has also been 
found for a few other tumour Ags, such as CEA (285).  
As 5T4 is a highly glycosylated protein, the use of synthetic peptides allowed us 
to exclude the detection of glycan-specific T cells. Therefore, responses monitored as 
described in this chapter were strictly directed against unmodified 5T4 peptides. 
However, studies have shown that glycosylation can affect the immunogenicity of 
glycoproteins. Such effect is thought to be mediated by protease, such as asparaginyl 
endopeptidase (286). For instance, Surman et al., showed after epitope mapping that 
immunogenic gp140 epitope hotspots are bordered by regions of heavy glycosylation 
(287). Similarly, Housseau et al., showed that T cells can recognise tyrosinase tumour 
antigen when expressed constitutively in melanoma cells but not when overlapping 
peptides are used in culture (288). It is possible that 5T4 peptide pools that were not 
associated with high immunogenicity contain peptides requiring glycosylation for T cell 
recognition. Stern et al., have characterised seven N-linked glycosylation sites in the 
extracellular domain of 5T4 (289). One of them (NASVSAPS) is found on peptide 17 
present in peptide pool 9. The low percentage of HD and CRC patients responding to 
peptide pool 9 may be caused by the absence of glycosylation on peptide 17.   
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When these Ag are not tumour specific and are expressed at low level in healthy 
tissues, it is likely that the cellular reactivity in donors is caused by auto-reactive T cells. 
The thymic deletion of T cells is not totally efficient and a low-avidity, self-reactive T 
cell population is present in the periphery (290). These self (tumour) Ag-specific T cells 
are controlled in the periphery by several mechanisms including Tregs. My data showed 
that Treg depletion can increase the number of healthy donors responding to 5T4 peptide 
pools demonstrating the role of these immunosuppressive cells in the regulation of self 
(tumour) Ag-specific T cells.  
Other studies performed in the lab have shown that 5T4-specific responses are 
restricted to the CD45RO+ memory compartment. This rules out the possibility that naïve 
5T4-specific T cells are expanded in culture but raises questions regarding how a pool of 
memory T cells specific for 5T4 is established. Although originally thought to be 
restricted to tumour cells, 5T4 expression was also observed on normal oral mucosa and 
inflamed gut [(291) and lab data]. Therefore, 5T4 expression in non-malignant cells may 
prime autoreactive T cells and maintain a pool of Ag-experienced T cells.  
Effect of Tregs on 5T4-specific responses 
Previous results from our group showed that depletion of CD25hi cells, which contains 
the vast majority of Tregs (as showed in the previous Chapter), unmasked new responses 
to 5T4 (247). These results were obtained using the whole 5T4 protein and they raised 
questions regarding which peptides within 5T4, if any, stimulated Tregs. In this chapter, 
stimulation of Treg-depleted and untouched cells with 5T4 peptide pools was carried out.  
First, in each individual, Treg depletion never affected responses to each of the 7 
pools. Instead, increased or new responses were regularly seen in response to only a few 
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pools. Second, most donors could respond to peptide pools even in the presence of Tregs. 
One interpretation of these results is that, in one individual, only a few 5T4 sequences are 
control by Tregs. Distinct patterns of suppression were observed in different individuals, 
implying that Treg-mediated inhibition of responses vary between individuals of different 
MHC type and TCR repertoires. Overall, the data presented in this Chapter indicate that 
Treg depletion does unmask T cell responses to 5T4-derived peptides: for the most part 
this appears to reflect total suppression of a given T cell response rather than a partial 
effect. 
The present results argue that Treg depletion can ameliorate 5T4-specific T cell 
responses in patients as long as effector T cells are not depleted at the same time. 
Treatments specifically targeting Tregs would be more appropriate than unspecific drugs 
such as anti-CD25 monoclonal Ab (daclizumab). Alternatively, in the case that the 
homeostatic system senses the loss of Tregs and generates more cells, functional Treg 
inactivation could prove a more efficient approach.   
Immunogenic 5T4 peptide pool in CRC patients 
In CRC patients, peptide pool 11 was found to be the most immunogenic pool in term of 
magnitude of responses with a mean of 348 spots / 105 cells (or 1/287). It also induced 
responses in a large proportion of patients (44%). This pool may contain one or several 
immunogenic 5T4 epitopes and is the most interesting for vaccination purpose. However, 
new responses to pool 11 were observed in some patients following CD25hi depletion. 
Both Th1 and Treg cells may thus recognise the same or different peptides present in pool 
11. This hypothesis is addressed in the next Chapter. 
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CHAPTER 5. MAPPING THE IMMUNOGENIC 
REGIONS OF 5T4 
 
5.1. Introduction 
The results of experiments described in Chapter 4 point to highly immunogenic regions 
within the 5T4 protein but also suggest that peptide epitopes can be found throughout the 
entire protein. Since the number of reported 5T4-derived peptide epitopes is thus far very 
limited [4 MHC-class I and 2 MHC-class II restricted peptides (240, 241, 243)] 
comprehensive mapping of T cell epitopes was conducted in order to further assess the 
usefulness of 5T4 as a vaccine Ag. 
For this purpose, the same peptides were used as in the previous section (41 peptides 
overlapping by 10 amino acids and spanning the entire sequence of 5T4; Table 2.4 in 
Materials and Methods). However, these peptides were now grouped into 13 different 
pools that were arranged in a matrix where each peptide was present in 1 row and 1 
column. Thus “horizontal” pools were used as before (pools 7-13) with the addition of 
“vertical” pools 1-6 (Table 2.4 in Materials and Methods). Therefore, the intersection of 
two positive pools in the matrix should theoretically correspond to the immunogenic 
peptide containing the T cell epitope. My objective was to identify peptide epitopes from 
across 5T4 and identify the restricting MHC molecule. The advantages of the strategy 
however, compared to the use of peptides predicted by bioinformatics is that it does not 
require identification of the donors’ HLA types before screening. Indeed, this was 
particularly important in this study, as the HLA-types of the donors were not available 
prior to the ELISpot assays due to logistical reasons. Ideally, peptide pools should be used 
for preliminary screening, followed by another screen based on the use of individual 
peptides present in the positive pools. However, due to the limited number of PBMCs and 
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the high number of pools eliciting responses in donors, this was not always possible. 
Responses from seven donors were verified by stimulating pool-reactive T cell lines with 
individual peptides deduced using the matrix.  
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5.2. Results  
5.2.1. Determining candidate 5T4 peptides using a peptide 
matrix 
Two representative examples of ELISpot assays using the peptide matrix are shown in 
Figure 5.1. In the first example (CRC patient, MB3), the 6 positive pools (PP1, 3, 6, 7, 11 
and 13) are highlighted in grey in the matrix (Figure 5.1.A). Peptides found in the 
intersections of these pools are in red and correspond to the candidate peptides recognized 
in the assay. Similarly, screening revealed that CRC patient MB12 was positive for pools 
1, 4, 6, 7, 11 and 13, which lead to the identification of 8 candidate peptides (Figure 
5.1.B).  
When several multiple pools are positive, results are harder to interpret in terms of 
peptide specificity. For instance, in MB3, three different peptides were potentially 
recognized within pool 1 and it is possible that all or just one peptide was recognised by 
T cells.  
Correlating HLA types of patients and healthy donors with peptide-specific T cell 
responses 
After the HLA-types of patients and healthy donors were obtained, responses were 
stratified based on the HLA class II genotype; Figure 5.2 shows results from all donors 
who (A) expressed HLA-DRB1*0101, (B) expressed -DRB1*1501  and (C) expressed -
DRB1*0301; Figure 5.3 shows results from all donors who (A) expressed HLA-
DRB1*0401, (B) -DRB1*0701 and (C) -DRB1*1301. The heat map shown beneath the 
Figures indicate the percentage of responders per individual peptide where different 
colours symbolize different response rates. 
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Figure 5.1. Determining candidate 5T4 peptides using a peptide matrix. After 12 days 
of stimulation, specific responses were measured in an IFN- ELISpot assay. The matrix 
allows the rapid identification of the peptide recognized. Two representative example are 
given with CRC patients MB3 (A) and MB12 (B). 
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Figure 5.2. 5T4 candidate peptides in HLA-DR1, -DR15 (-DR2) and -DR3 
individuals.  Candidate 5T4 peptides that induced responses in PP were deduced by using 
the 5T4 matrix. These data include responses from both CRC patients (MS, MB) and HD.  
HLA-DR1 (A), n=12; -DR15 (B), n=15; and -DR3 (C), n=9. Beneath is a summary with 
each colour indicating the proportion of positive responder. 
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C. HLA-DR3 
Peptide recognised in 20-30% of subjects 
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Peptide recognised in more than 40% of subjects 
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Figure 5.3. 5T4 candidate peptides in HLA-DR4, -DR7 and -DR13 individuals.  
Candidate 5T4 peptides that induced a response in PP were deduced by using the 5T4 
matrix. These data include responses from both CRC patients (MS, MB) and HD.  HLA-
DR4 (A), n=18; -DR7 (B), n=13; and -DR13 (C), n=7. Beneath is a summary with each 
colour indicating the proportion of positive responder. 
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Peptide recognised in less than 20% of subjects 
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5.2.2. Candidate 5T4 peptides 
Figure 5.4 summarizes the reactivity of the peptides in each of the 6 DR groups. These 6 
molecules are the most commonly expressed class II alleles encoded by the HLA-DRB1 
genes in our local population in Wales (as described on www.allelefrequencies.net). In 
line with previous observations examining the reactivity of the pools, heat maps revealed 
that 5T4 peptides are overall highly immunogenic. Indeed, screening of the entire amino 
acid sequence of 5T4 revealed 4 immunogenic regions (squares delimited by a black 
borders). These regions contain peptides potentially recognized by individuals with 
different HLA-DR genotypes with a reactivity of 30-40% (blue squares) in at least one 
HLA-DR type.  
The 5T4 region between amino acids 191 and 300 seems to be the most 
immunogenic as it comprises 10 peptides (peptides 20 to 29 within pools 10 and 11) with 
high reactivity for different HLA-DR molecules. In detail, peptides 20 and 21 are highly 
reactive in HLA-DR3+ donors where they were recognized by more than 40% of donors. 
Several peptides derived from other tumour Ags, such as NY-ESO-1, are broadly 
presented by multiple different HLA-DRαβ glycoproteins (292). Other immunogenic 
peptides were found between amino acids 11 and 40 (peptides 2 and 3 within pool 7), 61 
to 100 (peptides 7 to 9 within pool 8) and 371 to 410 (peptides 38 to 40 within pools 13). 
Only 4 peptides (5, 16, 18 and 19) did not induce responses in the tested donors. 
However, as responses to individual peptides, deduced from use of peptide pools, were 
not confirmed (as discussed above), it is possible that the number of peptide epitopes has 
been over-estimated. It is clear however, that amino acid regions 131 to 200 (peptides 14 
to 19) and 301 to 370 (peptides 31 to 36) contain fewest epitopes as indicated by the 
relatively low proportions of individuals responding to pools 9 and 12.  
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Figure 5.4. 5T4 T cell epitope heat map. Visual illustration depicting the reactivity of 
each peptide for the DR groups present in the cohort. Four colours are used to characterize 
the responsiveness to the peptides. Regions of 5T4 which are commonly recognised are 
enclosed in a black box. 
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Figure 5.4 also highlights the differential peptides. Whereas the HLA-DR7+ group 
could potentially recognize 20 peptides, only 12 5T4 candidate peptides were 
immunogenic in the HLA-DR1+ group. This difference was not caused by skewing 
towards HLA-DR7+ donors as the number of individuals in each group was comparable 
(HLA-DR1+ group contained 12 individuals and the -DR7+ group 13). Therefore, it is 
possible that HLA-DR7 molecules are more likely to present 5T4 peptides than DR1 
molecules.   
Detailed analysis of individual peptide responses 
Several peptides were selected for further investigations based on: 
 potentially presented by ≥ 3 HLA-DR types 
and 
 recognised by T cells in at least 20% of individuals in each HLA-DR groups  
Based on the above, 14 candidate peptides were selected: peptides 2, 3, 15, 20 to 
29 and 38. Each of these peptides (except peptide 15) was found in the immunogenic 
regions of 5T4. As predicted, these peptides are contained in pools that induced high 
frequency responses in many donors (Figure 4.7). 
Furthermore, 3 peptides were also added based on the use of NetMHC2.2 and IEDB 
prediction algorithms: Peptides 10 and 12 predicted to be good binders to different HLA-
DR molecules by both algorithms, peptide 11 predicted to bind to fewer HLA-DR 
molecules (Appendix Table 1). These 3 peptides were used in order to evaluate the 
accuracy of prediction algorithms.  
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5.2.3. Response to individual peptides  
Based on the results of the initial screening of the peptide pools, PBMCs from healthy 
donors and CRC patients were stimulated with individual 5T4 peptides, selected due to 
their ability to induce responses in a large proportion of donors. When enough PBMCs 
were available, they were tested against each of the 17 candidate peptides (peptides 2, 3, 
10, 11, 12, 15, 20 to 29 and 38).  
Figure 5.5 indicates the maximum number of spots in response to one peptide 
counted for each donor. The number of single peptides used ranged from 3 to 17 in healthy 
donors and from 7 to 16 in CRC patients. Positive IFN-spots were detected in 80% 
(8/10) of healthy donors and in 67% (12/18) of CRC patients. The tumour stage did not 
influence reactivity in cancer patients.  
As observed previously, T cell responses against peptides were variable between 
donors. In healthy donors, all peptides, with the exception of peptide 15, were able to 
induce IFN- secretion (Figure 5.6). However, in CRC patients all peptides other than 11 
and 29 induced a response, albeit responses to some peptides were seen only in very few 
individuals. No conclusion can be drawn with respect to peptide 29 due to low numbers 
of donors tested (n=2). These results validate the mapping strategy used previously as 
numerous strong responses were detected using peptides selected from the heat maps i.e. 
peptides 2, 3, 15, 20-29 and 38 (Figure 5.4). Also, as predicted by the algorithms, peptides 
10 and 12 were more immunogenic than peptide 11.  
The most common peptides recognized in healthy subjects were p12 (78%), p38 
(67%), p20 (63%) and p2 (56%). In CRC patients, responses to p38 (35%), p2 (33%), p3 
(28%) and p28 (28%) were the most often detected (Figure 5.6).  
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Figure 5.5. IFN- secretion induced by 5T4 peptides in healthy donors and CRC 
patients. Cytokine secretion in healthy donors, n=10, and in stage A, n=3, stage B, n=6, 
and stage C, n=9, CRC patients. Each dot indicates the chosen highest responder peptide 
in each donor.  The number of peptide-specific spots was calculated by subtracting the 
number of spots in the negative well. Horizontal lines represent the set threshold of 
positivity (25 spots / 105). 
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Figure 5.6. Response rates to individual 5T4 peptides. The percentage of healthy 
donors and CRC patients who had positive responses to 5T4 peptides is displayed. The 
number of individual tested for each peptide is indicated. 
  
160 
 
Alongside the number of responders, the magnitude of responses varied between 
individual 5T4 peptides (Figure 5.7). In healthy donors, the lowest mean response was 
induced by peptide 22 with 62 specific spots / 105 cultured cells (range 45-73) and the 
highest by peptide 21 with 135 specific spots / 105 cultured cells (25-333). In CRC 
patients, the lowest mean response was induced by peptide 24 with 40 specific spots / 105 
cultured cells (range 37-43) and the highest by peptide 12 with 258 specific spots / 105 
cultured cells (79-400). Mean responses to peptide 2 were similar in healthy donors and 
cancer patients (79 and 69 specific spots / 105 cultured cells, respectively). Also, both 
groups had equivalent mean responses to peptide 38 (79 and 70 specific spots / 105 
cultured cells in healthy and cancer individuals, respectively).  
Altogether these data indicate that peptides 2 and 38 are able to stimulate high 
frequencies of T cells in elevated proportions of subjects, independently of their health 
status and without restriction to specific HLA class II molecules. Indeed, many donors 
possessing T cells specific for these peptides expressed various class II alleles. This 
confirms data obtained after extrapolation of the matrix where p2 and p38 were found 
within 2 regions of high reactivity in different DR groups. Moreover, a low response rate 
to some candidate peptides was expected because the matrix may have overestimated the 
number of peptide recognized when several pools were positive. This is particularly true 
for peptides 20 to 29 which were described as immunodominant after the first screen. 
Mapping the fine specificity with single peptides showed that the immune response was 
mainly directed against only a few of these. Also, for all peptides tested (except for 
peptides 15 and 3), the 
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Figure 5.7. Specific immune responses against individual 5T4 peptides. Magnitude of 
positive IFN- ELISpot responses against candidate 5T4 peptides. Each dot represents the 
magnitude of the T cell response from one donor against the indicated peptide in healthy 
donors and CRC patients. Only responses superior to 25 / 105 PBMC (symbolized by dash 
lines) are indicated in both groups. 
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percentage of responders was higher in healthy donors than in CRC patients. This is 
consistent with early observations with peptide pools (Figure 4.7.C). 
 
5.2.4. Immunodominant peptides 
It is striking that some peptides appear to be recognised mainly by healthy donors 
including 11, 23 and possibly 29 (although the latter was only tested in 2 patients), and 
others are favoured by CRC patients such as peptide 15. However, the key information is 
how large the cognate T cell response is to a peptide, and what proportion of individuals 
actually recognise these peptides? Based on the magnitude of positive responses and 
response rates, some peptides have emerged as candidates for immunodominant regions 
of 5T4. The data shown in Figures 5.6 and 5.7 are re-organised in Figure 5.8, in order to 
displays the mean magnitude of peptide-specific IFN- positive responses coupled to the 
response rate in each population (healthy donors and patients) to each of the 17 candidate 
peptides. This graph allows a grouping of some of responses into the following: i) 
peptides which are seen with high frequency responses in many healthy donors and 
patients (i.e. upper outer quadrant of the graph) e.g. peptide 2, 20, and 38 (in green); ii) 
peptides which move from the lower inner quadrant (low frequency responses) to the 
upper outer quadrant  from healthy donors to CRC patients e.g. peptides 3 and 28 (in blue) 
; iii) peptides which move from the upper outer quadrant to the lower inner quadrant from 
healthy donors to patients (loss of responses) e.g. peptides 11 and 23 (in red).  
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Figure 5.8. Immunodominant 5T4 peptides. Two-dimensional graph displaying the 
mean of IFN- response as a function of response rate for each candidate peptide. The 
peptides were classified in different groups depending on 2 arbitrary parameters: 75 
IFN- spots / 105 PBMCs defining high frequency response and 25% defining a high 
prevalence of responders. 
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5.3. Discussion 
Among the Ags expressed by germ cells, trophoblasts and tumours (cancer testis Ags), 
5T4 is a good target for immunotherapy (293). However, the number of immunogenic 
5T4 peptides reported is very limited and mostly restricted to a set of peptides presented 
by MHC class I molecules (240, 241, 243). Given the crucial role of Th1 cells in anti-
tumour immunity (see Chapter 1), 20-mer peptides were used to stimulate T cells in order 
to identify MHC-class II peptides eliciting IFN- production.  
Four immunogenic regions within 5T4 tumour Ag (residues 11-40, 61-100, 191-
300 and 371-410) were identified using peptide pools for further studies. 14 peptides 
(11/14 previously unreported) were selected due to their potential for presentation by 
several HLA-class II molecules and because to > 20% of individuals with a given MHC 
class serotype responded. These 2 parameters are crucial in the context of vaccine design 
where a few peptides are used to induce or boost immune responses in a large population 
with different HLA-types. Three additional peptides were also chosen using predictive 
algorithms. Single peptide stimulation revealed that magnitude of responses and number 
of responders (i.e. immunoprevalence) were different between healthy donors and CRC 
patients.   
ELISpot assay to map antigenic peptide 
Whilst some ELISpot assays rely on initial in vitro T cell expansion with Ag-pulsed DCs 
and HLA matched or autologous PBMCs, I enriched specific T cells by pulsing APCs 
already present in the PBMC fraction. This quick and efficient protocol allowed me to 
significantly extend the list of immunogenic 5T4 peptides with a limited amount of 
donors’ PBMCs. For these reasons, the same protocol is currently used in TaCTiCC 
(TroVax® and Cyclophosphamide Treatment in Colorectal Cancer) clinical trial 
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monitoring 5T4 responses in CRC patients. IFN- ELISpot assay was used to map 5T4 
peptide Ags. The ability of T cells to secrete IFN-was evaluated after short-term peptide 
stimulation. Memory T cells are preferentially detected in cultured ELISpot assays whilst 
effector T cell responses are generally measured by ex vivo ELISpot (294). As memory 
cells induce strong and long lasting immune responses, identifying their specificity for 
tumour Ags is of crucial importance for vaccination. 
Pooling peptides in a matrix format minimized the number of assays required to 
identify candidate peptides. However, one limitation of using peptide pools (when several 
peptides are restricted through the same HLA allele) is the possible competition between 
peptides from the same pool for binding to HLA molecules. However, in order to reduce 
potential competition and compare results between pools, all peptides within the pools 
were at equimolar concentrations. The heat map (Figure 5.4) suggests that some peptides, 
e.g. peptide 19, do not induce T cells responses. But it is possible that, within the same 
pool, some peptides with stronger binding affinity were preferentially detected causing 
absence of T cell responses to peptide 19. This may also explain why some peptides used 
individually to stimulate T cells were more immunogenic than predicted by the heat map, 
e.g. peptide 12. Therefore our strategy may have favoured the recognition of peptides 
with high affinity for DR molecules.  
Immunogenicity of peptides selected from the heat map 
There was a good correlation between candidate peptides expected to bind to several DR 
molecules (heat map Figure 5.4) and the in vitro assays. Indeed, when used individually 
to stimulate T cells, almost all 14 peptides could elicit responses in at least 3 different 
HLA-DR groups, albeit number of responders varied between DR serotypes (Appendix 
Table 2). Therefore, the use of a matrix to interpret results obtained with peptide pools 
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permits the accurate identification of peptides able to bind to HLA-DRB1 molecules of 
various serotypes. There were only two exceptions; whilst the paucity of responses to 
peptide 29 may simply reflect the low number of donor tested, the same is not true for 
peptide 23. Only one donor responded to this peptide although it was tested in 9 healthy 
donors and 15 cancer patients. Using peptide pools, peptide 23 was expected to be 
recognised by a high number of DR3+ and DR4+ donors (heat map Figure 5.4). 
Responders identified using the matrix or obtained with single peptide stimulation 
did not always align. For instance, according to the matrix, peptides 2 and 20 are 
potentially recognised by 30 to 40% of HLA-DR1+ donors (Figure 5.4), whilst in fact 
when single peptides were used, they were respectively recognised by 75% (6/8) and 88% 
(7/8) of donors (Appendix Table 2). Furthermore, the previous Chapter showed that 
CD4+CD25hi cells could influence specific responses to all 5T4 pools. Therefore, it cannot 
be excluded that Tregs were stimulated by other peptides present in the pools and in return 
suppressed responses against peptides 2 and 20. On the contrary, the matrix indicated that 
peptide 25 is recognised by 20 - 30% of HLA-DR4+ donors but using single peptides, 
these were immunogenic in only 11% (1/9). Thus matrix and peptide pools give good 
indications regarding the ability of a peptide to bind to different DR molecules but do not 
provide accurate information regarding their immunoprevalence. This is likely to be 
caused by an overestimation of the number of peptides recognised when several positive 
pools are recognised. These results point the importance of the single peptide stimulation 
for validation of candidate peptides deduced using a matrix.   
Interestingly, individual peptide stimulation showed that all peptides were poorly 
immunogenicity in HLA-DR4+ CRC patients. In comparison, some peptide (e.g. 2, 3 and 
20) were more immunogenic in HLA-DR1+ patient. These data suggest that HLA-DR1 
serotype is protective in CRC patients. In contrast, HLA-DR4 may be associated with bad 
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prognosis as this allele is not associated with high reactivity for 5T4 peptides. 
Unfortunately, studies analysing the association between HLA and cancer risk are limited 
in number and mainly restricted to HLA A*2 (295). Only the HLA-DR17 gene 
(DRB1*0301 allele) is more frequent in individuals with ulcerative colitis-associated 
colorectal cancer (296). 
Immunogenic peptides in healthy donors and CRC patients 
By comparing magnitude of responses and percentage of responders in healthy donors 
and CRC patients, 3 groups of peptides were observed. In the first group, 3 peptides (2, 
20 and 38) had high immunoprevalence in both healthy donors and CRC patients; e.g. up 
to 67% and 35% positive responses to peptide 38 in healthy donors and patients, 
respectively. These peptides can be good candidates to monitor 5T4-specific immunity in 
CRC patients. Only a few tumour Ags with such high immunoprevalence have been 
reported; NYESO-1 (292), MELOE-1 (297) and Survivin (298). Given the relative long 
length of the peptides used (20 amino acids), it is possible that several epitopes of 
different 9-mer core sequences (with distinct HLA-DR restriction) are present within 
these peptides. As a results, many donors of different HLA types would respond. 
However, they may well be promiscuous peptides able to bind to various HLA-alleles. 
For instance, Wen et al showed that a short epitope (14-mer) derived from HCA587 
tumour Ag can stimulate T cells in the context of more than one HLA class II allele (299). 
Alternatively, recognition of these peptides may be caused by TCR cross-reactivity. This 
T cell degeneracy allows the recognition of potential pMHC complex by the limited 
diversity of -TCRs in one individual at a time (300). Provided molecular similarities, 
a T cell could thus recognise peptides 2, 38 and 20 which could explain high response 
rates observed in individuals.  
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In the second group, 2 peptides (3 and 28) had a low immunogenicity in healthy 
donors but were highly immunogenic in cancer patients. In addition to their high 
immunoprevalence in patients, the magnitude of responses elicited by these peptides were 
particularly high. Peptide 38 as mentioned above had a high immunoprevalence but was 
associated with low magnitude of IFN- responses. Peptides 3 and 28 may induce better 
T cell responses if used as peptide vaccine in CRC patients. The difference in 
immunogenicity of these peptides in healthy donors and CRC patients indicates that 5T4 
overexpression in tumour cells leads to specific T cell priming. This raises the question 
of natural de novo peptide reactivity in cancer patients. It is possible that chemotherapy 
has influenced recognition of some peptides that are non immunogenic in healthy donors.  
 
Also, these peptides were (with peptide 20) the most immunogenic in patients. In 
comparison, healthy donors had 6 peptides of high immunogenicity. It is possible that 
CRC patients have a more limited TCR repertoire of 5T4-specific T cells, as this has been 
shown for TRAG-3 tumour Ag in melanoma and breast cancer patients (301). 
Furthermore, change of TCR repertoire diversity is associated with overall condition of 
CRC patients (patients in remission have a broader diversity of TCR repertoire) (302). As 
all patients were in phase of cancer progression (T cells assays were performed with blood 
samples obtained before tumour resection), this could explain the low diversity of their 
TCR repertoire.  
Despite the presence of these immunogenic peptides in CRC patients, healthy 
donors had better responses. This can be attributed to a loss of expression of relevant 5T4 
Ag peptides on the surface of cancer cells, defects in antigen presentation or release of 
immunosuppressive substances (e.g. from myeloid-derived suppressor cells) affecting T 
cell function. Also, the role of the peripheral tolerance to self Ag (e.g. 5T4) in cancer 
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cannot be excluded. In the previous chapter, FACS analysis showed that Tregs were 
present at high percentage in blood of CRC patients which may explain the low 
immunogenicity of the candidate peptides. In contrast, healthy donors seem to have high 
degree of reactivity against 5T4 suggesting that peripheral tolerance does not prevent 
spontaneous T cell activity against 5T4.  
 
In the last group, specific responses against 2 peptides (#11 and #23) were seen in 
healthy donors but were lost in cancer patients. Responses against these peptides may be 
beneficial to prevent cancer in healthy donors. When a tumour is established however, 
cancer cells may suppress responses to these peptides by supporting Treg activity. CRC 
patients vaccinated with 5T4 vaccine and drugs targeting Tregs may regain responses to 
these peptides. Furthermore, studies in mice suggest that Tregs can selectively inhibit 
responses to the most immunodominant CD8 determinants (303). Peptides 11 and 23 may 
be immunodominant peptides in CRC patients preferentially suppressed by Tregs.  
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CHAPTER 6. HLA-DR RESTRICTED TH1 AND 
TREG 5T4 PEPTIDES 
 
6.1. Introduction 
Several groups have reported the existence of 5T4 peptides recognised by CTLs. 
Originally reported in healthy donors (240), they were subsequently observed in CRC 
patients vaccinated with TroVax (recombinant vaccinia viral vector encoding 5T4) (241). 
Despite the crucial role of Th1 cells for the optimal induction of CTL responses (242), 
the specificity of CD4+ T cells for 5T4 Ag remains poorly defined (243). In the previous 
Chapter, I provided evidence that 17 20-mer 5T4 peptides induce IFN-secretion by T 
cells. It is reasonable to suppose that these peptides are presented by MHC class II due to 
the culture conditions used (12 days, low dose IL-2), which my lab has shown previously 
to favour expansion of CD4+ T cells (304) (305). Also the majority of MHC class II-
restricted tumour Ags are between 15-20 amino acid long (cancerimmunity.org). The 
possibility that CTL epitopes were identified cannot be excluded. It has been shown that 
20mer peptides may contain overlapping CTL and CD4+ T cell epitopes as has been 
shown in two KIF20A tumour Ag-derived peptides bearing T helper and CTL epitopes 
(306). Thus, in this chapter, I describe experiments set up to determine whether the 5T4 
peptides previously found do indeed elicit CD4+ T cell responses and which HLA class 
II molecules are responsible for peptide presentation. Furthermore, previous findings 
described in this thesis revealed that Tregs critically affect responses to 5T4-derived 
peptide epitopes. Thus, this Chapter describes an investigation of Treg specificity for 5T4 
peptide Ags to gain new insights into their mechanism of activation.  
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6.2. Results 
6.2.1. Evaluation of the HLA restriction 
In order to investigate the HLA restriction of the immunogenic peptides identified, 
ELISpot assays were carried out as described previously but in the presence of HLA class 
I and II blocking Abs. Where available, each of the anti-HLA class I, anti-(HLA)-DQ and 
anti-(HLA)-DR blocking Abs were added into ELISpot cultures before peptide 
restimulation. As shown in the example in Figure 6.1, IFN- secretion was totally 
abolished by the addition of anti-DR Abs. In detail, anti-MHC class I Abs (HD18) or anti-
DQ Abs (MB26) had no effect and responses to 5T4 were similar to those obtained 
without Abs. 
MHC-restriction was assessed, in most cases, with PBMCs from several donors 
where responses to the peptides were abrogated in the presence of anti-HLA-DR Abs 
(Figure 6.2). Again, class I blocking Abs had no effect, demonstrating that these 
polyclonal responses are not HLA class I-restricted. 
Recognition of two peptides, i.e. peptides 11 and 21, was reduced but not totally 
abolished by blocking anti-DR molecules (more than 50% reduction). Use of anti-class I 
Abs did not alter the responses, thus it is likely that these peptides can be presented to T 
cells by MHC class II molecules other than HLA-DR. However, strong responses 
associated with > 200 spots / 105 cells (observed against peptides 2, 3, 15 and 26) were 
totally abrogated with anti-DR Abs demonstrating the HLA-DR restriction of these 
peptides.  
In addition, Table 6.1 indicates the HLA-types of the donors whose 5T4 responses 
were restricted in vitro by anti-DR Abs (as described in Figure 6.2). Donors with different   
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Figure 6.1. Representative examples of MHC-blocking experiments. PBMCs obtained 
from donors HD18 and MB26 were incubated in ELISpot plates for 16 hr in the absence 
or presence of either anti-HLA class I or class II Abs. Number of spot-forming cells / 7.5 
x104 cultured cells is indicated. PBMC were also plated in media only (background control 
indicated by media). 
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Figure 6.2. Immunogenic 5T4 peptides induce MHC-class II restricted responses. 
PBMCs were stimulated with the indicated peptides in the presence of MHC-blocking 
Abs. Results are expressed as the number of IFN- spots / 105 cultured cells after 
subtracting the background. When several donors were tested, each symbol represents 
one individual. 
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Donor HLA-DRB1 DR-restricted peptide 
HD18 *15, *10 p2 
HD214 *01, *12 p2 
HD207 *01, *15 p2 
MB29 *03, *04 p2 
HD214 *01, *12 p3 
HD207 *01, *15 p3 
MB29 *03, *04 p3 
MB27 *08, *14 p3  
MB49 *03, *15 p3 
HD18 *15, *10 p10 
HD207 *01, *15 p10 
HD204 *01, *15 p10 
HD18 *15, *10 p11 
HD210 *04, *15 p12 
HD204 *01, *15 p12 
HD222 *01, *07 p12 
MB26 *15, *04 p12 
MB27 *08, *14 p12 
MB41 *03, *04 p12  
MB26 *15, *04 p15 
HD225 *01, *09 p20 
HD207 *01, *15 p20 
HD222 *01, *07 p20 
MB49 *03, *15 p21 
HD204 *01, *15 p22 
MB41 *03, *04 p23 
HD18 *15, *10 p24 
HD207 *01, *15 p24 
HD207 *01, *15 p25 
HD210 *04, *15 p25 
HD207 *01, *15 p26 
HD18 *15, *10 p38 
HD207 *01, *15 p38 
MB26 *15, *04 p38 
Table 6.1. HLA-DRB1 molecules potentially involved in peptide presentation. Only 
peptides whose reactivities were abrogated with anti-DR Abs are indicated.   
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HLA-DRB1 types could respond to the same peptides. For instance, HLA-DR-restriction 
for peptide 2 was observed in 4 donors with 4 different HLA-DRB1 alleles. The absence 
of a unique DR-subtype restriction for these 5T4-derived peptides most likely reflects the 
20mer length peptides employed, facilitating the binding to several HLA-DR subtypes. 
 
6.2.2. Fine HLA-DR restriction analysis 
After characterizing DR as the restriction element of the immunodominant peptides, I 
next conducted experiments to determine which of the two HLA-DRαβ heterodimers (in 
heterozygotes) of a given donor was involved in the peptide presentation. Moreover, 
analysis of patients’ HLA types revealed that 3 donors were homozygous for 3 different 
DRB1 alleles. Thus their responses against DR-restricted 5T4 peptides gave indications 
of the HLA-DR subtypes involved. 
Table A (Figure 6.3) shows that peptide 2, 20 and 38 were not restricted to one 
particular HLA-DR subtype but can be presented by multiple -DR molecules. Indeed, p38 
induced IFN- secretion in HLA-DRB1*03 and –DRB1*15 homozygous donors (MB62 
and MB64) and peptides 2 and 20 in HLA-DRB1*01 and –DRB1*15 homozygous 
patients (MB62 and MB64).  These results are in line with the above observations and 
confirm that multiple HLA-DR subtypes are involved in presenting the same 5T4-derived 
peptides.  
The HLA-DR restriction of a peptide can easily be determined if the responder is 
HLA homozygous, as described above. In heterozygotes, more experiments are required 
to determine which individual HLA-DR subtypes are involved in peptide presentation. 
As T cell clones were not available, cell lines were maintained in culture. For this purpose, 
irradiated allogeneic PBMCs and PHA were added to provide feeder cells and 
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Figure 6.3. Fine HLA-DR restriction of 5T4-specific T cells. A. HLA-DRB1 types of 
donors who recognized the indicated peptides. B. HLA-DR restriction determinants of  
5T4 peptide 12. After 4 weeks of expansion, T-cells were incubated with peptide-pulsed 
HOM-2 and HO104 EBV-transformed B cells, homozygous for the indicated HLA-DR 
molecules, for 5h in IFN- ELISPOT wells. 
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MB62 03, - 38 
MB64 15, - 2, 20, 28 , 38 
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non-specific mitogens, respectively. When the cell number required was reached, cells 
were restimulated in ELISpot plates with HLA-DR-homozygous B cell lines used as 
APCs. Due to allo-reactivity against EBV-transformed B cells, peptide stimulation was 
shortened to 5h in ELISpot plates, in contrast to the normal 16 hours. PBMCs from donor 
HD204 were reactive for p12 and were restimulated with p12-pulsed HOM-2 and HO104 
cell lines, each expressing one of the two HLA-DRB1 alleles of the donor. As shown in 
Figure 6.3.B, p2 was only recognized in association with HLA-DR*01 expressed by 
HD204 and not the HOM-2 cell-line.   
Altogether these data suggest that most 5T4 peptides are presented by HLA-DR 
molecules, confirmed using anti-DR blocking Abs and HLA-matched/mismatched EBV-
transformed B cells to present the peptides. 
 
6.2.3. 5T4 Treg epitopes 
Indirect evidence for Treg-mediated inhibition of 5T4-specific responses  
Evidences shows that Tregs can inhibit the reactivity of T cells of the same Ag specificity 
(207). I therefore asked whether responses to the immunogenic 5T4 peptides identified 
above could be influenced by Tregs of the same peptide specificity. In these experiments, 
CD25hi T cells were depleted and IFN- ELISpot assays were conducted with total T cells 
and Treg-depleted PBMC. Then, cells of both fractions were stimulated with single 
candidate peptides. The potential effect of Tregs was classified as either: i) no effect: no 
enhancement or reduction; ii) Treg effect: a response was either unmasked or increased 
(by least 50%) post depletion of Tregs. 
In CRC patients, responses to 17 peptides were assessed in ELISpot assays using 
12-day cultures pulsed with single peptides. Cultures were established in the presence and 
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absence of CD25hi cells. The data are summarized in Table 6.2. Responses to 8 of the 
peptides (peptide 11, 15, 20, 21, 25, 26, 27 and 29) were comparable in cultures 
established in the presence or absence of CD25hi cells, a finding which may reflect the 
inability of these peptides to stimulate activation of Tregs. Interestingly, the highly 
immunogenic peptide p20 was one of them. Responses were altered in the case of the 
other 9 peptides tested. Following depletion of CD25hi cells, new or increased responses 
were observed against each peptide in at least one donor (Figure 6.4), a finding which 
may reflect the ability of these peptides to concurrently stimulate Tregs and Th1 cells. 
Variations were observed between donors. Peptides 3 and 12 were the most associated 
with Treg effects as 19% and 21% of donors, respectively, either had new or increased 
responses to these peptides after CD25hi depletion. These data indicate that Tregs can 
either fully or partially suppress responses to 5T4-derived peptide epitopes. A relatively 
high percentage of CRC patients (39%) had responses against at least one 5T4 peptide 
subjected to these effects. The low number of healthy controls tested (n=3) did not allow 
for a representative analysis. Therefore, Tregs affect responses to some, but not all, 
immunogenic peptides in a high number of CRC patients.  
Direct observation of Treg-mediated inhibition of 5T4-specific response  
The data above and those obtained with the use of peptide pools (Chapter 4) indicate that 
Tregs can influence 5T4-specific responses. The implication of the experiment described 
above is that where Tregs affect responses, these Tregs are of the same specificity as the 
effector T cells. It is also possible that Tregs may be stimulated by a given peptide but 
suppress in an Ag non-specific manner. An experiment was therefore designed to 
determine whether those 5T4 peptides, which rarely stimulated IFN-production (as 
indicated in Figure 5.4, Chapter 5), might in fact represent Treg epitopes. Peptides 5, 16, 
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 2 3 10 11 12 15 20   21 22 23 24 25 26 27 28 29 38 
 + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - 
MB26     24 4    0 0 400 15 289 4    8 0                    123 8     85 3 
MB27 25 177 13 264    4 4 264 25 1 0    1 1                    377 12     25 144 
MB28 1 0 1 0 3 1 0 0 0 0    0 0 1 0 9 0 0 0 0 0 0 0 1 0 4 0 7 0 5 0 0 0 
MB29 48 0 247 33 11 37 0 8 4 0    0 7 131 9 0 4 0 3 43 0 4 0 1 7 3 0 268 5 7 0 0 27 
MB30 1 0 0 0 0 0 7 0 0 0 139 0 25 1 25 0 8 0 4 0 0 0 0 4 27 0 0 7 0 28     144 55 
MB31 37  0  0     0  0  3  11  63  12  0  0  9  0   0       0   
MB41 0 0 0 0 0 0 3 0 16 47 0 0       0 0 0 39 0 0 1 0 0 0     0 0     0 0 
MB46 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0     0 0     0 0 
MB48 0 0 0 0 0 0    0 0 0  0 0    0 0 0 0 0 0 0         0 0     0 0 
MB49 0 0 85 0 0 0    0 0 0 0 0 0 88 32 0 0 0 0 0 0 0 0        0 0     4 0 
MB51 0 0 1 0 11 0    1 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 3      0 0     0   
MB52 0  0 0 0     0  0  0  0  0  0  0  0         0       0   
MB53 0  0 0 133     0  0  0  0  0  0  0  0         0       0   
MB56 228  193  13           287     0        28  0  127   63       4   
MB62 0 9 3 1 0 29    4 63    1 19       9 4    11 9 1 0     5 3     28 27 
MB64 25 1 3 7 3 0   0 1 0    52 0 13 5 1 0 3 1 1 3 3 0 5 8     32 1     67 8 
MB65 49 11 40 160 48 0    0 4    25 0 1 9 1 0 1 1 1 81 0 0 3 8 3 1 1 1       0 
MB66 9 31 67 148 140 11   5 79 264     3 1 20 9 4 388 8 5 37 1 13 1 5 0     8 13     76 93 
Table 6.2. Magnitude of IFN-secretion in CRC patients before and after depleting 
Tregs. Undepleted and Treg-depleted PBMC from CRC patients were stimulated with 
each of the candidat peptides. The numbers represent the spot-forming cells /105 cultured 
PBMC after subtraction of background spots, in the presence (+ sign) or absence (- sign) 
of CD25hi cells. Underlined numbers indicate positive responses. Blue numbers indicate 
an increase of at least 50% in depleted cells and red new responses, compared to 
undepleted cells. 
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Figure 6.4. Effect of Tregs on responses against 5T4 candidate peptides. Undepleted 
and Treg-depleted PBMC from CRC patients were stimulated with each of the candidat 
peptides in different IFN- assays.  
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18 and 19, which induced IFN-responses in less than 20% of donors were selected, and 
added together to make a putative “Treg pool”. 
PBMCs from one healthy donor were either depleted of the CD25hi cells or 
untouched. Both fractions were stimulated for 12 days with the individual candidate 
peptides described above and with and without the “Treg pool”. This in vitro stimulation 
was followed by IFN- ELISpot assay to evaluate the effect of the putative Treg epitopes 
on 5T4 responses.  
As shown in Figure 6.5, both fractions could respond to the recall Ag PPD, 
indicating that the cells were functional. When using the PBMC, a strong response to 
peptide 2 was detected but this was suppressed when cells were activated by peptide 2 in 
the presence of “Treg pool”. This effect was not apparent in cultures depleted of CD25hi 
cells indicating that Tregs can be activated by 5T4 peptides to exert a suppressive effect. 
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Figure 6.5. 5T4-specific Tregs can suppress 5T4-specific Th1 cells. PBMC and Treg-
depleted PBMC were stimulated with PPD in IFN- ELISpot assays. They were also 
stimulated with peptide 2 with or without Treg peptides. Experiment with peptide 2 were 
performed in duplicate. Asterisks on the top of the bars indicate positive responses.  
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6.3. Discussion 
In this chapter, the MHC-class II restriction of the majority of the most immunoprevalent 
5T4 peptides was proven. Also, using anti-MHC Abs their restriction elements were 
found to be mainly HLA-DR molecules.  
Several studies have investigated the specific responses to 5T4 and four MHC-class 
I restricted peptides have been delineated; 5T417-25, 5T497-105, 5T4153-161 and 5T4249-257 
(240, 241). Three of these epitopes are encompassed within peptides 2, 10 and 25 
respectively. The use of anti-class I Abs did not abrogate specific responses to these 
peptides (Figure 6.2). The absence of CD8+ responses is most likely due to the lack of the 
relevant restricting class I molecule in the tested donors. Peptide 26 encompassed one 
reported MHC-class II 5T4 epitope (residues 251- 265) (243). This peptide was found to 
be HLA-DR restricted confirming the CD4⁺ T cell- priming capacity of 5T4254-265.  
Furthermore, although specific responses to peptides 11 and 21 were unchanged 
using anti-class I Abs, they were not entirely abrogated using anti-DR Abs (50% 
decrease), suggesting that either HLA-DP or –DQ molecules can also present these 
peptides. CD4+ T cells can recognise the same epitope in the context of multiple HLA-
DR and DP molecules (cross-reactivity of TCR-peptide-MHC recognition). This has been 
shown with CD4+ T cell clones recognising NY-ESO-1119-143 presented by HLA-DR and 
-DP molecules (307). It is possible that within the polyclonal population present in a cell 
line, a T cell clone recognised the same epitopes, derived from peptides 11 or 21, in the 
context of HLA-DP and –DQ. It is also likely that peptides 11 and 21 comprise epitopes 
presented by several MHC-class II molecules and recognised by different T cell clones. 
Possible MHC-DR-binding residues in 5T4 peptides 
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The binding of peptides on MHC class II molecules relies on major anchor residues at 
positions 1, 4, 6 and 9 in the 9mer core sequence (Chapter 1). The anchor residues of 
several HLA-DR subtypes have been defined (308) and are indicated in the Appendix 
(Table 3). As 12/14 5T4 peptides were strictly restricted by HLA-DR (Table 6.1), it 
follows that these peptides must have specific HLA-DR- binding residues. The use of the 
published binding motifs revealed the residues involved in the HLA-DR binding of all 12 
peptides. Moreover, the majority of the peptides contain binding motifs for several 
different HLA-DR molecules explaining their immunogenicity in responders of different 
HLA types (Appendix Table 4). Interestingly, the presence of all and/or certain 
determinant motifs was associated with high immunogenicity in the relevant HLA-DR 
groups.  For instance, peptide 26, which elicited responses in 50% of HLA-DR1+ donors, 
(Appendix Table 2) contains each of the 4 reported HLA-DR1 motifs within the core 
sequence LTHLESLHL.  
In contrast, although peptides 10 and 38 did contain all 4 HLA-DR15 anchor 
residues, they induced specific responses in a high number of HLA-DR15+ donors; 57% 
for peptide 10 and 86% for peptide 38 (Appendix Table 2). This immunogenicity must 
be caused by the presence of distinctive bulky hydrophobic residues at position 4 in their 
core sequences (phenylalanine in peptide 10 and tyrosine in peptide 38), important 
primary anchors for binding to HLA-DR15 (309). Similarly, peptide 12 was highly 
immunoprevalent in HLA-DR1+ donors with 63% responders (Appendix Table 2). This 
immunogenicity may be explained by the presence of a small amino acid residue (alanine) 
at position 6 in its core sequence. This amino acid is a determinant residue binding within 
pocket 6 of HLA-DR1 molecules (308).  
Furthermore, peptide 20 is particularly interesting as it has 2 core sequences that 
enable binding to HLA-DR1 molecules, i.e. EGMVVAALL and FEGMVVAAL (anchor 
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residues underlined). However, it is most likely that FEGMVVAAL binds to HLA-DR1 
since position P1 is the most important HLA-DR1 anchor residue (with a preference for 
tyrosine or phenylalanine at this position) (310). In line with these observations, peptide 
20 was recognised in 88% of HLA-DR1+ donors.   
Safe 5T4 peptides 
It is well established that Treg activation is Ag-specific and that they are capable of 
recognising different types of Ag including tumour and viral Ags (204). The findings 
described in this chapter showed that Tregs and Th1 cells share the same specificity for 
some, but importantly not all, 5T4 peptides (Figure 6.4). Responses to six immunogenic 
HLA-DR restricted peptides (peptides 15, 20, 21, 25, 26 and 27) were unaffected by Treg 
depletion, i.e. no increase or new responses after CD25hi depletion. Among them, 5T4 
p20191-210 is the most promising because of its high immunoprevalence, especially in 
HLA-DR1+ and –DR15+ donors (Appendix Table 2). These Treg-independent peptides 
represent promising “safe” vaccine components, as they should not induce Tregs in 
patients. This is a crucial parameter as Tregs may either be induced or reactivated 
following peptide vaccination (232).  
Tumour peptides binding various HLA-DR molecules, i.e. universal cancer 
peptides, may represent the most useful for vaccinating large populations of diverse HLA 
types (311). However one potential problem is that these peptides may be presented to 
both Th1 cells and Tregs. Such peptides have been identified in the Study described here. 
For instance, peptide 12 was immunogenic in several HLA-DR groups but was 
recognised by Tregs in 3 patients with 3 different HLA-DR alleles. Thus, due to the likely 
presence of deleterious Treg peptides within tumour Ags, the use of agents modulating 
the Treg population may be essential to prevent Treg activation post-vaccination. 
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Moreover, some studies have reported that Tregs do not need to recognise the same Ag 
as Th1 cells in order to suppress them. For instance, HPV-specific Tregs can suppress 
influenza specific-Th1 cell activity when both cells are activated by their respective Ags 
(208). However, no studies have yet reported unspecific Treg suppression of tumour Ags. 
Bonertz et al showed that Tregs can recognise several tumour Ags but without evaluating 
their ability to suppress in an Ag non-specific manner (207). In vitro Treg assays 
performed in this Chapter showed that the addition of a pool of Treg peptides to a 5T4 
peptide-specific T cell line resulted in the inhibition of IFN-secretion (Figure 6.5). 
Importantly, the peptide used to stimulate the T cell line was not found in the Treg pool. 
Although this experiment needs to be repeated, it suggests that Tregs activated by their 
related tumour Ag peptide can functionally inhibit Th1 cells of a different tumour Ag 
specificity.   
Melief et al have shown that vaccination with HPV-derived long peptides induce 
HPV-specific CD4+CD25+Foxp3+ T cells in patients with different type of cancers (232, 
312). Notably, patients with large vulvar intraepithelial neoplasia lesions displayed strong 
HPV-specific Treg responses after vaccination and did not have complete regression. The 
use of this vaccine would require agents modulating Treg activity. A 5T4 vaccine based 
on some of the T helper peptides described in this Study would not require modulation of 
Treg activity / numbers as they do not appear to stimulate Tregs. It is therefore possible 
that such a vaccine, specifically designed to lack Treg epitopes, may best serve to increase 
the magnitude of the anti-tumour immune response in CRC patients. In conclusion, the 
results presented in this Chapter indicate the potential for the design of such vaccines.  
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CHAPTER 7. FINAL DISCUSSION 
 
In this thesis, I investigated the phenotype of CD4+CD25hi cells in CRC patients and 
examined the immunogenicity of 5T4 tumour Ag. Collectively, these data support the 
need to target the CD25hi cells as they exhibit a strong immunosuppressive phenotype 
(Chapter 3) and inhibit responses to 5T4-derived peptides (Chapter 4). It is the first time 
that both Th1 and Treg cells specificities for an entire tumour antigen are studied. 
Mapping using a two-step approach (first screen using peptide pools and second screen 
using individual peptides) revealed different degrees of immunogenicity of 5T4 peptides 
in healthy donors and CRC patients (Chapter 5), confirming my original hypothesis that 
specific regions and peptides are more immunogenic than others within 5T4 protein. 
Furthermore, 5T4 peptides recognized by Th1 cells and / or by CD25hi cells have been 
found confirming my hypothesis that TCRs expressed by Th1 and Treg cells share similar 
specificity for 5T4 tumour antigen. This is the most important finding of this work as it 
has great implications for immunotherapy and the design of 5T4-based vaccine. Although 
these data presented in this thesis followed my hypothesis, they also raise questions 
regarding the mode of action used by Tregs and TCR specificity for tumour antigens. 
These questions are discussed in this Chapter. These findings have implications for the 
design of more effective 5T4-based peptides.  
7.1. Ex vivo phenotype of CD4+CD25hi cells 
Staining PBMCs isolated from peripheral blood and cells isolated from colon and tumor 
of CRC patients offered the opportunity to characterize the CD25 population in these 
samples. The percentage of CD25- cells expressing the markers studied (HLA DR, ICOS, 
CTLA-4, CD39, LAG-3 and LAP) was higher in tumours than in the blood of CRC 
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patients. Whilst these observations were expected with the circulating cells as they are on 
the majority of a naïve phenotype (Figure 3.2), they may indicate the presence of either 
activated or immunosuppressive CD25- cells in CRC tumours. Characterizing these 
eventual CD25- suppressive cells, classified as non-conventional Tregs, is of a great 
importance in cancers where lots of attention have been put on CD25hi Tregs (justified by 
the poor prognostic of patients with high infiltration of CD25hi T cells). It would be 
interesting to look at the effect of these IL-2 independent cells on other CD25- that do not 
express Treg markers. Alternatively, these cells may represent intratumoral Tregs that 
have temporally lost Foxp3 and CD25 expression. These cells have been shown in mice 
to reacquire Treg suppressive activity upon TCR stimulation (313).  
Furthermore, although at different levels, all markers studied were expressed by 
CD25hi cells (independently of the samples they were isolated from).  This reflects the 
diversity of the immunosuppressive arsenal available by Tregs and their ability to affect 
a very large range of immune cells. Based on the high percentages of cells expressing 
these markers, it is likely that not one but a combination of suppressive mechanisms is 
used by intratumoral Tregs. However, it remains unclear whether all Treg-associated 
proteins can be used by all Tregs or by unique Treg subsets that have specific functions 
in different environments.  
  
7.2. 5T4 tumour peptides 
It is the first time that immunogenic sites within the oncofetal Ag 5T4 have been mapped. 
New HLA-DR restricted peptides derived from 5T4 tumour Ag were identified. These 
immunogenic peptides may serve to develop tools such as soluble MHC-peptide 
complexes called tetramers. Their use in immunology, especially in cancer research, has 
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been proven to be highly useful to gain insight into the frequencies, phenotypes and TCR 
of tumour Ag-specific T cells (314). However, obstacles such as the low yield of stable 
monomers that can be obtained and the low affinity of TCR/tumour peptide MHC-class 
II have limited their broad use. Six tetramers of DRB1*01 allele incorporating different 
5T4 peptides (P2, P3, p12, P20, P26 and P38) identified in this study have been generated 
in the laboratory (by Bruce MacLachlan). Current experiments are focussed on optimising 
the use of these tetramers. Many important factors are under consideration including 
time/temperature of incubation and the peptide-MHC tetramer concentration. 
Tetramers can be used to monitor the frequencies of tumour Ag-specific T cells 
mediating spontaneous or vaccine-induced immune responses in patients. Ex vivo 
tetramer staining of PBMCs of non-vaccinated ovarian cancer patients revealed low 
frequencies of NY-ESO-1-specific circulating CD4+ Th1 cells (314). Reports using ex 
vivo tetramer staining have shown that the frequency of tumour Ag-specific T cells was 
increased in patients vaccinated with NY-ESO-1-based vaccines (315). Tetramers can 
also serve to phenotypically characterise T cells used in the 12-day culture followed by 
IFN- ELISpot assays. To evaluate the nature of responses detected by IFN- ELISpot 
after 10-day in vitro culture, Todryk et al stained cultured T cells with tetramers 
comprising HLA molecules and viral peptide epitopes (294). Costaining with CCR7 and 
CD62L revealed that these T cells exhibit a central memory phenotype and their role in 
IFN- ELISpot was confirmed by depleting CCR7 cells at the start of the culture period.  
Tetramers may also be used to isolate live cells with a defined Ag specificity. 
Obtaining clones in this way would enable further functional assays to be conducted or 
characterisation of TCR for subsequent use in cell-based immunotherapies. Indeed, after 
detection and isolation of 5T4-specific T cells with tetramers, cDNA coding for TCR  
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and  chains that are specific for 5T4 could be amplified, cloned into a viral vector and 
used to transduce T cells isolated from the blood or tumour of cancer patients. T cells 
genetically modified in this way have been expanded and reinfused into patients with 
metastatic melanoma patients. Cancer regression was observed supporting the feasibility 
and potential of this approach for cancer therapy (316).  
 
7.3. Improving the immunogenicity of 5T4 peptides 
Both in the cohort of healthy donors and CRC patients studied, a number of 5T4 
immunodominant peptides were found. These peptides were defined as those inducing 
the highest numbers of IFN- producing cells and those recognised by the highest number 
of donors. Thus, they were defined as immunodominant based on both the intensity and 
frequency of responses (Chapter 5, Figure 5.8). Several factors can affect the 
immunogenicity of a given peptide such as effective Ag processing and presentation, a 
high binding affinity to MHC molecules and the precursor frequency of peptide-specific 
T cells. For therapeutic peptides used in vaccination, extrinsic factors are added such as 
the route of administration (intramuscular or intravenous administration).  
The relationship between MHC binding affinity and immunogenicity of peptides 
has long since been described, at least for MHC class I molecules (317). More recently, 
by determining the crystallographic structure of gp100209-217 tumour Ag, Borbulevych et 
al showed that one amino acid substitution in the Ag was associated with an enhanced 
affinity for HLA-A2 molecules leading to an increased immunogenicity (318). Whether 
or not increasing the affinity of peptides for MHC class II molecules results in a better 
immune response has not been studied. It would be interesting therefore to define the 
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binding characteristics of the identified 5T4 immunogenic peptides to HLA molecules by 
crystallography in order to design superior vaccine candidates.  
Only a few crystal structures of tumour-Ag/MHC class II complexes have been 
reported thus little is known about the chemical properties permitting optimal peptide 
binding to MHC-class II molecules. The crystal structure of HLA-DR4 with gp10044-59 
epitope has recently been reported (319). This study revealed the identity of the anchor 
residues binding to the pocket of HLA-DR4 molecules. Substitution of these residues by 
certain other amino acids was shown to enhance the MHC–peptide affinity underlining 
the potential of this approach. However, such substitutions in the peptide core sequence 
may prove counterproductive as these have been shown to alter the TCR specificity (320). 
An alternative option to improving CD4+ T cell responses might be to alter amino acid 
residues in the nonbinding terminal regions of peptides, named flanking regions. Cole et 
al have shown that C-terminal modifications in the influenza hemagglutinin HA305−320 
epitope can lead to enhanced CD4+ T cell activation (24). More precisely, the presence of 
an Arginine at position 10 or 11 in the C-terminal flanking region could enhance 
TCR/pMHC-II affinity. Surprisingly, despite the clear utility of this approach, no attempt 
has ever been made to improve the affinity of TCRs to tumour Ag/MHC class II by 
altering peptide flanking residues. The 14 MHC-class II-restricted 5T4 peptides identified 
in this study represent good candidates for such experiments.  
 
7.4. Tumour Ag-specific Tregs 
One aim of this PhD was to define 5T4-derived peptides recognised by Tregs. These 
suppressive cells had a negative impact on 5T4-specific responses as the majority of CRC 
patients could recognise more peptide pools after depletion of CD25hi cells (Chapter 4, 
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Figure 4.6). One striking observation is that all pools were susceptible to be affected by 
Treg depletion in CRC patients. These results raise questions regarding the advantage of 
a broad Treg tumor Ag specificity. Since Tregs only exert a suppressive activity after 
antigenic stimulation through their TCRs (321), they may have a broad TCR repertoire to 
keep regulatory functions in case one peptide is made unavailable.  
Also, single peptide-stimulation assays revealed that Tregs can recognise the same 5T4 
peptides as Th1 cells and suggested that they can suppress Th1 cells of a different Ag 
specificity (Chapter 6, Figures 6.4 and 6.5). This results confirm our hypothesis that 5T4-
specific Th1 and Treg cells can be identified in CRC patients. 
Although human Tregs were discovered approximately 20 years ago, their TCR 
specificity has not been extensively studied. The lack of tools allowing quick and direct 
identification and quantification of Ag-specific Tregs is, in part, responsible. Instead, 
several approaches, which have proven laborious and difficult to reproduce, have been 
reported for the identification of tumour-specific Tregs. For instance, several studies 
found tumour Ag-reactive Tregs by cloning and subsequent immune profiling (203, 206). 
Whilst informative, such methods are not applicable for routine detection of Tregs. Of 
note, the assays carried out during the course of this PhD were based on functional assays 
where Tregs were depleted or “Treg peptides” added to reactive T cell lines and are thus 
more effective than reported assays. Indeed, only 14 days were required to evaluate 
whether or not T cell responses against a 5T4 peptide were controlled by Tregs. This high 
throughput screening allowed the analysis of Treg activity in a high number of donors.  
Beckhove et al showed that HLA-class II tetramers can be used to assess the 
presence and quantify tumour Ag-reactive T cells in cancer patients and healthy donors 
(210). Using this approach they revealed ex vivo the presence of effector and Treg cells 
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specific for mam34-48-derived mammaglobin protein. Mammaglobin (mam) is a tumour 
associated Ag overexpressed in breast tumours. Both populations were expanded in breast 
cancer patients in comparison to healthy subjects. Since data presented in Chapter 6 
showed that Tregs can recognise the same 5T4 peptides as Th1 cells, it will be interesting 
to compare frequencies of both populations using tetramers. Also, CD4+CD25hi cells are 
enriched in tumours of CRC patients (Chapter 3, Figure 3.7); thus it will be of interest to 
determine if the proportion of 5T4-specific Tregs is also highly increased within the 
tumours. To the best of my knowledge, there are no studies using HLA-class II tetramers, 
which have so far revealed the presence of Ag-specific Tregs in tumours. 
An alternative approach for the detection of Ag-specific Tregs without the need to 
generate tetramers has been reported. It is based on the observed down-regulation of 
CD3/TCR complexes following TCR recognition (322). Using this approach, Ebert et al 
concluded that the NY-ESO-1/ISCOMATRIXTM peptide-based vaccine was able to 
induce new or increase pre-existing Treg  responses against  NY-ESO-1 in advanced 
melanoma patients (233). However, this finding has not been validated by other groups 
thus precaution must be taken when assessing Treg activity based on CD3 
downregulation. Furthermore, Ebert et al defined Tregs as CD25+Foxp3+ cells in their 
study. Even though the advantage of this approach lies in the simplicity of its routine use, 
40% of peripheral CD4+CD25int effector T cells express Foxp3 (Chapter 3, Figure 3.5), 
so suppressive Tregs may not be the population down regulating CD3. It would be of 
interest to evaluate the ability of CD4+CD25hi cells to down regulate CD3 after activation. 
 
7.5. Implications for immunotherapy 
Stimulating pre-existing anti-5T4 T cells  
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Memory T cells are preferentially detected in cultured ELISpot assays whilst Teff 
cell responses are generally measured by ex vivo ELISpot [our group and (294)]. 
Therefore the 5T4-reactive T cells measured in the cultured ELISpot assays described 
herein are likely derived from pre-existing memory T cells in the blood of donors. This 
pre-existing CD4 memory Th1 cell repertoire specific for 5T4 tumour Ag in cancer 
patients is of major importance for the development of cancer vaccines. Indeed, 
vaccination with such peptides may allow a fast, strong and long-lasting secondary Th-
mediated anti-tumour immune response (Figure 7.1). In contrast, epitopes recognised by 
naïve T cells will only elicit slow and weak primary Th responses when injected into 
cancer patients (Figure 7.1). Another reason for the failure of vaccines may be the use of 
peptides recognised by both Th1 and Treg cells considerably limiting the effectiveness of 
the vaccine (Figure 7.1).  
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Figure 7.1. T cell populations induced by peptide-based vaccines and consequences. 
Anti-tumour immunity is either rapidly enhanced, slowly increased or inhibited 
depending on the tumour peptide used in vaccination and the nature of the cells activated.     
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 T helper peptide-based vaccine with checkpoint inhibitors 
 
Kenter et al showed that a HPV vaccine containing long overlapping peptides was safe 
and immunogenic in cervical cancer patients but could not exert effective therapeutic 
action (323). Further analysis of the T cell responses post vaccination in cervical cancer 
patients showed that not only did the vaccine induce CD4+ Th and CD8+ cells but also 
Tregs (232). Due to the presence of Treg epitopes, the use of Treg modulating agents 
would therefore be required for such vaccines in cervical cancer. Nevertheless, this HPV 
vaccine could induce clinical responses (including complete regression) in a majority of 
vulvar intraepithelial neoplasia patients (324). The therapeutic activity of the vaccine may 
be caused by the absence of HPV-specific Tregs in these patients.    
The six HLA-DR restricted peptides (15, 20, 21, 25, 26 and 27) identified in this 
study represent good candidates for vaccines as i) they were immunogenic in CRC 
patients of different MHC background and ii) were not recognised by Tregs. These T 
helper peptides can therefore be used in a multipeptide-vaccine overcoming the need to 
modify Treg activity.  
Targeting inhibitory receptors that normally reduce the immune response represent 
another strategy to enhance anti-tumour immunity. Checkpoint inhibitors, such as anti-
CTLA-4 and anti-PD-1 mAbs, have been reported to enhance anti-tumour immunity in 
cancer patients (180, 325). However, clinical trials have so far only showed low objective 
response rates. Following vaccination with anti-CTLA-4 Abs (Ipilimumab), objective 
responses were observed in 5% of melanoma (326) and in 12.5% of renal cell carcinoma 
(327) patients. Low objective response rates are also observed following anti–PD-L1 Abs 
treatments; 11.8% in renal-cell cancer and 5.9% in ovarian cancer patients (328). 
Furthermore, such treatments are often associated with severe grade III/IV side effects 
(329). Their use as monotherapies or as adjuvants is thus not entirely safe but they are so 
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far the most promising drugs in immunotherapy. It will be of interest to determine the 
clinical benefit of such drugs in association with vaccines, including vaccines inducing 
5T4-specific T cell responses. 
 
Engineered 5T4 neoAntigens 
Vaccination with mutated tumour Ags represent a promising approach alongside to native 
Ags. These neoAgs are not affected by central T cell tolerance and their expression is 
strictly tumour specific. Since somatic mutations take regularly place in CRC (330), it is 
likely that 5T4 mutated peptides are presented by tumour cells. Introducing mutations in 
the 5T4 Th peptides reported in this Study may create neoAgs which could induce specific 
responses in vivo in cancer patients. Also, as checkpoint inhibitors, at least anti-PD Abs, 
work better against mutated Ags (331), such treatment would make CRC more sensitive 
to 5T4 neoAg therapy.  
After exome sequencing, potential neoAgs are selected on the basis of their 
predicted strong affinity for MHC molecules (332). The 5T4 peptides described in this 
study are immunogenic in CRC patients which may reflect, among other factors, their 
good affinity for MHC class II molecules. Therefore, modification should be limited to 
amino acid substitution at TCR contact residues (position 2, 3, 5, 7 and 8) within their 
core sequences, which would not modify their binding properties to MHC molecules. 
Furthermore, the immunogenicity and thus the clinical potential of the engineered neoAgs 
could easily be assessed in in vitro IFN- ELISpot assays with PBMCs of CRC patients.  
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7.6. Conclusion 
I have shown that a strategy, based on use of overlapping peptide pools and validation 
with single peptides, can be successfully used to identify CD4 epitopes on the entire 5T4 
tumour Ag. Four immunodominant regions within 5T4 were unveiled, which contained 
MHC-class II peptides presented by different HLA-DR alleles. This approach, purely 
based on in vitro assays, was independent of computational prediction and thus allowed 
a, previously undescribed, T cell mapping of peptides present on the entire 5T4 protein. 
Tregs from CRC patients were phenotypically characterised and their influence on 5T4-
specific responses studied. The high expression of inhibitory molecules on their 
membrane and the shared Ag specificity with helper T cells argue for the redesign of 
cancer vaccines to specifically exclude peptides commonly recognised by Tregs. The 
identification of immunogenic helper peptides not recognised by Tregs will, not only be 
useful to track T cells responses during vaccination, but also should help to make cancer 
vaccines more efficient in patients with 5T4+ tumours.    
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APPENDIX 
 
Appendix Figure 1. Controls for commonly used fluorescently labelled antibodies. 
 
  
  
CD39 - PECy7 
 
Helios - FITC 
 
 
HLA-DR - PECy7 
 
CTLA-4 - PE 
 
 
ICOS - FITC 
 
Foxp3 - APC 
 
Foxp3 - APC 
 
Foxp3 - APC 
CD45RO - FITC 
 
CD4 – Pacific Blue 
 
LAP - PerCPCy5.5 
CD45RA - PerCPCy5.5 
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Appendix Figure 2. Proportions of circulating and intratumoural CD4+CD25hi and 
CD4+Foxp3+ cells within the CD4+ population in CRC patients. 
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Appendix Table 1. In silico predicted MHC class II-restricted peptides of 5T4 
protein. Grey boxes indicate predicted strong binders and white boxes non-binders. 
Default prediction thresholds were used for both algorithms to predict strong binders; 
IC50 <500 nM for NetMHC2.2, percentile rank below 10% for IEDB. 
 
NetMHC2.2 
  
 
 
 
EIDB  
Algorithm Nb peptide binding to Nb peptide matching Nb peptide not  Nb peptide 
   3 HLA-DR alleles  heat map matching heat map  missed 
NetMHC2.2 6 5 1 14 
IEDB 20 13 7 6 
*0101  
 *1501 
*0301 
*0401 
*0701 
*1302 
*0701 
*1302 
*0101  
 *1501 
*0301 
*0401 
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Appendix Table 2. Responses to individual 5T4 peptides stratified by HLA-DR 
serotype. Each peptide was used to stimulate T cells from healthy donors (HD) and CRC 
patients (MB) The numbers represent the spot-forming cells / 105 cultured PBMC after 
subtraction of background spots. Underlined bold numbers indicate positive responses. 
Absence of numbers indicate peptides not tested 
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Appendix Table 3. MHC binding preferences of most common HLA-DR subtypes in 
Wales. Motifs were found using the Syfpeithi database. 
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Appendix Table 4. 9mer core sequences (red) and anchor residues (underlined) of HLA-
DR restricted 5T4 peptides. The analysis only includes the DR subtypes of patients from 
whom peptides were found DR-restricted using blocking Abs. Absence of sequence 
indicates that less than 3 residues matched the published motifs (weak binders). Since 
only 2 anchor residues are reported for HLA-DR15, core sequences with 1 determinant 
motif defined strong DR15 binders. 
   
Peptide 2 
Peptide 3 
Peptide 10 
Peptide 12 
Peptide 15 
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Peptide 20 
Peptide 22 
Peptide 23 
 
Peptide 24 
 
Peptide 25 
 
Peptide 26 
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Peptide 38 
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Patient Information Sheet: 
An Investigation into the role of lymphocytes 
on the generation of tumour immunity in 
humans. 
You are being invited to take part in a 
research study. Please ask us if anything is unclear or if you 
need more information. Take time to decide whether or not 
you wish to take part. 
Purpose of the Study: 
Your immune system is involved in fighting infections such as bacteria and viruses using 
white blood cells. However, there is strong evidence that the immune system is important 
in causing inflammatory conditions such as Crohn’s disease or ulcerative colitis, and also 
in fighting abnormal cancer cells, which might arise in normal or inflamed tissue. The 
purpose of this study is to examine the way your white blood cells recognise and attack 
cells of the body, including malignant tumour cells. 
The Volunteers 
We are interested in patients who are about to undergo a resection of their colon for 
malignancy or a complication of inflammatory bowel disease. 
Do I have to take part? 
It is up to you whether or not to take part. If you do decide to take part, you will keep this 
information sheet and be asked to sign a consent form. If you decide not to take part, it 
will not affect the standard of your care in any way. 
What does it involve? 
To carry out this research, we would require a small sample of blood (30-40 mls, i.e. one 
syringe full) before your operation. After your operation, it is usual for the resected bowel 
to be sent down to a pathologist for examination. In the course of this standard 
examination, the pathologist will remove a small sample of the abnormal bowel and 
adjacent lymph nodes, required for use in this study. The white cells in these samples will 
also be analysed. After you have made a full recovery from your operation, 2-3 further 
blood samples would be analysed over a 12 month period. These samples will usually be 
obtained by us when you are attending outpatients. 
Are there any risks? 
There are no extra risks in taking part. This study in no way impinges or alters your 
treatment. There is only the inconvenience of an extra blood sample. 
What are the benefits of taking part? 
This is a valuable study in allowing us to understand how and why our white blood cells 
attack our own tissues. This knowledge would potentially allow new therapies to be 
designed in the future that manipulate this response to treat certain cancers or 
inflammatory conditions. 
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What happens when the research is over? 
When we have all the results, we will aim to present the data at local, national and 
international meetings. At these meetings, experts in the field will be able to review and 
discuss the new information. The work will also be published in journals so that the 
information can reach a wide audience.  
Patient Confidentiality 
All information collected during the study will be kept confidential. Any information 
about you that leaves the hospital will have your name and address removed so that it 
cannot be recognised. All results obtained from blood or tissue samples that you provide 
will be completely anonymous. 
Who is organising the research? 
This study is supervised by Dr Andrew Godkin (Consultant Gastroenterologist) in close 
liason with Mr Mike Davies, Miss Rachel Hargest or Mr Simon Phillips (Consultant 
Surgeons) who is performing your operation and looking after you whilst you are in 
hospital. The research is carried out in the Henry Wellcome Building (Cardiff University) 
at the Heath Hospital site. 
Who has reviewed the study? 
This study has been reviewed by the Cardiff and Vale NHS Trust Research and 
Development Committee and the Local Research Ethics Committee. The study is being 
funded by a grant from Cancer Research Wales and was initially sent out for external 
review. 
Who to contact 
If you wish to discuss any issues, please ask the houseman looking after you on the ward. 
If issues arise that he / she cannot deal with, Mr Davies or Dr Godkin will be able to 
discuss these further 
Last Updated: 3/2/2011 
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Please tick 
box 
 
Please tick 
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Please tick 
    Centre Number:  
    Study Number: SPON 900-10 
   
    Patient ID Number: ……………… 
 
CONSENT FORM 
An Investigation into the role of lymphocytes on the generation of tumour 
immunity in humans. 
      Name of Researcher:  Matthieu Besneux (PhD Student) 
       Research Supervisor:  Dr Andrew Godkin (Consultant Gastroenterologist) 
1. I confirm that I have read and understand the information sheet dated 3/2/2011 for the above 
study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected during the study, 
may be looked at by responsible individuals from Cardiff University or the Cardiff and Vale 
NHS Trust. I give permission to these individuals to have access to my records. All information 
will remain confidential. 
 
4. I consent for my anonymized results of this study to be published in scientific / medical 
journals. 
 
5. I consent for obtained samples to be stored for future research. 
 
6. I agree to take part in the above study. 
 
Name of Patient                                Signature                             Date 
Name of Person taking consent                  Signature      Date 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes / 
histopathology. 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes / 
histopathology. 
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